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CHAPTER I 
 
INTERFACING BIOLOGY AND NANOMATERIALS FOR 
SENSING APPLICATIONS1 
 
Introduction 
The characterization of functional nanostructures is crucial in determining their 
efficacy for life sciences.  Nanostructure design requires careful consideration of 
recognition units and material properties, while synthesis can be meticulous, but 
evaluation and characterization of the system is equally challenging and important.  
Nanostructure creation can not easily be deemed successful without analytical evaluation.  
Furthermore, it may not be used to its potential if it is not well defined and well 
understood.  The design and development of analytical tools and techniques for 
characterization of nanomaterials is, therefore, imperative.  A widely-used and effective 
tool for structure assembly evaluation is the quartz crystal microbalance (QCM).  QCM is 
a sensitive technique based on the propagation of evanescent acoustic waves, which are 
affected by adsorption processes as well as local changes in density and viscosity of the 
contact liquid.  Real-time analyte adsorption is monitored through simultaneous 
measurement of the quartz crystal’s resonant frequency of oscillation and the damping 
resistance caused by liquid loading.  One of the paramount applications of QCM has been 
the study of adsorption of biomolecules on functionalized surfaces.  It has also been used 
in a variety of other applications and is particularly suited to the study of nanoscale 
materials.2, 3  This chapter will address the importance of interfaces between biology and 
nanoscale materials and detail the principles and operational aspects of QCM.  Examples 
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of QCM applications to the life sciences, as well as nanoparticle-based chemical, 
biological, and immunological sensors will then be addressed.  Subsequent chapters will 
detail QCM analysis of several antigenic nanoparticle/antibody interfaces.  An initial, 
proof-of-concept example of a successful interface between glutathione-protected 
nanoparticles and antibodies and the evaluation of that interface will be described in 
Chapter II.  This was one of the first examples of such an interface and showed that QCM 
is an effective technique for quantitative analysis.  A more complicated and, perhaps, 
biologically-relevant nanostructure displaying a linear epitope from the hemagglutinin 
protein of influenza was developed and shown to effectively interface with monoclonal 
antibodies, as discussed in Chapter III.  Antigen mimic design was taken one step further 
to include secondary structure or local conformation and allowed the conformational 
epitope mapping of the Protective Antigen of B. Anthracis.  This antigen mimic was 
shown to be more antigenic than its linear counterpart and showed some immunogenicity 
in mouse model studies, as illustrated in Chapter IV.  Chapter V describes a different 
union between biology and nanomaterials, where a protease-labile peptide is used to join 
Pt and Au nanoparticles, resulting in enhanced near-IR fluorescence.  Additional 
nanostructures and QCM detection strategies and applications are reported in the 
Appendices. 
 
Interface Between Biology and Nanomaterials 
Fundamental advances in chemistry and biology have allowed biotechnology and 
materials science to develop over the past decades.  Biotechnology has attempted to 
emulate naturally occurring functional assemblies, from the double helix of DNA to the 
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multi-subunit protein cage, ferritin.  On the other hand, material science has taken 
advantage of chemical methods for the miniaturization of functional devices.  The further 
evolution of these disciplines into the emerging field of bionanotechnology depends on 
the successful development and evaluation of structurally well-defined interfaces that 
bridge biology and inorganic materials chemistry.  Interdisciplinary collaboration 
between these fields will allow for improved biological components to generate new 
materials while advanced materials will be used to ameliorate biological problems.4  The 
design, synthesis, and characterization of readily programmable, structurally well-defined 
biological interfaces for inorganic materials represent significant challenges for the 
realization of these goals. 
Progress has been made towards the development of such interfaces, though many 
options have yet to be explored.  Some encouraging synthetic attempts have used DNA, 
semiconductor-binding peptides, genetically-engineered viruses, and silica-precipitating 
peptides.  Specifically, synthetic single-stranded oligonucleotides coordinated to 
nanoparticles have been shown to self-assemble with the appropriate compliment to form 
higher ordered structures (Figure 1a).5  Phage-display libraries have been used in the 
successful selection of 12-mer peptides that specifically bind to the 100 face of GaAs 
single crystals (Figure 1b).6  Bivalent peptides of this nature could be used in the directed 
assembly of nanoscale components.  Recently, the iron-storage protein ferritin, which 
contains its own interface between biology and inorganic iron oxide, has been used as 
inspiration for the design of a genetically-engineered viral cage that has the ability to 
precipitate nanoclusters.  The virus, cowpea chlorotic mottle virus, was engineered with  
 4
 
Figure 1.  Examples of successful interfaces between biology and inorganic materials.  
(a) TEM image of 8 nm diameter Au nanoparticles connected to a 31 nm diameter Au 
nanoparticle through complimentary strands of DNA.  (b) Fluorescently labeled 
antibody bound to peptide presenting phage, which specifically recognized the 100 
face of GaAs.  (c)  TEM image of virus templated synthesis of Au nanoparticle.  (d)  
Electron micrograph of silica particles precipitated via a synthetic peptide. 
 
 
HRE peptide epitopes on its surface and provided a template for the symmetry directed 
synthesis of Au nanoparticles (Figure 1c).7  Another attempt at interfacing biology and 
inorganic materials has made use of a synthetic peptide based on silaffin from a variety of 
eukaryotic algae or diatoms.  This peptide was shown to efficiently precipitate silica 
under mild conditions, mimicking diatom activity (Figure 1d).8  These functional 
materials have enjoyed success in the assembly of nanoscale materials, but have limited 
application to sensor development.  Still, they have succeeded at interfacing biology and 
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inorganic materials and have served as inspiration for the subsequent design of sensor 
interfaces. 
One biomolecular recognition method that has not been widely employed in the 
assembly of nanoscale materials is immunomolecular recognition.  Immunoglobulin G 
(IgG) antibodies have affinities (association constant, Ka) on the order of 106 – 1012   M-1 
and have been well-studied for sensor development.9-12  Applications of such 
immunoassays have had a tremendous impact on medical diagnosis and the treatment and 
understanding of disorders and diseases.  Interfacing immunology and nanomaterials will 
expand these applications and provide potential for improvements on existing assays and 
treatments.  There are several cases where immunology and inorganic materials have 
been successfully brought together to provide a ground work for further development. 
Progress began with the non-specific immobilization of antibody on micron-sized, 
hydrophobic, latex beads.13-15  Antigen binding to immuno-reactive beads causes 
agglutination, which can be quantified by changes in solution turbidity.15  Similarly, 
antibodies have been non-specifically immobilized on 11 nm diameter colloidal gold 
particles.  These particles were used in traditional sandwich immunoassays, where the 
gold particle provided signal amplification when binding was detected with surface 
plasmon resonance spectroscopy (SPR).16  More recently, Nam, et al. created an 
immunoassay using micron-diameter immuno-magnetic particles in conjunction with 13 
nm diameter DNA/antibody derivatized gold clusters.  Magnetization allowed for facile 
separation of agglutinated particle, while double stranded DNA provided an amplification 
avenue through polymerase chain reaction (PCR).17  Other strategies have used 
nanocluster/antibody interfaces as means for multiplexing and amplification.18-20  
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Another approach made use of a peptide epitope known to bind monoclonal antibody 
associated with the human malarial parasite, Plasmodium falciparum, and was the first 
example of antigen encapsulated nanoclusters assembling with antibodies through the 
antibody (paratope)/antigen (epitope) interface.21  This important advancement appears to 
provide a robust, functional nanostructure that has the potential of successfully 
mimicking a biological entity.  Together these interface-dependent techniques have 
suggested new routes for the study and detection of human IgG, prostate specific antigen, 
hepatitis B surface antigen, and the human malarial parasite. 
Antibodies will continue to be studied as analytical reagents and recognition units in 
interfacing with nanoscale materials due to their extraordinary binding affinities, ease of 
use, and relevance to medical disorders.  The classic IgG protein has a prototypical Y-
shape made up of two heavy and two light chains (Figure 2). 
 
SS
SS
SS SS
Fa
b D
om
ain
Fc Domain
An
tig
en 
Bin
din
g S
ite
Heavy Chain
Light Chain
CDR
 
Figure 2.  Cartoon structure of a typical IgG antibody, highlighting heavy and light 
chains joined by disulfides, a constant fragment (Fc), two fragments of antigen 
binding (Fab), and complimentarity determining regions (CDR). 
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The antigen binding site (paratope), within the Fab (fragment of antigen binding), is 
formed by the three dimensional arrangement of the complimentarity determining regions 
(CDR).  In antibodies, this is the key region of immunorecognition and results in the 
proteins valency.  Three major types of antibody preparations are in use for 
immunoassays:  polyclonal, monoclonal, and single chain fragment variable (ScFv).  
Polyclonal antibodies (pAb) are generally collected from animals and result as a response 
to the injection of an antigen.  They are produced by many different B lymphocytes and 
recognize different epitopes within the same antigen, resulting in a mixture of antibodies, 
with only a subset of total IgG recognizing the epitope of interest.  Monoclonal 
antibodies (mAb), on the other hand, are produced in a colony of identical B cells.  Each 
antibody binds to the same epitope and the mAb sample is homogeneous.9  Single chain 
fragment variable (ScFv) antibodies represent the smallest functional domain of a 
traditional monoclonal or polyclonal antibody as they consist of one linked Fab domain 
(Figure 3).22, 23   
 
 
Figure 3.  (a) Single-Chain Fragment Variable recombinant antibody with cysteine 
incorporated into linker, (b) Rabbit IgG, (c) Interaction between immobilized ScFv 
and rabbit IgG. 
 
 
Phage-display recombinant antibody technology has produced high-quality, antigen-
specific ScFv antibodies with affinities (binding strengths) comparable or greater than 
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those of traditional antibodies.6  This technique and these antibodies are particularly 
useful for antigens that are poorly immunogenic, readily degrade, or for which 
monoclonal or polyclonal antibodies are difficult to obtain.  These three types of 
antibodies provide a range of options for interfacing immunology with nanoscale 
materials. 
The interface between biology and inorganic materials has manifested in many 
different forms, covering the range of biological systems and the range of inorganic 
materials.  Immunology has interfaced with many substrates, including two-dimensional 
surfaces,23-25 organic polymers,13, 15, 17 large metal particles,16, 21 semiconductor quantum 
dots,26 and small, ligand-capped metal cores.2  The interface of antibodies with each of 
these substrates has produced interesting functional materials, though ligand-capped 
noble-metal clusters (monolayer-protected clusters, MPC) have recently received 
attention for their unique consolidation of self-assembly techniques and metal 
nanoparticle chemistry.27-29  Furthermore, their chemical, electronic, and physical 
properties, a lack of air and water sensitivity, and convenient characterization make them 
robust materials.21, 30-33  Programmed specificity through the introduction of biologically 
relevant molecules is one of their most promising features and lends to the development 
of an immuno-interface.34, 35 
Synthesis and assembly of MPCs can occur through several routes, using various 
metals (Au, Ag, Cu, Pt, CdS, ZnS, Ag2S),36 reductants (citrate, Na2S, NaBH4), and 
capping ligands (thiolate, disulfide, amine, imidazole, carboxylic acid, phosphine, 
iodine).  Surfactants, templates, and physical methods (photochemistry, sonochemistry, 
radiolysis, thermolysis) have also been employed.37  Conventional methods have 
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primarily been based on the Brust-Schiffrin Method, published in 1994.38  This was 
originally a two-phase synthesis with stabilization by organic soluble thiolates and 
reduction by NaBH4 (Figure 4a).   
 
 
Figure 4.  Representative synthesis and characterization for a tiopronin-protected 
cluster.  (a) Synthesis conditions based on a modified Brust method and cartoon 
schematic of a monolayer protected cluster.  MPC ligands are connected through 
thiolate moieties at one end and generally have a functional group at the opposing end 
(turquoise).  (b) TEM image of MPC showing spherical shape, size, and size 
dispersity.  (c) 1H NMR of tiopronin MPC showing broad -CH3 (~1 ppm) and -CH2-/-
CH- (~3.5 ppm) peaks.  The water peak is at 4.8 ppm. 
 
 
This method was subsequently adjusted for the synthesis of water-soluble MPCs, which 
is generally a one-phase synthesis and follows the simple equation below (Eq. 1).31 
 
HAuCl4•xH2O(aq) + 3RSH(aq) + 10NaBH4(aq) Æ AuoaSRb + RS-SR(3-b)/2          (Eq. 1) 
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Templeton, et al. reported the synthesis of water-soluble tiopronin (N-(2-
mercaptopropionyl)glycine) MPCs with a 1.8 + 0.7 nm diameter according to this 
method.  Characterization of these nanoclusters follows from traditional materials 
techniques, as previously described in depth.28, 31, 39  Examples of a transmission electron 
microscopy (TEM) image and proton nuclear magnetic resonance spectroscopy (1H 
NMR) spectrum are available in Figures 4b and 4c.  A more complete review of gold 
nanoparticle synthesis, characterization, and applications was recently published by 
Daniel et al.37 
One of the most promising features of MPCs is their ability to exchange thiolate 
ligands with ligands in solution.  This allows for the specific introduction of biologically 
active molecules, programmable specificity, and the synthesis of functional nanoclusters.  
In this way, nanoscale inorganic materials make potentially interesting solid supports for 
the immobilization and presentation of antibody or antigen, leading to a successful 
interface with an immunological system.  Place exchange of free thiol onto three-
dimensional MPCs is a relatively facile process that is regulated by solvent, reaction 
temperature, reaction time, and properties and concentration of original and replacement 
thiol.34  Investigation of the dynamics, kinetics, and mechanism of place exchange are 
abundant and generally support an associative, SN2 mechanism.34, 35, 40, 41  Place exchange 
on MPCs has been compared to preceding studies of place exchange on two-dimensional 
self-assembled monolayers.42, 43  Exchange is more likely to occur on 3D surfaces 
(MPCs) over 2D surfaces (SAMs) due to the higher propensity for defect sites in 
structures with a substantial radius of curvature.34  Another important feature of place 
exchange reactions is the idea that fast-exchange sites are not static.  Evidence for this 
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has come from the exchange of several different ligands onto the same MPC28, 35 and 
from an inability to completely remove ligand that had been previously exchanged on a 
cluster.34, 35  A significant implication of these results is the ability of a thiolate to migrate 
across the monolayer of an MPC and position itself for an optimal interface. 
There are many examples of successful place exchange and coupling reactions with 
organic and water soluble MPCs, resulting in functional nanostructures.  For example, 
Templeton et al35 used traditional amide coupling techniques to attach 12 different 
functional ligands to nanoclusters, introducing spin labels, amino acids, fluorophores, 
sugars, and electroactive moieties.  Place exchange has also introduced fluorescein and an 
electroactive viologen species.  Electrochemical quartz crystal microbalance of this MPC 
showed redox activity of the viologen as well as deposition of the MPC upon viologen 
reduction.44  Antimicrobial nanoclusters have been prepared by functionalization with 
vancomycin,45 glutathione-protected nanoclusters have been shown to interact with the 
enzyme glutathione transferase,46 and biotinylated nanoclusters bind to streptavidin.46  
This type of MPC functionalization produces nanostructures with specific activity and 
suggests potential for further nanocluster modulation in the design of bioreactive 
materials. 
There are two ways that functional nanoclusters can interface with immunology 
through paratope/epitope recognition:  an antibody can be covalently attached to an MPC 
or an MPC can play the role of the antigen (Figure 5).  Antibody/nanocluster complexes 
have been previously studied as mentioned above.  Briefly, immunoassays for human IgG 
have been developed using antibody bound latex beads,14, 15 signal amplification was 
observed with antibody bound gold nanoclusters in SPR immunoassays,16 and antibody  
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Figure 5.  Cartoon schematic of (a) nanocluster presenting antibody (antibody mimic) 
and of (b) nanocluster presenting antigen (antigen mimic).  Epitope antigens are 
generally smaller than antibodies and can be presented at a higher areal density than 
antibodies. 
 
 
bound magnetic microparticles have been used as capture agents.17  There is further 
interest in using nanoparticle labeled antibodies as nanoprobes for imaging.47 
An alternate approach would be to attach an antigen to an MPC or functionalize an 
MPC with a peptide epitope (Figure 5b).  An epitope is the antigenic determinant of a 
protein and corresponds to the region of the protein that is specifically recognized by the 
antibody.48  Accordingly, epitopes are only defined in an operational or functional sense: 
anything that is bound by an antibody is, by definition, an epitope.  Therefore, epitope 
regions from proteins have been synthesized and expressed as smaller functional units 
and have been shown to bind antibodies.  Examples of these would be the FLAG or E 
tags commonly used in protein expression.23, 25   
Motivation for the design of antigen mimics is widespread in the realm of biology, 
medicine, and materials research (Figure 6).  The medical field and population health 
could improve through the establishment of antigen-fuctionalized nanoclusters, or antigen 
mimics, that act as effective, inexpensive, non-toxic vaccines for bacterial, viral, and 
toxin-related diseases, such as anthrax, ebola, respiratory syncitial virus, and small pox.   
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Figure 6.  Possible applications for immuno-functionalized nanoclusters.  (top) Non-
toxic vaccines for bacterial, viral, toxin-related disease; (middle) Nanocluster array 
for medical diagnosis or antigen mimics for sensor calibration; (bottom) Assembly of 
nanoscale architectures. 
 
 
Diagnostic techniques could also benefit from using antigen mimics to confirm immunity 
or identify disease.  Field sensors could be regularly tested using non-toxic antigen 
mimics as positive controls.  In a very different area, engineering feats could be 
performed using high-affinity interfaces to build nanoscale architectures.  These benefits 
are far-reaching future goals, but provide motivation for antigen mimic design. 
The current approach to this type of antigen mimetics is to synthesize the linear 
epitope and rely on primary structure (amino acid sequence) to provide specificity.  
Combining this type of mimetics with nanoscale materials produced the first example of 
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antigen encapsulated nanoclusters assembling with antibodies through the 
paratope/epitope interface.  A linear peptide epitope known to bind monoclonal 
antibodies associated with the human malarial parasite, P. falciparum, was used in the 
assembly of a robust, functional nanostructure that successfully mimicked a biological 
entity.21  A more recent example used glutathione-protected nanoclusters and polyclonal 
anti-glutathione antibodies.  This approach confirmed the ability to assemble epitope-
protected nanoclusters with antibodies and provided quantitative binding information 
through improved analytical techniques.2 
These two examples used nanoclusters with peptide epitopes completely covering 
their surface and were synthesized with large amounts of ligand, rather than specifically 
functionalized with small amounts of peptide.  The next step in antigen mimic design is 
to functionalize pre-existing nanoclusters through place exchange reactions described 
above.  This type of assembly provides a more complex nanostructure with three or more 
components and allowed for the use of more complicated linear and conformational 
epitopes.  In a recent study a linear peptide epitope, from the hemagglutinin (HA) protein 
related to influenza, was synthesized and specifically presented at a controlled density on 
the surface of a pre-existing tiopronin-protected cluster.49  This mimic of the HA protein 
was shown to interface with monoclonal anti-HA antibodies and was compared to a self-
assembled monolayer of the same peptide epitope. 
Linear peptide epitopes used in the malaria, glutathione, and HA examples rely on 
primary amino acid sequence to provide antigenicity and specificity.  This does not take 
into account the complex secondary structure (local conformation) exhibited by native 
proteins, which is essential to antibody recognition.  Cyclization of peptides to 
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approximate a loop structure has been used to introduce epitope conformation,50 but the 
development and presentation of a peptide epitope that reconstitutes a physiological 
conformation is an interesting alternative.  This was recently achieved through the 
bidentate presentation of a peptide epitope from a loop region of the protective antigen 
(PA) of B. anthracis.51  The conformational antigen mimic was able to interface with 
monoclonal anti-PA antibodies and showed enhanced affinity over a linear antigen 
mimic. 
This variety of antigen mimics using small molecule, linear, and conformational 
epitopes suggests multiple routes to interfacing inorganic nanoclusters with biological 
antibodies.  Many other options are also available and, together, supply a “toolbox” of 
interfaces that can be used and studied in a multitude of systems.  The three cases of 
GSH-MPC, HA-MPC, and PA-MPC are detailed in Chapters II, III, and IV, respectively. 
 
Principles and Operation of QCM 
The quartz crystal microbalance relies on the converse-piezoelectric effect, reported 
by the Curie brothers in 1880.  Piezoelectricity describes the electrical charge produced 
by pressure applied to solids having certain geometries, while the converse effect 
produces a strain on the crystal when an electric field is applied.52  Coupling the crystal to 
an oscillating circuit provides crystal oscillation at a resonant frequency (Figure 7).  
These quartz resonators have been widely used in communication devices, commercial 
acoustic electronics, and sonar.52, 53  Sauerbrey first demonstrated the usefulness of this 
effect for analytical chemistry by showing a linear relationship between mass deposited 
on the crystal and the frequency of oscillation (Eq. 2).2, 52 
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∆f = -Cf ∆m          (Eq. 2) 
 
Initially, QCM was used in the gas phase, where oscillator resistance is low and mass 
adsorption is rigid.  The device was improved in 1982 by the advent of circuitry capable 
of crystal operation in liquids.   
 
 
Figure 7.  Top and side view of a QCM resonator (top) and cross sectional view of a 
QCM resonator in contact with a liquid (bottom).  Wave propagation is relatively 
loss-less in the piezoelectric material, but becomes evanescent in the viscous liquid. 
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While this advancement introduced QCM to the world of bioanalytical chemistry, it also 
introduced new challenges.  The first is that operation in liquid slows the mass transport 
of analyte to the sensor surface.  The second is that many binding events in liquid, 
especially those biological in nature, are not static, but tend to be in equilibrium.  The 
third is resonator damping and viscous loading (Figure 7).54  It has been shown that the 
density and viscosity of the contact solution affects crystal frequency response, 
convolutes mass measurements, and requires modification of the Sauerbrey equation (Eq. 
2).52, 55  Careful consideration of simultaneous mass and liquid loading by Kanazawa56 
and Martin57 has shown that ∆f relates to adsorbed mass and the density and viscosity of 
the contact liquid, according to the following equation (Eq. 3):57 
 
∆f ~ Cf∆m – Cf(∆ρη/4πfo)1/2          (Eq. 3) 
 
It is, therefore, impossible to distinguish mass loading from liquid loading by frequency 
measurements alone.  Fortunately, the independent term of liquid loading resistance, RL, 
depends solely on density and viscosity (Eq. 4):57 
 
∆RL ~ (ηq/[c66C1]) + (NπC1)-1(∆ρη/πfoc66ρq)1/2          (Eq. 4) 
 
Measuring both changes in frequency and resistance provide a means for decoupling 
mass and liquid loading effects, though different methods have been described.2, 52, 54, 56-59  
Applying the above equations (Eq. 3 and 4) to frequency and resistance measurements to 
reliably calculate adsorbed mass has proven to be non-trivial.  A simple approach to a 
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reliable mass measurement has been to create a calibration curve of change in frequency 
as a function of change in resistance for a system in which mass loading is minimal.  In 
one case, sucrose, a hydrophilic molecule that will not independently adsorb to the QCM 
electrode, was dissolved in DI water at 0, 5, 10, 20, and 40% by weight.  Sequential 
addition of these five solutions to the QCM sensor provided simultaneous changes in 
frequency and resistance that were due to density and viscosity effects only (Chapter II, 
Figure 11).2  The relationship between frequency and resistance within this range is linear 
and provides an accurate calibration.  Above approximately 40% sucrose, the relationship 
deviates from linearity, making this approach only applicable to systems in which the 
resistance changes by less than 500 Ω.56, 60  Problems also occur with this calibration, as 
in any QCM measurement, when coupling to the sensor is non-rigid and the analyte has 
its own viscous properties.  Calibration allows for the calculation of ∆m through 
simultaneously solving equations 3 and 4 and using a sensitivity factor, Cf, of 56.6 
Hz•cm2•µg-1, which is known for a 5 MHz crystal.61  Decreasing the crystal thickness 
increases the resonant frequency and can provide enhanced sensitivity. 
Since his study of simultaneous QCM mass and liquid loading in 1991,57 Stephen 
Martin from Sandia National Laboratory and collaborators at Leicester University have 
continued to contribute experimental and theoretical-based insight into the details of 
QCM measurement in liquids.  Four contributions, since 1997, have covered resonator 
response to liquid loading,54 the modeling of resonator response under loading 
conditions,62 the modeling of viscoelastic film response,63 and a model for wetting 
characteristics of roughened surfaces.64  This collective work has provided a better 
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understanding of loading responses in QCM and has supported more rigorous evaluation 
of important systems. 
Another area of QCM sensor development has been in the area of multi-channel 
QCM.  Using arrays of resonators or micro-fluidics to partition individual resonators 
could provide the simultaneous measurements needed for multi-analyte detection 
strategies.  A significant challenge in multi-channel QCM is the isolation of each 
electrode.  Circuit shorting or resonance overlap from electrode to electrode could cause 
considerable problems.  Two approaches to this problem have made use of electrode 
miniaturization65 and the restriction of oscillation to indented areas surrounded by thicker 
quartz.66  Both of these approaches have had success in the construction of a multi-
channel QCM instrument. 
QCM has been shown to work well with 3D substrates and multilayer adsorptions 
often encountered in materials applications.2  QCM acoustic shear waves are evanescent 
and decay exponentially in the contact liquid, causing a loss of sensitivity at distances 
from the sensor surface (Figure 7).  Mass that is rigidly coupled to the sensor propagates 
the wave without loss, where viscous material causes immediate wave decay.58  The 
depth at which these waves penetrate the contact liquid affects instrument sensitivity.  
QCM, at 5 MHz, has a calculated penetration depth of 250 nm,52 with a total decay length 
of 1 µm,58 though experiments have shown no loss of sensitivity for layers as large as 400 
nm.2, 58, 67, 68  In comparison, surface plasmon resonance spectroscopy (SPR) has a 
calculated penetration depth of only 150 nm and has shown significant peak broadening 
with layers less than 200 nm.69, 70  Examples of peak broadening in SPR come from the 
use of metal nanoclusters for signal amplification.16, 71, 72  It was shown that antibody-
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presenting gold nanoclusters binding to immobilized anti-IgG increased the SPR shift as 
compared to free antibody.16, 71  This also caused broadening of the SPR curve, which 
increased in width as the density or diameter of the colloidal gold was increased.72  QCM 
has not suffered from this sensitivity loss, even at extensive adsorption.2 
A challenge in QCM, and in many biosensors, is sensor functionalization for 
improved specificity.  While the gold QCM electrode imparts almost no specificity of its 
own, it provides a substrate for a variety of functionalizations.  The gold electrode is 
amenable to hydrophobic interactions, is well-suited for self-assembled monolayer 
(SAM) formation, and enables electrochemical surface reactions.  Approaches to improve 
specificity in QCM have used SAMs,24, 43, 73 ionic interactions,74-77 electrochemical 
deposition,44, 78 and protein adsorption (Figure 8).79-81  These methods allow for the 
immobilization of a variety of biological species and nanostructures and permit a variety 
of detection schemes.  SAMs have been studied extensively42, 73, 82 and feature a defined 
orientation, high areal density, and programmability in the exposed head-group.  They 
have recently been used for the covalent immobilization of oligosaccharides24 and 
peptide epitopes.25 
Ionic layering, using polyelectrolyte75-77 or SAMs with ionic head-groups,74 has 
allowed for effective immobilization and orientation of a variety of nanoparticles.  
Though the interaction is generally non-specific, relying on electrostatic and van der 
Waals interactions, layer-by-layer growth is high tunable according to concentration, 
ionic strength, and pH.  This promotes high affinity binding, reversibility, and high 
packing density, and has been used for single layer deposition and multilayer 
nanorainbow assembly.75, 77  
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Figure 8.  Examples of QCM functionalization techniques to impart specificity.  (a) 
Self-assembled monolayers immobilize ligands in a high density and often use 
polyethyleneglycol spacers.  (b) Polyelectrolyte provides a thin layer of charge 
(positive or negative) for ionic interactions. (c) Viologen functionalized electroactive 
nanoclusters can be electrochemically deposited on the QCM surface. (d) X-ray 
crystal structure of a Protein A fragment commonly used in the immobilization of 
antibody. 
 
 
Electrode functionalization and nanoparticle immobilization has also been pursued 
with electrochemical deposition, using electrochemical quartz crystal microbalance 
(EQCM).  Viologens, such as N-(methyl)-N’-(ethylamine)-viologen dinitrate (MEAV), 
have been previously studied78 as electroactive species and are known to adhere to 
electrodes upon reversible reduction of the [viologen]2+/1+ couple.  Attachment of MEAV 
to nanoclusters allows similar adhesion to electrodes, thereby immobilizing the 
nanocluster on the QCM surface.44 
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Another route employs Protein A for immobilization of antibodies in an 
accommodating conformation.  Protein A is a cell well protein that forms stable 
complexes with gold through van der Waal interactions (Ka ~ 108 M-1)79 and contains five 
tandem domains that bind the Fc region of IgG with high affinity and selectivity.  These 
properties optimize the presentation of antibodies such that both antigen binding regions 
(Fab) are unobstructed (see also Figures 2 and 3).79-81 
Another advantage of QCM would be the ability to make time-resolved 
measurements, which allows the derivation of equilibrium binding constants and kinetic 
rate constants.  These constants provide valuable information concerning the affinity or 
avidity of one material for another, the rate at which they interact, and the interaction 
order.  A molecule’s affinity is defined through the equilibrium association constant (Ka) 
for the interaction and is generally valid for monovalent, one-to-one interactions.  Avidity 
is related to the same equilibrium process (Kv), but describes multivalent processes.  For 
example, at low ligand concentrations a multivalent ligand could bind to several 
monovalent receptors, increasing the affinity of the ligand for the receptor.  There are 
also cases of multivalent receptors with monovalent ligands as well as multivalent 
receptors with multivalent ligands.83  The complexity of these interactions can be 
daunting, especially for molecules like lectins that are designed for increased affinity 
through multivalency.  The simplest case would be the interaction of a monovalent ligand 
(an antigen, for example) with a monovalent receptor (a ScFv antibody, for example):  
Ag + Ab ↔ Ag-Ab.  The elementary equilibrium expression for the formation of the 
complex is (Eq. 5), 
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Ka = [Ag-Ab]/([Ab][Ag])          (Eq. 5) 
 
Ka is the equilibrium association constant and is generally in the range of 106 to 1012 M-1 
for monoclonal antibody interactions, indicating a large equilibrium shift to product 
formation when antigen is in the presence of antibody.  If this association and equilibrium 
shift occurs at a surface, where the first component adsorbs to the surface-supported 
second component, the equilibrium expression can be rearranged to an adsorption 
isotherm.  The adsorption isotherm represents the connection between the amount of 
substance adsorbed, the concentration of the bulk solution, and the equilibrium constant, 
Ka.  The Langmuir isotherm is commonly used and relies on three important 
assumptions:  (1) there is no lateral interaction between adsorbed species; (2) the surface 
is homogeneous; (3) the maximum adsorption is saturation to a monolayer.  Adsorption 
isotherms are sometimes written in terms of fractional coverage (Θ) or percent of 
monolayer formation.  A generalized Langmuir isotherm in this form is (Eq. 6), 
 
Θ/(1-Θ) = KaC          (Eq. 6) 
 
In the case of QCM studies, the fractional coverage is related to the change in mass (∆m) 
and the initial concentration of surface immobilized antibody is related to the maximum 
change in mass (∆mm).  Rearranging to solve for ∆m provides a commonly used form of 
the Langmuir isotherm (Eq. 7), 
 
∆m = ∆mm(KaC/(1+KaC))          (Eq. 7) 
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Plotting ∆m as a function of bulk concentration (C) shows a steep increase in adsorption 
that levels off with increasing concentration as a complete monolayer is achieved (see 
Chapter II, Figure 16).  This line can be fit to non-linear regressions, but does not provide 
a simple means for extracting the equilibrium constant.  Instead a reciprocal plot can be 
used to obtain a straight line fit.  There is more than one way to obtain a reciprocal plot 
by rearranging the Langmuir isotherm (Eq. 7).  Two options are (Eq. 8) and (Eq. 9), 
 
∆m = -(Ka)-1(∆m/C) + ∆mm          (Eq. 8) 
C/∆m = (∆mm)-1(C) + (∆mmKa)-1          (Eq. 9) 
 
In (Eq. 8) ∆m is plotted against ∆m/C and the inverse of the slope provides the Ka.  In 
(Eq. 9) C/∆m is plotted versus C and the Ka must be extracted from a combination of the 
slope and y-intercept.  Both techniques have been used in literature and provide reliable 
Ka values.2, 24, 84-86  Once the equilibrium association constant is known, it can be used to 
calculate both the fractional coverage at an infinite time point (Θ∞, Eq. 10) and the Gibbs 
free energy of adsorption (∆Gads, Eq. 11), 
 
Θ∞ = C/(C + Ka-1)          (Eq. 10) 
∆Gads = -RT lnKa          (Eq. 11) 
 
This method offers a simple way to determine equilibrium constants for systems that 
generally follow the assumptions outlined for a Langmuir isotherm, though variations on 
the Langmuir isotherm can account for more complex systems.87 
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Equilibrium association constants for antibody/antigen interactions can be determined 
with different techniques, not necessarily involving real-time measurements.  Kinetic 
information, on the other hand, requires time-resolved information.  The rate at which an 
interaction takes place can be valuable in evaluating component efficacy.  The time 
course for monolayer formation is given by (Eq. 12), 
 
Θ(t) = [C/(C+Ka-1)][1-exp(-(kfC+kr)t)]          (Eq. 12) 
 
According to (Eq. 10) Θ∞ can be substituted in and the exponent can be simplified by 
calling (kfC+kr) equal to the time constant, τ−1, (Eq. 13), 
 
Θ(t) = Θ∞[1-exp(-τ−1t)]          (Eq. 13) 
 
For a given concentration of the bulk solution (C), Θ(t) is related to ∆m at a particular 
time and Θ∞ is related to the maximum change in mass (∆mm, Eq. 14), 
 
∆mt = ∆mm[1-exp(-τ−1t)]          (Eq. 14) 
 
Fitting (Eq. 14) to each time point in the real-time adsorption binding curve yields the 
time constant.  Knowing the concentration of the bulk solution allows the extraction of 
forward (kf) and reverse (kr) rate constants.  The ratio of these kinetic constants is equal 
to the equilibrium constant (Ka = kf/kr) and can be used for comparison with isotherm 
methods. 
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QCM Applications to Life Sciences 
The benefits of QCM and detailed functionalization strategies have allowed the study 
of many biological and chemical systems.52, 88  An early and notable example of a 
chemical study, is the direct kinetic measurements of thiolate molecules self-assembling 
on two-dimensional gold surfaces.82  This helped provide a foundation for QCM kinetic 
studies and was quickly followed by a kinetic study of antifluorescyl antibody binding to 
fluorescein lipids in Langmuir-Blodgett films.85  The fluorescein hapten was coupled to 
lipids and mixed with unfunctionalized lipids to form a bilayer with approximately 5% 
fluorescein lipid.  Through QCM measurements, monoclonal antibody was found to have 
an affinity (Ka) in the range of 107 - 108 M-1 and forward and reverse rate of reaction 
constants of approximately 2 x 105 M-1s-1 and 2 x 10-3 s-1, respectively. 
More recently, Zeng, et al. conducted two immunoassay experiments using QCM.23, 24  
The first was a study of α-Gal carbohydrate antigen as anti-Gal antibodies are of interest 
for therapeutics in xenotransplantation.  Thiolated trisaccharides were immobilized on the 
surface of the QCM through the formation of a self-assembled monolayer and exposed to 
polyclonal anti-Gal antibodies, a lectin from Griffonia simplicifolia, and a lectin from 
Marasmius oreades.  The antibody displayed the strongest binding, with a dissociation 
constant (Kd) three orders of magnitude greater than either of the lectins.   They 
concluded that this QCM approach is competitive with established label-free 
techniques.24  The second immunoassay made use of single-chain fragment variable 
(ScFv) antibodies to increase the surface density of antigen binding sites (Figure 3).  The 
recombinant antibodies were genetically engineered to contain a linker arm and cysteine 
residue to ensure self-assembly in a defined orientation.  Considering their size (27 kDa) 
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and ease of engineering, they have a considerable advantage over Fab fragments or full-
sized IgG for the detection of antigen.  The ScFv antibodies were initially expressed and 
evaluated using SDS-PAGE and Western Blot Analysis.  After immobilization on the 
QCM gold electrode, the monolayer assembly was verified electrochemically with cyclic 
voltammetry and electrochemical impedance.  This confirmed surface coverage, but 
provided no information on antibody orientation.  The ScFv rabbit anti-IgG antibody was 
successful in detecting rabbit IgG down to 1.1 nM, which is more than 7 times lower than 
that detected with an anti-IgG Fab fragment sensor.  Another benefit of this system is the 
reversibility of IgG binding coupled with the stability of the ScFv monolayer to allow 
regeneration and reusability of the sensor.23 
A piezoelectric immunosensor has also been developed for the detection of 
aerosolized SARS-associated coronavirus (Figure 9a).89  Since the introduction of 
circuitry able to operate QCM in liquids, gas phase measurements have primarily been 
used in metal vapor deposition techniques, rather than biological studies.  A 
functionalized QCM crystal could be used as a biological “nose” for the detection of 
aerosolized agents, such a coronavirus.  In this example, polyclonal anti-SARS-CoV was 
presented on the gold QCM electrode through a specific Protein A intermediate.  Antigen 
powder was then reconstituted in the saliva of a healthy volunteer and aerosolized in the 
presence of the sensor.  The antigen bound quickly to the antibody and was detected at 
concentrations down to 0.60 mg/mL. 
Many other interesting and pertinent biological systems have been studied, including 
the use of glycosphingolipids for detection of ricin,90 the use of high resonant frequency  
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Figure 9.  Representative QCM-based sensors for chemical, biological, and 
immunological applications.  (a) QCM immunosensor for aerosolized SARS-
associated coronovirus; (b) EQCM chemical sensor using change in electron flow 
through nanoparticle films; (c) QCM DNA base mismatch detection using gold 
nanoparticle growth for signal amplification; (d) QCM immuno-detection of lung 
carcinoma cells and gold nanoparticle growth for signal amplification. 
 
 
quartz crystals (39 to 110 MHz) for the detection of phages,91 and the study of annexin 
A1 binding to solid-support membranes.92  A complete review of QCM applications to 
the life sciences is not the scope of this chapter, though other sources can be consulted for 
further examples.52, 88 
 
QCM Nanoparticle-based Chemical Sensors 
The evaluation of interfaces between biology and nanotechnology has been an area of 
recent research interest, but originally started through the early development of chemical 
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sensors.  Originally, QCM was designed for gas phase measurements and has been used 
in the control of metal vapor deposition.  QCM continues to be used for gas phase 
measurements, but has employed polymer and nanoparticle films for organic vapor 
sensing.93-95  In 2001, dodecanethiol MPCs of 2 and 5 nm diameter were covalently 
assembled on a QCM substrate through dithiol linkages or non-covalently through 
carboxylic acid hydrogen bonding.93  The nanoparticle thin-layers were then studied for 
their ability to partition toluene, hexane, methanol, ethanol, and water vapors.  Vapor 
sorption was detected by simultaneous monitoring of frequency and resistance.  Results 
suggested the viability of nanostructure films for vapor sensing and highlighted 
similarities and differences between the size of MPC used and the assembly technique. 
Shortly thereafter, Zamborini, et al used electrochemical QCM to simultaneously 
measure conductivity and vapor partitioning in MPC films (Figure 9b).94  This approach 
used small (1.6 nm diameter) nanoclusters with mixed monolayers of alkanethiolate and 
ω-carboxyalkanethiolate.  The free carboxylic acid was used in conjunction with Cu2+ 
ions to assemble a network polymer of carboxylate-Cu2+-carboxylate bridges.  These ion 
bridges allowed for electron transport through the polymer, while film swelling due to 
vapor partitioning (ethanol or dichloromethane) diminished electron flow. 
Another example95 made use of a greater variety of nanoclusters, protected with 
dodecanethiol, benzenethiol, 4-chlorobenzenethiol, 4-bromobenzenethiol, 4-
(trifluoromethyl)benzenethiol, 4-hydroxybenzenethiol, and 4-aminobenzenethiol.  
Nanoparticle films were spray coated onto a QCM substrate and monitored by QCM to a 
final change in frequency of ~10,000 Hz.  It was important to deposit a film with a 
thickness large enough to partition vapor, but small enough to rigidly couple the entire 
 30
film to the sensor, maintaining an accurate sorption response.  Motional resistance was 
monitored during film deposition to ensure rigidity as resistance is related to film 
viscoelastic properties.  Results implied that different nanocluster films had increased 
sensitivity for different vapors (hexane, toluene, butanone, and butanol) and compared 
with vapor partitioning into organic polymers. 
 
QCM Nanoparticle-based Biosensors 
Inspired by the success of QCM bioassays and bionanotechnology, researchers have 
developed nanoparticle-based detection schemes using QCM for improved sensitivity.  A 
popular area of analytical biochemistry involves the detection of DNA for a range of 
applications from gene analysis to forensic applications, where low detection limits are 
required.  Willner, et al. have developed three different amplification paths for the 
detection of single-base mismatches in DNA with QCM detection (Figure 9c).96-98  Each 
path begins with the immobilization of ssDNA (25 bases) through SAM technology.  Its 
complimentary strand with an extra 16 bases is then introduced and allowed to base pair.  
In some cases a compliment DNA strand with a single base-pair mismatch is purposely 
assembled.  This allows for a single nucleotide, coupled with biotin, to bind at the 
mismatch site.  At this point, three different approaches can be used:  (1) free avidin can 
bind to the base-pair biotin, followed by biotin-labeled liposome binding; (2) avidin-
labeled nanocluster can bind, followed by controlled nanoparticle growth for 
amplification; (3) avidin-labeled alkaline phosphatase can bind and catalyze the 
precipitation of an insoluble organic product for amplification.  These methods lead to 
mismatch detection with detection limits ranging from 10-12 – 10-16 M.  The QCM 
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gravimetric technique is well-suited for these types of precipitation/amplification 
schemes. 
A similar approach to DNA hybridization detection and amplification also uses 
avidin-labeled alkaline phosphatase (as above).99  In this case, the enzyme catalyzes the 
production of the reducing agent, p-aminophenol, from a p-aminophenyl phosphate 
precursor.  The reducing agent reduces Ag+ ions in solution, which biomineralize into Ag 
nanoparticles on the DNA strand or on the QCM sensor surface, causing QCM signal 
amplification.  The deposited silver can then be used in anodic stripping voltammetry to 
further confirm DNA binding, down to 100 aM concentrations. 
 
QCM Nanoparticle-based Immunosensors 
The design, synthesis, and assembly of functional nanostructures are important 
challenges in the interface with immunology.  Finding key recognition units and 
presenting them in the appropriate environment and conformation are crucial to 
programming material specificity and affinity.  A unique and creative idea for interface 
assembly may provide a good starting point, but redesign and optimization is difficult 
without a method for evaluating the proposed interface.  The understanding of an 
interaction places interface development and application within reach.  Traditional 
techniques have supplied qualitative information on antibody recognition for interface 
design and are widely used.  Nanotechnology has expanded immunoassay options for the 
study of more diverse systems and, combined with QCM, provides a label-free, 
quantitative alternative.  These analytical techniques can determine structural integrity of 
assembled nanoarchitectures, can provide equilibrium and kinetic binding constants of 
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biological entities, and can detect analytes (antibodies, toxins, etc.) for medical diagnostic 
applications. 
Radiolabelled immunoassays were one of the first techniques used in the detection of 
antibody or antigen in biological systems.  In this assay, radioisotopes, commonly 125I, 
were used to label the antibody or antigen and scintillation counters measured the gamma 
or beta emission of the isotope.  This provided low detection limits needed for 
immunoassays, but regulation of radioactive isotopes made this technique inconvenient to 
use.100 
Another standard immunoassay is the enzyme-linked immunosorbant assay (ELISA).  
Its success comes from the ability to amplify binding through an enzyme reaction, which 
produces a spectroscopic signal.  There are many formats for an ELISA experiment, 
though the indirect sandwich assay format has been widely accepted.  In this format, the 
primary antibody is immobilized on a solid support (typically a well-plate) and antigen is 
allowed to bind.  A second, polyclonal antibody for the antigen from a different species 
than what was used as the primary antibody is then added and binds to the other side of 
the immobilized antigen, creating a “sandwich”.  An antibody that recognizes the second 
antibody (an anti-antibody) is functionalized with an enzyme (typically horseradish 
peroxidase) and allowed to bind.  Finally, a substrate for the enzyme is introduced, which 
produces an enzyme product that is chromogenic.  The chromophore is detected by 
conventional spectroscopic methods.12  While the signal amplification from the enzyme 
reaction is beneficial, there are certain limitations to ELISA experiments.  A lack of 
simple quantitation and excessive time required to assemble the complex 
immunomolecular biosensor, as in the case of an indirect sandwich assay, are poignant 
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drawbacks.  An example is the recent development of a quantitative ELISA assay for the 
detection of human IgG, which requires 19 hours from analyte immobilization to 
chromophore detection.101  Other limitations include the need for labeling with a bulky 
enzyme, which could interfere with the antibody/antigen interaction, and the nonspecific 
adsorption of analyte to a hydrophobic well plate could lead to random orientation of 
binding sites and possible denaturation of substrate.12 
Surface plasmon resonance spectroscopy (SPR) has recently been used for the 
detection of antibody binding.  The details of SPR phenomena have been previously 
outlined.70, 102  Briefly, SPR is an optical technique that takes advantage of plasmon 
excitation in bulk metal by wave vector matched photons.  The photons induce 
oscillations of free electrons in the metal, which then propagate an additional field into 
the contacting dielectric medium.  The plasmon excitation requires a transfer of energy 
from the photons, which can be observed through the sharp minimum of reflectivity 
during resonance, leading to an SPR signal.102  Therefore, measuring the change in 
reflection angle provides real-time, label-free detection of antigen/antibody interaction.  
SPR has been used to study several different systems, an example being the 
characterization of FLAG peptide epitope arrays.25  Important drawbacks of the SPR 
method are the complicated and expensive optics required for operation, loss of 
sensitivity at distances from the sensor, and interference from molecules with high molar 
absorptivity (Chapter II). 
Radiolabelling, ELISA, and SPR are important and effective techniques for the 
evaluation of traditional antibody/antigen interactions.  Inorganic materials, such as 
nanoclusters, offer useful spectroscopic and nanoscopic properties that can make analysis 
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convenient, but can also introduce added challenges.  One of the first interfaces between 
materials and antibodies13 was designed because radiolabel immunoassays were 
cumbersome and enzyme immunoassays require delicate procedures.14  The potential of 
materials was harnessed to design a more simple method and successfully used antibody-
functionalized latex beads and turbidity measurements to detect agglutination.13, 15  
Improvements to this method quickly followed using electric pulses to promote 
antibody/antigen interaction and decrease reaction time.14 
A similar, though more recent, nanoimmunoassay also used antibody-functionalized 
particles.  These 70 nm diameter silica particles had exterior antibody functionalization 
and interior fluorophore entrapment.  Fluorescent-labeling techniques have enjoyed long-
lived success, though low fluorescence intensity and photoinstability have been recurring 
problems.  Encapsulation of Ru(bpy)32+ fluorophore in silica nanoparticles yielded high 
intensity fluorescence and increased photostability due to exclusion of damaging 
oxygen.103  These nanoparticles were compared to popular quantum dots (QDs), which 
are semiconductor nanoparticles with intense intrinsic fluorescence, and were found to 
have similar intensity and stability.  Antibody-functionalized QDs have also been used as 
fluorescent tags for the imaging of live cells.26, 104 
Metal nanoparticles have been used as electrochemical labels for the simultaneous 
detection of four antigens, β2-microglobulin, IgG, bovine serum albumin, and C-reactive 
protein.20  In this experiment, a large magnetic bead was functionalized with four types of 
antibodies corresponding to the four different antigens.  After binding antigen to the 
antibody on the magnetic bead, antibody with unique nanoparticle labels bound to the 
immobilized antigen.  Collection of the nanoparticle-labeled antibody and detection with 
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square-wave stripping voltammetry provided four unique signals from the reduction of 
four unique metal nanoparticles.20 
A microscopic technique often used in nanocluster characterization, but not in 
immunoassay, is transmission electron microscopy (TEM).  Metal nanoclusters absorb 
electrons, making them visible in TEM, while small carbon-based molecules do not.  In a 
recent study, antibody-functionalized nanoparticles were incubated with pathogens 
Staphylococcus saprophyticus and Staphylococcus aureus and examined with TEM.  
Functionalized nanoclusters bound to antibody binding sites and were detected.  
Furthermore, bacteria-bound magnetic particles were collected, thereby concentrating 
target pathogens.19 
Success with traditional immunoassay formats prompted SPR research in the area of 
nanoimmunotechnology.  In 1998, the Natan group showed SPR signal amplification of 
antibody-nanocluster complex binding as compared to free antibody.16  The usefulness of 
this technique was confirmed with the detection of human complement factor 4 (C4) and 
C4 attached to colloidal Au particles.105 
These techniques, along with others, have had some success in the evaluation of 
interfaces between immunology and nanoscale materials.  They also have their 
drawbacks.  Many suffer from a lack of sensitivity and use large diameter particles (50 – 
1000 nm) with relatively low surface area.  Others rely on labeling to provide a detectable 
signal, which can interfere with recognition events and change the immunoassay 
dynamics.  In the case of SPR, nanoparticle labeling is used to acquire enhanced binding 
signals.  Unfortunately, this has also been shown to significantly broaden peaks, leading 
to a loss of sensitivity, complicated time-resolved measurements, and limited structural 
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information.69, 70  Efforts to develop a label-free, time-efficient, quantitative assay format 
that allows for 3D substrates and multilayer adsorptions have involved the quartz crystal 
microbalance (QCM).2 
Piezoelectric biosensors developed since 1990 have gained ground on traditional 
labeling experiments and on competing label-free instrumentation such as SPR.52, 106, 107  
The field of QCM immunosensors has also developed rapidly.88  Considering the age of 
the new, though explosive, field of nanotechnology (the Brust nanoparticle synthesis was 
published in 1994), QCM immunosensors for nanotechnology applications are limited.  
One example used gold nanoparticle growth to amplify antibody-mediated lung 
carcinoma cell detection using QCM (Figure 9d).108  In these experiments a monoclonal 
antibody to cell surface antigen was immobilized on a polystyrene film and captured lung 
carcinoma cells.  The same antibody conjugated to 10 nm diameter citrate-reduced gold 
nanoparticles bound to the immobilized cell in a typical sandwich scheme.  Auric acid 
and NH2OH were then introduced, reacted with the pre-existing gold nanoparticle, and 
caused the nanoparticle to grow.  This growth created an increased QCM signal and 
allowed for the detection of cells at levels as low as 100 cells/mL.  This method provided 
results similar to ELISA, but was less time consuming.   
Another example used polymer immobilized colloidal gold particles (~ 15 nm 
diameter) as an alternative approach to antibody immobilization.109  Thiol-terminated Fab 
antibody fragments will often denature on an unprotected hydrophobic gold QCM 
electrode, but retained activity when bound to the polymer/nanogold mixture.  This 
nanoparticle-based immunosensor supplied a means for phenotyping leukemia cells for 
medical diagnostics with detection limits of 6000 cells/mL.  An important technical detail 
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of this work was the ability to detect four different phenotypes simultaneously using an 
array of QCM sensors. Other nanoparticle-based QCM immunosensors have made use of 
peptide epitope functionalized nanoclusters (Chapters II-IV). 
 
Conclusions and Future Directions 
The future of bionanotechnology lies at the interface between biology and inorganic 
nanomaterials and relies on the ability to probe and evaluate that interface.  Many 
analytical techniques, including AFM, TEM, NMR, and molecular imaging, have been 
developed for this very purpose, for the analysis of all types of interfaces.  The quartz 
crystal microbalance is another technique that has evolved to become a central tool in the 
study of both biological and nanomaterials applications.  QCM has principal advantages 
for the investigation of bionanotechnology over existing immunological techniques:  low 
cost and ease of operation, quantitation, real-time measurements, and large wave 
penetration depth, to name a few.  For these reasons QCM technology has been applied to 
the exploration of a variety of life science applications.  Quartz crystal microbalance 
nanoparticle-based immunoassays are a relatively new field, but have been designed for 
the evaluation of several antigen mimics.  Specifically, QCM has shown that antibody 
can recognize and interface with immunoreactive nanomaterials designed with linear and 
conformational peptide epitopes presented on the surface of monolayer protected clusters.  
This is only one interface that QCM has successfully characterized.  Given the virtues of 
this technique and the vast number of possible combinations between biology and 
nanotechnology, more systems will doubtlessly be studied. 
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The prospects of biotechnology and nanomaterials science are most promising at their 
interface, where they overlap in the emerging field of bionanotechnology.  This 
interfacial discipline further relies on analytical techniques that can probe the boundary 
where they meet.  The quartz crystal microbalance is certain to be an integral tool in the 
exploration of this frontier.  Specifically, QCM can expand its applicability through the 
design of new immobilization strategies for repeated, reversible interactions.  An 
improved, commercially available, multichannel detection apparatus will improve 
throughput and multiplexing.  In the realm of medical diagnostics and defense-based 
toxin detection, a blood sample, water-way, or gaseous area could be largely 
characterized through multi-analyte detection.  This is possible because of the portability, 
low cost, and ease of use of existing QCM instruments and potential devices.  
Furthermore, advances in nanotechnology and improved understanding of biology will 
produce smart sensors and functional devices capable of carrying out an environmental 
analysis or capable or modulating an environment.  Continued research on advanced 
nanomaterials in a biological paradigm using an effective QCM transducer can make this 
a reality. 
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CHAPTER II 
 
QUARTZ CRYSTAL MICROBALANCE DETECTION OF GLUTATHIONE- 
PROTECTED NANOCLUSTERS USING ANTIBODY RECOGNITION 
 
Introduction 
Biosensors, particularly immunosensors, have received increasing attention in recent 
years due to the threat of bioterrorism,101, 110 the emergence and proliferation of 
disease,101, 111, 112 and the promise of biotechnology.5, 6, 21, 113  Enzyme-linked 
immunosorbant assay (ELISA) has become a standard detection method for its ability to 
amplify a spectroscopic signal from an enzyme reaction, but certain obstacles have 
limited its success.  These limitations include a lack of simple quantitation and excessive 
time required to assemble the complex immunomolecular biosensor, as in the case of an 
indirect sandwich assay.12  A case in point is the recent development and qualification of 
a quantitative ELISA assay for the detection of human IgG.  The outlined procedure 
requires 19 hours from analyte immobilization to binding confirmation by chromophore 
detection.101  Furthermore, chromophore, fluorophore, or enzyme tags required for 
detection can affect the antigen/antibody (Ag/Ab) interaction and non-specific adsorption 
of analyte to a hydrophobic well-plate can lead to random orientation of binding sites and 
possible denaturation of substrate.12  These issues present formidable challenges to 
accurate quantitation using ELISA.  
Efforts to develop a label-free, time-efficient, quantitative assay format that allows 
for 3D substrates, multilayer adsorptions, and non-rigid biological recognition are an area 
of concentrated research interest.52   Two techniques that have emerged are surface 
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plasmon resonance spectroscopy (SPR) and the quartz crystal microbalance (QCM).  
Both techniques make use of wave-propagation phenomena: QCM uses acoustic waves 
and measures the frequency of acoustic impedance minimum, and SPR uses optical 
waves and measures the angle of reflection minimum.  Similar performance is observed 
for both methods in detection limit, sensitivity, speed of real-time detection, and flow 
capabilities.106, 107  These benefits have allowed SPR to become a widely used 
technique,25, 114 but important advantages make QCM an attractive alternative for 
immunosensing.  Advantages include the ease of setup and operation and the low cost of 
QCM as compared to the complicated and expensive optics of commercial SPR.  Another 
advantage of QCM is the ability to work with 3D substrates and multilayer adsorptions.  
Due to evanescent shear waves, the sensitivity of both QCM and SPR exponentially 
decays with the thickness of substrate adlayer.  Sensitivity depends on the depth at which 
these waves penetrate the contact liquid.  Penetration depths have been calculated to be 
150 nm in SPR and 250 nm in QCM (at 5 MHz), with a total decay length as large as one 
micron for QCM.52, 58, 68, 106  Experimentally, QCM showed no loss of sensitivity for 
layers as large as 400 nm,58 where SPR showed significant peak broadening with layers 
less than 200 nm.69  This peak broadening not only affects sensitivity, but can influence 
time-resolved measurements and limit information on structural effects.69, 70 
Examples of peak broadening in SPR come from the use of metal nanoclusters for 
signal amplification.16, 71, 72, 115  It was shown that binding of antigen-presenting 
nanoclusters to immobilized antibody increased the SPR shift as compared to free antigen 
binding.16, 71  This technique has been touted as a label-dependent amplification scheme 
for small molecules that are not readily detected by traditional SPR and compares to 
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amplification possibilities using antigen-nanoclusters, DNA-nanoclusters,116 or DNA-
liposomes98 with QCM.  A result of this amplification is the increased broadening of the 
SPR curve with increased density of nanocluster or diameter of nanocluster.72  QCM has 
not suffered from this loss of sensitivity, even for extensive nanocluster adsorption 
(below).  
Benefits of QCM have allowed a number of biological and non-biological systems to 
be studied.  The development of an immunosensor for rapid detection of the food 
pathogen, Listeria monocytogenes, was reported117 and a study of stain formation as 
related to the large commercial market for tooth-whitening products was performed.118  
More recently, a study between α-Gal oligosaccharide and anti-Gal antibody for 
therapeutics in xenotransplantation24 and the development of an immunosensor for the 
detection of SARS-associated coronavirus89 have been completed.  An important non-
biological system studied with QCM was the determination of adsorption kinetics of self-
assembled monolayers (SAM) for materials and separations applications.82  A more 
complete review of QCM and its application to life sciences was recently reported.52 
This success does not imply that QCM is without challenge.  Inherent complications 
include determination of a reliable relationship between frequency and adsorbed mass 
and the functionalization of a non-specific Au electrode surface.24  Progress towards a 
reliable mass measurement has been facilitated by co-determination of oscillation 
frequency and damping resistance, but the mathematical relationship between the two 
terms remains complicated.56, 57  In 1959, Sauerbrey discovered a linear relationship 
between the frequency response of an oscillating piezoelectric crystal and mass deposited 
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onto that crystal. This is mathematically expressed by the Sauerbrey equation (Eq. 2),52, 
57, 61  
 
∆f = -Cf ∆m          (Eq. 2) 
 
where, ∆f is the change in frequency, Cf is the sensitivity factor, and ∆m is the change in 
mass.  This relationship holds for mass loading that is rigid and strongly coupled, but has 
been shown to overestimate mass adsorption in liquid loading, viscoelastic samples, and 
in non-rigid recognition and binding of biological molecules.24, 52  Careful consideration 
of simultaneous mass and liquid loading has shown that ∆f relates not only to adsorbed 
mass, but also to the density and viscosity of the contact liquid, as seen in Eq. 3,56, 57 
 
∆f ~ -Cf ∆m – Cf (∆ρη/4πfo)1/2          (Eq. 3) 
 
where, ∆ρ is the change in density, ∆η is the change in viscosity, and fo is frequency of 
the unperturbed crystal.  As such, it is impossible to distinguish between mass adsorption 
and liquid loading by measurement of resonant frequency alone.  Fortunately, the 
independent term of liquid loading resistance, RL, depends solely on density and 
viscosity, according to Eq. 4.57, 59 
 
∆RL ~ (ηq/[c66 C1]) + (NπC1)-1(∆ρη/πfsc66ρq)1/2          (Eq. 4) 
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Measuring both changes in frequency and resistance permits decoupling of mass loading 
and density and viscosity effects.57  A simple approach has been to create a calibration 
curve of change in frequency as a function of change in resistance for a system in which 
mass loading is minimal.  This calibration allows for an adjusted frequency to be 
calculated, which is due to mass loading only.  Adjusted frequency is then reliably 
converted to mass according to the sensitivity factor, Cf, which is known to be 56.6 
Hz*cm2*µg-1 for a 5 MHz crystal.52, 61 
Approaches to improve specificity in QCM have used self-assembled monolayers,24, 
42, 73 ionic layering,74, 75 and electrochemical deposition.44, 78  Another route employs 
Protein A for immobilization of antibody in an accommodating conformation.  Protein A 
is a cell wall protein that forms stable complexes with Auo through van der Waal 
interactions (Ka ~ 108 M-1)80 and contains five tandem domains that bind the Fc region of 
IgG with high affinity and selectivity.  These properties optimize the presentation of 
antibodies such that both antigen binding regions are unobstructed.79, 80  With these 
improvements and previous advances, QCM continues to move forward as an effective 
analytical tool for immunosensing. 
Monolayer-protected clusters (MPC) are nanoscale substrates whose unique 
properties of size and high ligand valency make them a potentially interesting platform 
for epitope presentation.  MPCs consist of nanometer-sized metal cores that are 
completely passivated and protected by organic molecules through surface metal-sulfur 
bonds.  They have received considerable attention for the unique consolidation of self-
assembly techniques and metal materials chemistry, as well as for their chemical, 
electronic, and physical properties, a lack of air and water sensitivity, and convenient 
 44
characterization.31, 34, 39  Programmed specificity through the introduction of biologically 
relevant molecules is one of their most promising features and lends to the objective of 
creating functional nanodevices as protein mimics or to the assembly of nano-scale 
architectures.  Progress towards these goals began with use of micron-sized immuno-
latex beads, which had a small amount of antibody non-specifically adsorbed to the 
hydrophobic latex surface.15  Nam, et al. then created an immunoassay using micron 
diameter immuno-magnetic particles in conjunction with 13 nm diameter DNA/antibody 
derivatized gold clusters.17  Use of even smaller particles took further advantage of 
increased surface area and multivalency of biologically active ligand through the 
functionalization of various metal cores ranging from 3 to 12 nm diameter.21  A peptide 
epitope known to bind monoclonal antibody associated with the human malarial parasite, 
Plasmodium falciparum, was used and through a qualitative detection scheme it was 
shown that antigen-encapsulated nanoclusters could bind their target antibody.21  
Through the development of a quantitative QCM binding assay, research presented here 
demonstrates the feasibility of accurate recapitulation of an epitope on a MPC.  
Furthermore, it provides a method for detecting nanocluster-antibody interactions, which 
will be important to future studies of the nanomaterials/immunology interface.  
 
Experimental 
 
Chemicals 
 Gold shot (99.99%) was purchased from precious metal vendors and was initially 
converted to HAuCl4•3H2O by boiling Au0 in HCl/HNO3 solution.119  N-(2-
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mercaptopropionyl) glycine (tiopronin, reagent), Protein A (recombinant from E. coli, 
>95%), bovine serum albumin (BSA, fraction V, 96%), and sodium phosphate 
(monobasic, reagent) were purchased from Sigma.  MUA (11-mercaptoundecanoic acid) 
(95%) was obtained from Aldrich.  Glutathione (reduced, 98%) was purchased from 
Acros.  Copper (II) perchlorate hydrate, iron (II) perchlorate hydrate, iron (III) 
perchlorate hydrate, zinc (II) perchlorate hydrate, and calcium chloride hydrate were 
obtained from Alfa Aesar company as reagent grade.  Anti-glutathione rat polyclonal 
antibody was purchased from Abcam Ltd.  NMR solvents were obtained from Cambridge 
Isotope Laboratories and water was purified using a Modulab Water Systems unit (~18 
MΩ).  Buffers were prepared according to standard laboratory procedure.  Other 
chemicals were reagent grade and used as received. 
 
MPC Synthesis and Characterization 
Nanometer-sized gold MPCs were synthesized with glutathione (GSH) and tiopronin 
as passivating substrates, as previously described.30, 31  Briefly, GSH particles were 
synthesized by co-dissolving GSH and HAuCl4•3H2O in a 3:1 molar ratio in water, 
stirring for one-half an hour, and cooling in an ice bath.  NaBH4 was then added in a 10x 
molar excess of gold. Stirring proceeded one hour followed by removal of solvent under 
vacuum and lowering of pH to ~1 with HCl.  Purification was achieved by dialysis with 
cellulose ester membranes (Specta/Por CE, MWCO = 10,000).  Tiopronin clusters were 
synthesized in a similar manner.31  Characterization techniques for all MPCs are 
described below: 
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Nuclear Magnetic Resonance. Proton NMR experiments were run at 300 MHz on a 
Bruker DPX-300 instrument with 5 sec relaxation times. Samples were dissolved in D2O 
or D2O with 10 mM sodium phosphate. 
UV/vis Spectroscopy. Scans from 200-800 nm were taken of aqueous solutions in a 1 
cm quartz cell and recorded with a Cary 100 BioSpectrophotometer. 
Transmission Electron Microscopy. TEM images were taken on a Philips CM20 
instrument after applying aqueous MPC samples to Formvar-coated 200 mesh copper 
grids (Ted Pella). The microscope operated at 200 keV with magnification in the range of 
150 - 540000x. 
Thermogravimetric Analysis. Percent organic by weight was determined by TGA on 
a TA Instruments TGA 2950 Module with Thermal Analyst 3100 using aluminum pans. 
Approximately 10 mg of MPC were dried, placed in a desiccator overnight, and analyzed 
under nitrogen from 0 to 550 oC. 
 
Quartz Crystal Microbalance 
 Two separate Quartz Crystal Microbalance instruments were used in the detection of 
binding events.  Initial experiments involving ionic layering with transition metal ions 
were completed on a battery-operated, QCM oscillator circuit of local design with a 
Fluke PM6681 Frequency Counter.  The instrument was interfaced with a National 
Instruments GPIB card and was controlled with a LabVIEW 6i software program 
specifically designed for the instrument.  The quartz crystal was held in a custom-
designed glass cell between ¾ in. o-rings with a spring-loaded clamp and connections 
were made by attaching wires with silver epoxy (Epoxy Technology, EPO-TEK).  The 
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glass cell was capped to prevent solvent evaporation and magnetic stirring was used 
when necessary.  One inch, Ti/Au, AT-cut, polished, 5 MHz quartz crystals were 
purchased from Maxtek, Inc.  This circuitry did not allow for ∆RL measurements, making 
mass calculations suspect.  As such, data (Figure 14) is plotted as ∆f and approximate ∆m 
is listed. 
All other experiments were completed using a Research Quartz Crystal Microbalance 
(RQCM) with phase-lock oscillator, Kynar crystal holder, flow cell (100 µL cell volume), 
and 1 in., Ti/Au, AT-cut, polished, 5 MHz quartz crystals, all purchased from Maxtek, 
Inc.  The holder was mounted with crystal face positioned 90o to ground to minimize 
gravity precipitation onto the surface.120  A Variable Flow Mini-Pump (Ultra Low Flow) 
peristaltic pump with 1/16 in. silicon tubing was purchased from Fisher and used with the 
flow cell at rates in the range of 10 to 36 µL/min.  Fresh tubing was cut before each run 
in order to keep contamination to a minimum and limit flow-rate deviations.  The RQCM 
phase-lock oscillator provided loading resistance measurements and allowed for the 
examination of crystal damping resistance during frequency measurements. A calibration 
of resistance change as correlated to change in frequency and change in density and 
viscosity was completed using varying concentrations (0 to 40% w/w) of sucrose in 
water.  All measurements were made at room temperature.  Sensitivity is known to be 
56.6 Hz*cm2/µg for a 5 MHz crystal and a sensitive area of 1.28 cm2 was used.61, 87 
 
Immunosensor Assembly 
Detection of substrate binding was possible through the assembly of a sensitive and 
selective immunosensor.  Two different sensor assemblies were used for the detection of 
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antibody.  Initial experiments involved the immobilization of nanocluster on the surface 
of the quartz crystal gold electrode.  This was achieved by first forming a self-assembled 
monolayer (SAM) on the gold electrode.  Prior to formation, the gold electrode was 
cleaned with piranha (3:1 H2SO4/H2O2) and by electrochemical cycling for 15 min in 0.5 
M H2SO4 from 0.1 to 1.3 V at 0.1 V/s.  The SAM was assembled by soaking the Au in a 
5 mM solution of 11-mercaptoundecanoic acid in ethanol for 24 hours.  After rinsing 
with 1 mM aqueous NaOH and ethanol, excess metal perchlorate (Cu2+, Zn2+, Fe2+, Fe3+, 
Ca2+ [as chloride]) was added in ethanol or ethanol/water mixtures.  Rinsing with ethanol 
continued, the gold was placed in ethanol, and excess GSH-MPC was added in a small 
amount of 1 mM aqueous NaOH. 
The second immunosensor assembly consisted of the purchased quartz crystal with 
Au electrode, Protein A, and polyclonal antibody.  In order to assemble the 
immunosensor, the Au electrode was first cleaned with piranha, a 3-to-1 mixture of 
concentrated H2SO4 and 30% H2O2, rinsed with ethanol, and cleaned in a Jelight UVO-42 
ozone cleaner.  The crystal was then mounted in the holder/flow cell, rinsed with 50 mM 
pH 7.2 phosphate buffer (PB), and brought to resonant frequency.  Protein A was 
dissolved in equal parts PB and 0.1 M sodium acetate buffer (pH 4.5) to a concentration 
of 4.5 µM and pumped through the flow cell at 36 µL/min for 45 min.  After a 10 min 
rinse with PB, BSA (76 µM) in PB was pumped for 10 to 20 min at 36 µL/min.  Again, 
the crystal was rinsed with PB for 10 min.  Polyclonal antibody in PB had a total protein 
concentration of 0.76 µM and was pumped through the flow cell at 28 µL/min until the 
saturation point was reached (usually 90 to 120 min).  Total protein concentration was 
determined spectroscopically with a Bio-Rad Protein Assay kit, using BSA for 
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calibration, and a Bio-Tek Synergy HT spectrophotometer.  Antibody binding was 
followed by 10 min of rinsing with PB, making the sensor ready for analyte binding. 
 
Analyte Detection 
 In the case of immunosensor assembly by ionic layering, the structure was rinsed with 
10 mM phosphate buffered (pH 7.4) saline (0.1 M NaCl) solution (PBS) and placed in 
PBS.  Ten microliters of polyclonal antibody was then added directly into solution and 
stirred for a short period of time (~2 sec).  Diffusion of antibody to the crystal was 
allowed over 2 - 6 hours. 
In the case of antibody immobilization via Protein A, two nanocluster detection 
strategies were used.  The first detection method involved constant flow of analyte in PB 
at various concentrations over extended periods of time.  Concentrations of GSH-MPC 
ranged from 0 to 10 µM, control analyte was 4.1 µM Tiop-MPC or 1.0 mM free GSH.  A 
flow rate of 36 µL/min was used and adsorption values were recorded after 100 minutes 
or several hours of addition.  Control experiments were conducted as above and newly 
prepared immunosensors were used for each sample. 
In the second method, analyte was dissolved in PB at GSH-MPC concentrations 
between 0 and 10 µM and pumped through the flow cell at 36 µL/min for a set time 5.0 
min, with each 5.0 min sample introduction being termed a “dose”.  Flow dependent 
studies made use of 14 and 36 µL/min rates.  In all cases, adsorption values were 
recorded after unbound analyte was rinsed out of the flow cell.  Newly prepared 
immunosensors were used for each dose. 
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Results and Discussion 
 
Monolayer-Protected Cluster Synthesis and Characterization 
Monolayer-protected clusters were synthesized as previously reported,30, 31 with GSH 
completely protecting the metal core.  Though not a traditional antigen, GSH was used 
for its previous success with MPCs and the commercial availability of polyclonal anti-
GSH.  Control MPCs were also synthesized31, 44 with tiopronin, which is an effective 
truncate of the GSH tripeptide (Figure 10). 
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Figure 10.  Structures of cluster-protecting ligands, with similarities in red.  (A) 
Glutathione.  (B) Tiopronin. 
 
 
Although synthesis was slightly different for each of these nanoparticles (GSH-
protected and tiopronin-protected), characterization was the same in all cases.  Careful 
characterization was important for quantitative calculations and was completed via 1H 
NMR, UV/visible spectroscopy, TEM, and TGA.  Representative NMR, TEM, and TGA 
characterization data can be found in Figure 11.  Organic molecules on MPCs yield 
characteristically broad peaks in 1H NMR, which indicates cluster formation and purity.   
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Figure 11.  Characterization data for GSH-MPC and Tiop-MPC.  (a) 1H NMR of 
GSH-MPC in D2O; (b) 1H NMR of Tiop-MPC in D2O; (c) TEM image of GSH-MPC, 
showing spherical clusters, (inset shows histogram with average near 3.7 nm); (d) 
TEM image of Tiop-MPC, showing spherical clusters, (inset shows histogram with 
average near 3.5 nm); (e) TGA of GSH-MPC showing loss of organic material 
between 200 and 400 oC; (f) TGA of Tiop-MPC showing initial decrease in mass 
from water, followed by loss of organic material between 200 and 400 oC. 
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Broadening has been proposed to be a result of large size distributions, fast spin 
relaxation associated with the very large molecules, and chemical shift distribution 
associated with different Au-SR binding sites (terrace, edge, vertex).  It has been 
suggested that protons closest to the core of the MPC will experience the most 
broadening and the protons furthest from the core will experience the least, as those 
protons are most like a dissolved species.39  The presence of sharp peaks in a 1H NMR 
spectrum indicates unreacted starting material in the sample. In the 1H NMR of tiopronin-
MPC (Figure 11b), taken in D2O, the large peak at ~4.6 ppm is the water peak, the peak 
at ~3.7 ppm is due to -CH2- and -CH- protons, and the peak at ~1.2 ppm is due to the -
CH3- protons.   
UV spectroscopy is used to confirm the presence and estimate size of MPC by the 
plasmon resonance band.  This band is characteristic of nanoparticles due to the 
collective dipole associated with aggregation, but is absent in the bulk product.  
Experimental evidence has pointed to a decrease in energy and increase in line width 
associated with decreasing size of particle.32   
Transmission electron microscopy (TEM) is a valuable characterization technique in 
estimating size and shape of MPCs.  Other important features such as core population 
(from “magic numbers”),39 aggregation, and molecular bridging121 have been elucidated 
with the aid of TEM.  Representative TEM images and histograms for GSH-MPC and 
Tiop-MPC can be found in Figures 11c,d.   
Thermogravimetric analysis (TGA) is a simple technique that provides an MPC 
percent weight organic that is consistent with elemental analysis.39  The sample is 
generally dried to remove adsorbed water and heated to the point at which all organic 
 53
material burns away, leaving only elemental gold.  From the recorded change in mass, the 
percent organic composition can be calculated.  Representative TGA data can be found in 
Figures 11e,f. 
Estimation of the total MPC composition can then be made based on cluster diameter, 
percent organic composition, and certain assumptions: (1) the MPC is spherical with 
volume equaling 4/3πr3, (2) the Au packs in a face-centered cubic formation with packing 
efficiency of 74.05%, and (3) the van der Waal radius of Au is 0.170 nm.122  These data 
and assumptions allow an average estimation of the total number of Au atoms and total 
number of ligands in an MPC, allowing complete characterization.   
 
Table 1.  Results of calculations from MPC characterization. 
MPC Diameter, davg, (nm) Avg. Composition Avg. MW (kDa) 
GSH 3.7 ± 1.2 Au953GS199 220 
Tiop 3.5 ± 1.0 Au807Tiop246 199 
 
 
Results for nanoclusters used in these experiments (Table 1) suggest that there is high 
ligand valency with 199 GSH epitopes per cluster.30, 31, 39  Control Tiop-MPC showed a 
ligand valency of 246, consistent with previously published data.31, 44 
 
Quartz Crystal Microbalance 
 A substantial difficulty in QCM has been ensuring an accurate measurement of mass 
loading.  While resonant frequency is directly related to mass adsorption, frequency can 
also be altered by changes in density and viscosity of the contact solution.  In traditional, 
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gas-phase experiments this was rarely a problem, but in biosensor applications where 
solutions of varying composition are continuously delivered to the sensor, density and 
viscosity become very important considerations.  The effects of density and viscosity can 
be monitored and accounted for by measuring the changes in loading resistance of the 
QCM.  Practical decoupling of viscous loading from mass loading was completed using 
simple experimental calibration.  Sucrose was assumed to have no affinity for the QCM 
substrate, but affected the properties of the contact liquid.  Increasing concentration of 
sucrose (changes in density and viscosity) caused decreases in frequency and increases in 
loading resistance that mirrored each other.  Plotting ∆f against ∆RL gave a straight line 
with slope of -2.095 for a 5 MHz crystal and -15.27 for a 9 MHz crystal (Figure 12).   
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Figure 12.  (a) QCM mass calibration for a 5 MHz crystal using different 
concentrations of sucrose to show the relationship between frequency and resistance 
in a non-mass loading system; (b) linear relationship between ∆f and ∆RL with slope 
= 2.095 and R2 = 0.999. 
 
 
This is the calibration factor and is the effect that a change in resistance (viscous loading) 
has on the frequency measurement.  A measured ∆RL can then be adjusted by the 
calibration factor and added or subtracted to ∆f to provide an adjusted ∆f that is due only 
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to mass loading.  Sucrose concentrations of 0.00%, 5.02%, 10.0%, 20.0%, and 40.0% 
(w/w) were used in the representative example shown in Figure 12. 
 
Immunosensor Assembly 
 The initial immunosensor used in the study of antibody binding to GSH-MPC 
involved the immobilization of the nanocluster and subsequent antibody detection.  
Immobilization of the MPCs on the gold QCM electrode proceeded by ionic layering 
using transition metals.  This method was first examined as both GSH- and Tiop-MPCs 
were already functionalized with carboxylic acid groups.  The protocol for this metal-
carboxylate chemistry was adapted from literature74 and is summarized in a cartoon 
schematic (Figure 13a).  Cu2+ ion was initially used, as literature suggested,74 and binding 
of Cu2+ to carboxylate, MPC to Cu2+, and antibody to MPC was recorded.  The addition 
of the carboxylic acid-terminated thiol (MUA) to the gold in the form of a SAM could 
not be followed in real time as the kinetics of the reaction appeared to be very slow.   
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Figure 13.  Cartoon of immunosensor assembly (not to scale).  (a) Ionic layering, 
presenting MPC to solution for antibody binding (Mn+ = Cu2+, Fe2+, Fe3+, Zn2+, or 
Ca2+); (b) Protein A presentation of antibody for MPC binding. 
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Formation of the monolayer was confirmed by observing a discrete change in frequency 
of -19.1 Hz over 12+ hours and by cyclic voltammetry of the bare gold vs. SAM covered 
gold (data not shown).  Sequential addition of Cu2+, GSH-MPC, and anti-glutathione 
polyclonal antibody was completed and provided encouraging results (Figure 14).   
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Figure 14.  Detection of Cu2+, GSH-MPC, and antibody binding via QCM (solid lines 
indicate rinsing and a change of solution). 
 
 
Changes in frequency for the Cu2+ and MPC additions were both sharp and apparently 
rigid, but upon rinsing and change of solution from 87.5% ethanol to phosphate buffered 
saline the frequency began to slowly rise.  This is suspected to be from the slow solvation 
of MPC and its removal from the QCM surface.  This lack of stability in the complex led 
to an examination of other cations (e.g., Fe2+, Fe3+, Zn2+, and Ca2+).  The stability of these 
complexes should depend on strength of coordination (Irving-Williams series) and the 
solubility product (Ksp) of the complex.  According to these parameters, it was thought 
that either Fe2+ or Ca2+ would provide the most stable complex, but acceptable stability 
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was not observed in either case when aqueous solutions of moderate ionic strength were 
used.  Nonetheless, GSH-MPC was immobilized, at least briefly, on the surface of the 
QCM, forming a moderately viable immunosensor. 
Assembly of a more stable, selective, and sensitive immunosensor proceeded by 
layering of Protein A, BSA, and anti-GSH polyclonal antibody onto the gold QCM 
electrode (Figure 13b).  These steps led to the immobilization of antibody in an 
appropriate conformation and the detection of antigen-protected clusters.  Construction 
began with rigorous cleaning of the Au electrode with piranha and ozone and continued 
with immobilization of Protein A.  Recombinant Protein A from E. coli was used at a pH 
consistent with its isoelectric point (pH 5.5) in order to provide the tightest binding, while 
the non-specificity of the interaction led to rapid association.  Binding was also relatively 
consistent, as six discrete experiments showed an average ∆m of 1.83 + 0.08 µg and a 
relative percent deviation of 4%.  The magnitude of this signal allows easy measurement, 
but does not correlate to an ordered monolayer of protein.  If Protein A (45 kDa) is 
assumed to be 5 nm in diameter (from crystallographic data123 of a protein of similar 
size), its adsorption footprint would have an approximate area of 20 nm2.  The area of the 
Au electrode is 1.28 x 1014 nm2, which would allow 6.4 x 1012 proteins or 0.48 µg in a 
perfectly packed monolayer.  Our data indicates a multilayer of protein bound to the 
surface, ensuring complete coverage of the Au electrode.  A representative case of 
Protein A binding can be seen in the first 60 minutes of adsorption in Figure 15. 
After thorough rinsing, the sensor surface was blocked with BSA to limit non-specific 
adsorption of antibody and analyte and to ensure that no Au remained exposed.  Repeated 
independent measurements of BSA adsorption yielded an average ∆m of 0.1 + 0.1 µg  
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 Figure 15.  Representative Protein A, BSA, IgG, and MPC binding. 
 
 
(Figure 15), consistent with complete Protein A coverage in the previous step.  Unbound 
BSA was removed by rinsing with PB. 
Immobilization of polyclonal anti-glutathione antibody by Protein A completed the 
immunosensor preparation.  Due to the use of a slower flow rate and the nature of 
protein/protein recognition, saturation of binding sites took significantly longer (90 to 
120 minutes).  Considering the multilayer of Protein A on the electrode, antibody binding 
was reasonably stable and consistent with an average ∆m of 1.8 + 0.3 µg, and relative 
percent deviation of 20%.  This equates to 9.4 x 10-12 mol/cm2, but due to accessibility, 
sterics, and the size of IgG as compared to Protein A (150 kDa vs 45 kDa), the 
stoichiometry of multilayer binding is unclear.  Representative antibody binding data is 
presented in the 90 to 200 min block of Figure 15. 
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Analyte Detection 
 Following the completion of the immunosensor, analyte was detected.  In the case of 
the preliminary immunosensor design (ionic immobilization of GSH-MPC), the analyte 
was polyclonal anti-GSH antibody.  Due to the instability of the immunosensor 
architecture, GSH-MPC was likely separating from the QCM surface, giving rise to a 
slow increase in frequency (Figure 14, 45-60 min).  This is suspected to be from the slow 
solvation of MPC and its removal from the QCM surface.  Upon antibody addition, the 
frequency began to decrease.  This is due to the antibody slowly recognizing and binding 
to MPC still on the crystal, thereby ceasing MPC solvation and decreasing frequency.  
The effect of non-specific binding was also considered by building the same ionic layers, 
but introducing monoclonal anti-HA antibody instead of polyclonal anti-glutathione.  
Anti-HA antibody recognizes an epitope with amino acid sequence YPYDVPDYA, 
which is vastly different than glutathione.  As expected, anti-HA did not bind as well or 
as specifically as anti-GSH.  There was some amount of non-specific binding though, as a 
change in frequency of ~25 Hz was observed.  Further progress with the use of ionic 
layering has since ceased as the complexes are not stable in aqueous solutions of 
moderate ionic strength. 
Following completion of the more stable, Protein A-based immunosensor, analyte 
was detected by two different approaches.  In this case, the analyte was the nanocluster, 
rather than the antibody.  The first method involved analyte addition over extended 
periods of time, which provided large, easily observable ∆m values, but adsorption was 
not exclusive to antibody recognition.  It is hypothesized that the nanocluster was 
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recognized by the antibody, causing binding and nucleation that led to random 
aggregation of MPCs.  This precludes the application of a Langmuir isotherm as analyte  
 
Figure 16.  Antibody recognition and binding of GSH-MPC, followed by non-specific 
aggregation over an extended period of time, showing no saturation point.  (a) 2.8 µM 
GSH-MPC; (b) 5.1 µM; (c) 5.1 µM; (d) 6.8 µM; (e) 9.1 µM. 
 
 
molecules are clearly interacting with each other.  Data from these experiments are 
available in Figure 16. 
The second approach introduced analyte by small “dose” amounts.  This used smaller 
total amounts of cluster and biased stronger antibody recognition over weaker non-
specific binding, but produced smaller ∆m values.  Additionally, this method was more 
time and material efficient than multi-hour experiments.  Detection was ultimately 
achieved by introducing MPC for a set time of 5.0 minutes, with each sample 
introduction being termed a “dose.”  Six doses, ranging in MPC concentration from 0.45 
to 9.1 µM, provided ∆m values that fit a logarithmic curve, showing saturation of the 
immunosensor (Figure 17a).  Altering the flow rate used in dose delivery affects ∆m, as 
expected, with an increased flow rate yielding an increased ∆m (Table 2). 
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Table 2.  Data for ∆m dependence on flow rate for two doses of equal [GSH-MPC]. 
 
 Dose A Dose B Ratio B/A 
[GSH-MPC] (µM) 4.5 4.5 1.0 
Flow Rate (µL/min) 14 36 2.6 
Total mol/dose 1.6 x 10-12 4.1 x 10-12 2.5 
∆m (ng) 71 150 2.1 
 
 
The significance of these results is supported by control experiments using tiopronin-
MPC and free GSH.  Tiop-MPC displayed minimal binding (∆m ~ 0.01 µg) and was not 
recognized by the antibody, highlighting its specificity.  Free glutathione showed an 
unexpected result of a negative ∆m or mass removal.  It is suspected that GSH, with its 
free thiol from Cys, is small enough to penetrate the IgG and Protein A layers to form 
Au-S bonds.  This partial self-assembly of a monolayer of GSH displaces Protein A and 
IgG causing a rise in frequency or a negative ∆m and masks free GSH recognition.  
Binding curves for three doses as compared to these control experiments are available in 
Figure 18.  
Equilibrium parameters, association constant (Ka) and dissociation constant (Kd), 
were determined by fitting to a Langmuir adsorption isotherm (Eq. 7).24, 52, 87 
 
∆m = ∆mm(KaC/(1+KaC))          (Eq. 7) 
 
Eq. 7 can be rearranged such that ∆m is plotted versus ∆m/C to obtain a straight line with 
slope 1/Ka and a y-intercept of ∆mm (Eq. 8). 
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∆m = -(Ka)-1(∆m/C) + ∆mm          (Eq. 8) 
 
Plotting the data in this fashion provides a maximum binding value for saturation (∆mm) 
of 0.25 + 0.01 µg, a Ka of 3.6 + 0.2 x 105 M-1 and a Kd of 2.8 + 0.2 x 10-6 M (Figure 17b).  
The steady-state fractional coverage, Θi, can then be found for various concentrations of 
analyte using Ka and Eq. 10.82 
 
Θi = C/(C + Ka-1)          (Eq. 10) 
 
Values for steady-state fractional coverage are plotted parallel to ∆m in Figure 17a and 
agree with immunosensor saturation and the calculated ∆mm.  The affinity (Ka = 3.6 + 0.2 
x 105 M-1) of these antibodies for an antigen-protected cluster is similar to reported Ka 
values for some monoclonal antibodies.  Several studies of anti-Gal monoclonal antibody 
binding to a variety of substrates24 have described Kd measurements in the range of 10-6 
to 10-12 M and monoclonal anti-FLAG M2 antibody25 has been shown to bind peptide 
epitope arrays with a Ka of 1.5 x 108 M-1.  Equilibrium constants for anti-GSH antibodies 
determined by QCM are comparable to literature, though indicate a lower affinity.  This 
is reasonable as the antibodies are polyclonal, with only a subset recognizing the antigen 
presented. 
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Figure 17.  (A) Plot of ∆m against the [GSH-MPC] for six doses, fit to a logarithmic 
curve with equation y = 54ln(x) + 72.3 and R2 = 0.99.  Θi is included for these 
concentrations and ∆m values.  (B) Linear langmuir adsorption isotherm fit with 
equation y = -2.8 x 10-6 x + 2.5 x 10-7 and R2 = 0.98.  (C) Adsorption kinetics using 
four doses, according to Eqs. 15 and 16, with equation y = 54x + 0.00015 and R2 = 
0.98. 
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Kinetic information can also be calculated from the time-dependant binding curves, 
like those in Figure 18, through fitting to the exponential expression (Eq. 15) and plotting 
τ-1 vs. C (Eq. 16), 
 
ln (1 – mt/mi) = -(τ-1) t          (Eq. 15) 
 
τ-1 = kfC + kr          (Eq. 16) 
 
where, mt is the mass at time (t), mi is the mass at an infinite time, τ-1 is the time constant 
for a dose, kf is the forward rate constant, and kr is the reverse rate constant.82, 84, 85   
 
 
Figure 18.  Binding curves for three of six GSH-MPC doses, Tiop-MPC, and free 
GSH.  (A) 1.0 mM free GSH; (B) 4.1 µM Tiop-MPC; (C) 2.3 µM GSH-MPC; (D) 4.5 
µM GSH-MPC; (E) 9.1 µM GSH-MPC. 
 
Binding curves for four different [GSH-MPC] were used to obtain τ-1 values by fitting to 
Eq. 15 and determining the slope of the linear portion after forcing the y-intercept 
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through zero.  Time constants were plotted against concentration, according to Eq. 16, to 
obtain rate constants, as seen in Figure 17c, where kf is 5.4 + 0.7 x 101 M-1s-1 and kr is 1.5 
+ 0.4 x 10-4 s-1.  The equilibrium adsorption constant, Ka, is equal to the ratio of kf/kr and 
was calculated to be 3.6 x 105 M-1, which correlates very well with the Ka found in the 
previous method (Figure 17b).  As with the equilibrium constants, calculated kinetic 
constants are generally consistent with reported values for monoclonal antibody binding, 
protein receptor binding, and self-assembled monolayer (SAM) formation.  Monoclonal 
anti-fluorescyl antibody has been reported85 to bind to fluorescein-conjugated lipids with 
kf of 1.99 x 105 M-1s-1 and kr of 2.18 x 10-3 s-1.  It is reasonable for this forward rate 
constant to be larger than the rate constant for polyclonal anti-GSH due to the 
heterogeneity of a polyclonal sample and the lower effective concentration of active 
antibody.  As such, the kr values, which do not depend on concentration of active 
antibody, correlate very well.  Deviations from rate constants for protein receptors, which 
also make use of molecular recognition, occur for similar reasons.  Bracci, et al.114 have 
reported kf in the range of 101 to 104 M-1s-1 and kr in the range of 10-3 to 10-4 s-1 for 
binding of snake neurotoxin α-bungarotoxin to synthetic peptide mimitopes.  SAMs have 
been described82 with kf ranging from 102 to 103 M-1s-1, which falls between the rate of 
formation constants for monoclonal anti-fluorescyl antibody85 and polyclonal anti-GSH 
antibody. 
Equilibrium and kinetic constants calculated above indicate that recognition and strong 
association of polyclonal antibody with glutathione-protected cluster occurs, while 
important control experiments suggest where the recognition occurs.  Tiopronin, which is 
an effective truncate of GSH (Figure 10), lacked recognition, suggesting that either the 
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non-natural, γ-glutamic amino acid or the tripeptide structure is essential for antibody 
recognition.  This agrees with observations that non-natural amino acids are often 
important to biological structure, in the case of hydroxyproline, hydroxylysine, and 
crosslinked amino acids in collogen.9  Furthermore, presentation of the epitope through 
thiolate coordination to the MPC surface precludes possible antibody recognition of the 
cysteine thiol.  This suggests that efficient antibody recognition depends on recapitulation 
of the peptide epitope through MPC presentation. 
 
Conclusions 
The QCM immunoassay presented has been shown to provide quantitative binding 
information concerning the detection of antigen-protected nanometer-sized cluster with 
immobilized antibody.  This type of assay has several advantages over ELISA and SPR 
techniques, including the cost, ease of operation, and ability to detect multilayer 
adsorptions.  Benefits of this particular method involve calibration for density and 
viscosity effects in frequency measurements, reliable response for multilayer adsorption, 
continuous sample introduction, and dose dependent antigen recognition and signal 
response.  Signal amplification by coupling of antigen molecules to MPCs is an inherent 
benefit of this system, but was not considered a goal in immunosensor design.  Using this 
technique we report Ka and Kd values of 3.6 + 0.2 x 105 M-1 and 2.8 + 0.2 x 10-6 M and kf 
and kr values of 5.4 + 0.7 x 101 M-1s-1 and 1.5 + 0.4 x 10-4 s-1 for the binding of a 
multivalent antigen-protected MPC to its polyclonal antibody.  These findings confirm 
the usefulness of this QCM method as a quantitative immunoassay and support previous 
observations21 that presentation of biologically-active antigen epitopes on nanocluster 
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surfaces produces robust immunoreactive materials with potential for nanoscale materials 
assembly and as diagnostic agents. 
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CHAPTER III 
 
HEMAGGLUTININ LINEAR EPITOPE PRESENTATION ON MONOLAYER- 
PROTECTED CLUSTERS ELICITS STRONG ANTIBODY BINDING 
 
Introduction 
 Biologically functional nanostructures rely on a solid support scaffold to provide a 
tunable surface for the presentation of functional units.  Many materials scaffolds, such as 
two-dimensional surfaces,42, 124 carbon nanotubes,125, 126 dendrimers,127, 128 and 
semiconductor nanoparticles26 exist and have been outfitted for different purposes.  
Monolayer protected clusters (MPCs) of nanometer dimensions have supported many 
functional units, in part due to the physical, optical, and electronic handles they offer.37, 39  
Early examples of chemical functionalization of MPCs comes from the Murray group 
where they were successful in attaching spin labels, chromophores, fluorophores, 
electroactive species and other units to the surface of nanoclusters using traditional 
coupling reactions and place exchange reactions.28, 35, 44  This showed the ease with which 
nanoclusters can be functionalized and provided additional chemical reactivity. 
 Biological recognition units, in contrast to chemically and spectroscopically active 
units, can provide means for modulating biological systems or for nanostructure assembly 
through agglutination.  These recognition units are often inspired by biological 
components or encompass a complete biological entity.  This approach has been used in 
the assembly of DNA-functionalized nanoclusters,5 in the assembly of vancomycin-
presenting antimicrobial nanoclusters,45 and in many other areas of biology. 
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 A particular biological system that has received considerable attention in nanoscale 
assembly is the immune system.  There are numerous examples of covalent and non-
covalent attachment of antibodies to latex beads,13 large colloidal gold clusters,16, 17 and 
large magnetic clusters.19  These nanoassemblies have been successfully used in 
advanced immunoassays and biodiagnostics but have limited potential as variable 
multifunctional structures.  Due to the large size (150 kDa) of antibodies, packing density 
and ligand valency are low.  Furthermore, their size and currently used attachment 
methods make it difficult to control antibody presentation or achieve the presentation of 
several different antibodies.  While these antibody-presenting nanoclusters, or antibody-
mimics, are useful, an alternative way to assemble immunoreactive nanostructures is 
through antigen presentation.  Antigens are generally large proteins, viruses, or bacteria, 
but are known to interact with antibodies through discrete contact points, known as 
epitopes.48  Epitopes can be continuous or discontinuous through the protein’s amino acid 
sequence.  Continuous epitopes have been routinely synthesized and are commonly used 
in epitope arrays for biodiagnostics,25, 114 but there are relatively few examples of peptide 
epitope functionalized nanoclusters. 
 The first example of a peptide epitope encapsulated nanocluster assembling with an 
antibody through the antibody/epitope interface was reported by Slocik, et al.21  A 
histidine-rich epitope from the histidine-rich proteins (HRP II and III) of the malarial 
parasite Plasmodium falciparum was used to stabilize the surfaces of a variety of metal 
and semiconductor nanoclusters.  This produced a nanostructure with a single component 
monolayer that was immunoreactive with monoclonal anti-HRP II antibodies.  The ability 
to assemble antigenic nanoclusters was further confirmed by the construction of a  
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Figure 19.  Cartoon representations of functional nanostructures: (a) GSH-MPC with 
a single component (3-amino acid peptide) three dimensional monolayer; (b) 
HA/Tiopronin-MPC with a dual component (10-amino acid peptide) three 
dimensional monolayer; (c) HA/Tiopronin-SAM with a dual component (10-amino 
acid peptide) two dimensional monolayer. (not drawn to scale) 
 
 
glutathione-protected gold cluster and the development of a quantitative, real-time, quartz 
crystal microbalance (QCM) immunoassay.2  This nanostructure consisted of a three 
amino acid peptide in a single component monolayer (Figure 19a) and was shown 
quantitatively to recognize polyclonal anti-glutathione antibody with an affinity constant 
of 3.6 x 105 M-1. 
 The next step in peptide epitope presentation, or antigen mimic design, is to control 
epitope presentation and epitope density in a dual component monolayer nanocluster.  
This can be completed through well-established place exchange reactions that have been 
previously used in MPC functionalization.28, 34  In these reactions, a thiolate-coated 
nanocluster is reacted with free thiolate in solution to promote one-to-one exchange, 
possibly through an associative, SN2 mechanism (Figure 20).34, 41  Reaction conditions 
can greatly affect the extent of place exchange, allowing exquisite control of the 
functionalization procedure. 
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Figure 20.  Cartoon schematic showing one-to-one place exchange between peptide 
thiolate in solution and thiolate on the surface of an MPC.  Numbers indicate (1) fast 
exchange at vertex site, (2) moderate exchange at edge site, and (3) slow exchange at 
terrace site.  Condition optimization allows for the presentation of multiple ligands. 
 
 
 Research herein demonstrates the assembly of a dual-component immunoreactive 
nanostructure through the place exchange of a peptide epitope from the hemagglutinin 
protein of influenza onto the surface of a tiopronin-protected nanocluster.  Immunological 
evaluation of this functional nanostructure was completed using a QCM immunoassay 
and was compared to traditionally used peptide epitope arrays.  Preparation and 
evaluation of these antigen-mimic nanostructures have important implications in the 
responsible handling of threatening toxins, in medical diagnostics, and in the 
development of anti-viral vaccines. 
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Experimental 
 
Chemicals 
 Gold shot (99.99%) was purchased from precious metal vendors and was initially 
converted to HAuCl4•3H2O by boiling Auo in HCl/HNO3 solution.119  N-(2-
Mercaptopropionyl)-glycine (tiopronin, reagent), bovine serum albumin (BSA, fraction 
V, 96%), α-cyano-4-hydroxycinnamic acid (α-CHCA, matrix grade), and sodium 
phosphate (monobasic, reagent) were purchased from Sigma.  
Poly(diallyldimethylammonium chloride) (400,000-500,000 MW) (polyelectrolyte), 
bromoethylamine hydrobromide (99%), potassium hexafluorophosphate (98%), and 
tetrabutylammonium nitrate (97%) were obtained from Aldrich.  Thioacetic acid (98%), 
4,4’-dipyridyl anhydrous (98%), 1-[3-dimethylamino)propyl]-3-ethylcarbodiimide 
(98+%), and 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (99%) were obtained 
from ACROS Chemicals.  Tetraoctylammonium bromide (98%) and N-
hydroxysuccinimide sodium salt (98.5%) were obtained from Fluka, Inc.  Anti-HA 
mouse monoclonal antibody (12CA5M5) was purchased from Vanderbilt Molecular 
Recognition Core Facility.  NMR solvents were obtained from Cambridge Isotope 
Laboratories and water was purified using a Modulab Water Systems unit (~18 MΩ).  
Buffers were prepared according to standard laboratory procedure.  Other chemicals were 
reagent grade and used as received.  
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MPC Synthesis and Characterization 
 Nanometer-sized gold MPCs were synthesized with tiopronin as the passivating 
substrate, as previously described.2, 31, 44  Characterization of MPCs was completed using 
nuclear magnetic resonance spectroscopy, UV/visible spectroscopy, transmission electron 
microscopy, and thermogravimetric analysis, as previously described.2  MPCs used in the 
following experiments had a diameter of 3.5 + 1.0 nm and an estimated composition of 
Au807Tiop246 (199 kDa).2, 39 
 
Peptide Synthesis and Characterization 
Peptide epitopes were synthesized according to standard continuous flow fmoc solid-
phase peptide-synthesis methods on an Advanced ChemTech Model 90 or Advanced 
ChemTech Apex 396 system using Wang resins.  Deprotection of the fmoc-amino acids 
occurred in 20% piperidine for 15 min.  Activated amino acids were in four-fold excess 
of resin loading capacity and in a 1:1:1:2 ratio (amino acid:HBTU:HOBt:DIPEA) with 
coupling reagents.  The coupling step lasted 2 hours and was followed by a final fmoc 
deprotecting step.  Cleavage from the resin and sidechain deprotection was completed in 
a one hour reaction with Reagent K (82.5% trifluoroacetic acid [TFA], 5% phenol, 5% DI 
water, 5% thioanisole, 2.5% ethanedithiol) or Reagent R (for Boc deprotecting, 90% 
TFA, 5% thioanisole, 3% ethanedithiol, 2% anisole).  The peptide was then precipitated 
with diethyl ether, dissolved in water with a minimal amount of acetonitrile, and 
lyophilized on a Labconco Freezone 4.5 system.  Purification was completed via 
reversed-phase HPLC on a Waters Prep LC 4000 with a 2487 Dual λ Absorbance 
 74
Detector (210 and 254 or 280 nm) and a Waters Delta Pak C18 (30 x 300 mm) column.  
Purity and composition were assessed by HPLC and MALDI mass spectrometry. 
 
Place Exchange 
 Place exchange reactions between tiopronin-MPCs and thiolate-containing peptides 
were performed according to Hostetler, et al.28, 34  In exchange reactions, nanoclusters 
were co-dissolved in DI water (final concentration of 3.0 mg/mL MPC) with free 
thiolated peptides in varying ligand/peptide ratios (Table 3).  Solutions were stirred at 
room temperature for approximately 3 days, collected, and purified by dialysis as 
previously described.2, 31  Extent of exchange was determined by 1H NMR and by iodine 
reaction.35  In the case of the iodine reaction, ~20 mg of mixed monolayer MPC was co-
dissolved with 10 mg I2 in 10 mL DI water and stirred for several hours.  After removal 
of the iodine-passivated nanoclusters by centrifugation the supernatant was lyophilized 
and examined via 1H NMR.  The number of peptides per cluster was determined through 
NMR integration values and the following equation: 
 
[Normalized Peak Area]Tiop/[H per Ligand]Tiop : 
[Normalized Peak Area]peptide/[H per ligand]peptide          (Eq. 17) 
 
Immunosensor Assembly 
 Detection of substrate binding occurred through the assembly of a sensitive and 
selective biosensor.  Biosensor assembly proceeded according to three different 
immobilization techniques: electrodeposition, monolayer formation, and polymer ionic 
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layering.  In all cases, the biosensor began with the quartz crystal gold electrode, which 
was cleaned with piranha, a 3-to-1 mixture of concentrated H2SO4 and 30% H2O2, rinsed 
with ethanol, and cleaned in a Jelight UVO-42 ozone cleaner.  In some cases, cleaning 
continued electrochemically in 0.1 M H2SO4 by scanning from 0.0 to 1.3 V against a 
silver wire reference electrode and platinum wire counter electrode at 50 mV/sec. 
 Electrodeposition of MPCs required the functionalization of tiopronin-protected 
MPCs.  The redox couple, N-(methyl)-N’-(ethylamine)-viologen dinitrate (MEAV), was 
synthesized as previously reported.44, 78  Briefly, 4,4’-dipyridyl, was refluxed with 0.9 eq. 
of iodomethane in acetone to yield the monomethyl-viologen species.  This product then 
refluxed with 4 eq. of bromoethylamine hydrobromide in acetonitrile under nitrogen.  
MEAV was collected as the monoiodide, monobromide salt and converted to the dinitrate 
salt according to Tang et al.129  Coupling of the free amine on MEAV to the free 
carboxylic acid group on tiopronin proceeded according to standard amide coupling 
techniques44, 78 and tiopronin/MEAV complex was place exchanged onto MPC as above.  
Proton NMR was used to follow the steps of the reaction and determine purity.  
Electroactivity was followed by cyclic voltammetry using a CH Instruments potentiostat, 
gold working electrode (1.6 mm diameter), Pt wire counter, and Ag/AgCl reference.  The 
working electrode was polished between each use with 0.050 micron alumina powder 
(Buehler Micropolish II), rinsed, and sonicated in water and ethanol.  Redox couples 
were dissolved in borate buffer (pH 9.2, 100 mM) and CVs were recorded at a scan rate 
of 50 mV/sec from 0.0 to -0.75 V.  Cluster was further functionalized with peptide as 
above.  Biosensor assembly began with mounting a clean crystal in the QCM flow cell, 
rinsing with borate buffer, and bringing to resonant frequency.  All solvents and solutions 
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were purged with N2 for 10+ min and capped before introduction to the QCM.  The 
electrochemical setup consisted of the Au QCM electrode as the working electrode, Pt 
wire counter electrode, and Ag/AgCl reference electrode connected to a BAS CV-27 
potentiostat.  The counter and reference electrode were placed in solution at the outlet 
stream of the flow cell.   MPC (100 nM) was dissolved in borate buffer and introduced to 
the QCM at 36 µL/min for 8 minutes.  Flow rate was then decreased to 28 µL/min and 
the potential stepped from 0.0 V to -0.8 V for 30 sec, stepped back to 0.0 V for 30 sec, 
and set to standby (no voltage) for 30 sec.  This was repeated 4 to 5 times for 
reproducibility.  This was also repeated in borate buffer with no MPC present.  
 Single and dual component monolayers were self-assembled on the gold QCM 
electrode.  Typically, thiolate molecules were dissolved in ethanol at 1 mM concentration 
and reacted with a clean electrode overnight (~ 16 hours).  In the case of a mixed 
monolayer, tiopronin and peptide were co-dissolved at final concentrations of 0.75 mM 
and 0.25 mM, respectively.  After reaction, the QCM crystal was rinsed in ethanol and 
dried for use. 
 The mixed monolayer (tiopronin/peptide) was evaluated to approximate the amount 
of peptide in a typical monolayer.  This was completed by forming a monolayer over 
night and then removing the monolayer with portions of piranha (3:1 H2SO4/H2O2; 
CAUTION: handle piranha solutions with care).  The freed ligands were collected, the 
piranha neutralized with NaOH, and the sample was desalted using a Sep-Pak C-18 filter 
prior to lyophilization.  1H NMR was used to determine the ratio of peptide to tiopronin 
and this ratio was compared to the ligand density on a nanocluster to estimate the moles 
of peptide in the SAM. 
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 The polymer ionic layering immobilization technique involved sequential layering of 
polyelectrolyte, MPC, and BSA on the surface of the QCM crystal’s gold electrode.  
Before assembly the gold electrode was cleaned in piranha and ozone,2 mounted in a 
holder with flow cell, rinsed with PB, and brought to resonant frequency (~5 MHz).  A 
constant flow of 28 µL/min was used throughout this assembly procedure.  
Polyelectrolyte (0.05%) in PB was pumped through the flow cell for 15 min.  After a 10-
min rinse with PB, MPC (2.4 µM) in PB was pumped for 30 minutes.  Again the crystal 
was rinsed with PB for 10 min and was followed by BSA (16 µM) for 25 min.  After a 10 
min rinse with PB, the sensor was ready for antibody binding. 
 
Analyte Detection 
Antibody at various concentrations in PB was incubated with 100 nM MPC for 30+ 
minutes and purged with N2 for 10+ minutes.  Ab/MPC complex deposition was 
completed as above and compared to MPC deposition.  Clean electrodes were used for 
each deposition. 
 Antibody binding to the SAM was completed by flowing antibody solutions for 17 
min at 28 µL/min and following with a PB rinse.  A new SAM was assembled for each 
concentration of antibody studied. 
 Antibody binding to immobilized MPC consisted of flowing antibody solutions for 
15 min at 28 µL/min and following with a PB rinse.  A new immunosensor was 
assembled for each concentration of antibody studied. 
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Results and Discussion 
 
Nanostructure Assembly 
 Water-soluble, nanometer-sized monolayer-protected clusters were synthesized with 
tiopronin, a glycine derivative, as the protecting monolayer.  Synthesis and 
characterization followed established procedure2, 31 and provided a cluster with the 
following properties:  an average diameter of 3.5 + 1.0 nm, an average composition of 
Au807Tiop246, and an average molecular weight of 199 kDa.  Representative TEM image 
and proton NMR spectrum are available in Figures 21a and 21b, respectively.   
 
 
Figure 21.  Nanocluster characterization.  (a) TEM image of Tiop-MPC, showing 
spherical cluster.  (b) 1H NMR of Tiop-MPC.  Broad peaks are indicative of 
nanocluster formation.  A lack of sharp peaks indicates purity. 
 
This synthesis provided a robust, water-soluble nanocluster with a single-component 
monolayer that acted as a scaffold on which to impart biological specificity.  Such 
specificity was introduced via synthetic peptide epitopes. 
The HA peptide epitope was identified from literature as an immuno-tag and a target 
for antibody neutralization.130, 131  The peptide sequence comes from the hemagglutinin 
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protein, which is one of two viral membrane glycoproteins of the influenza virus, and 
spans amino acids 98-106.132  The peptide was synthesized with an extra Cys residue at 
the C-terminus to facilitate place exchange and yield the sequence YPYDVPDYAC 
(1205 Da, pI = 3.56).  Representative HPLC chromatogram and mass spectrum are 
available in Figures 22a and 22b, respectively.  This synthesis provided a linear peptide 
epitope that is known to be immunoreactive with a commercially available monoclonal 
antibody. 
 
 
Figure 22.  Peptide epitope characterization.  (a) Chromatogram from the purification 
of the crude HA peptide using semi-preparative HPLC.  The relatively sharp peak and 
lack of other major peaks indicates a homogenous sample.  (b) MALDI-MS of HA 
peptide collected from the major peak of HPLC (a).  Major peak (1206 m/z) is 
indicative of the pure peptide + H+.  Other peaks are listed according to their adducts. 
 
 
Assembly of the antigenic nanocluster was completed through place exchange 
reaction, where free thiolated peptides exchanged with tiopronin thiolates on the MPC.  
Reaction conditions can greatly affect the extent of exchange and have allowed the 
successful presentation of the HA peptide at varying degrees of peptide density.   
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Table 3.  Ratio of nanocluster thiolate to exchanging thiolate alters the extent of 
peptide exchange.  aInitial ratio of moles of nanocluster ligand to moles of free 
thiolated peptide.  bFinal ratio of moles of ligand to moles of peptide on the surface of 
the nanocluster. 
 
# Feed Ratio L/Pa 
Resulting Ratio 
L/Pb 
Peptide Density 
(Peptides/MPC) 
1 52 61 4 
2 27 48 5 
3 5.2 21 11 
4 2.6 6.5 33 
 
 
Altering feed ratios produced MPC samples with densities ranging from 4 to 33 peptides 
per cluster (Table 3), according to characterization by 1H NMR (Figure 23).  This array 
of functionalized nanoclusters was used to determine the optimal amount of peptide 
displayed for this particular antibody.  The QCM immunosensor (discussed below) was 
used to ascertain the extent of antibody binding to each nanocluster and provided results 
 
 
Figure 23.  1H NMR of Tiop-MPC after place exchange with HA peptide epitope.  
Tiopronin peaks are still present.  Peptide peaks are visible at approximately 0.8, 2.8, 
6.8, and 7.0 ppm. 
 
 
 81
suggesting that a low density of peptide provided the most efficient antibody/epitope 
interaction (Figure 24).  Accordingly, a nanocluster with 4 peptides per cluster 
(Au807Tiop242HA4) was assembled for further study.  A representation of this functional 
nanostructure is available in Figure 19b. 
Three-dimensional, functionalized MPCs were compared to two-dimensional self-
assembled monolayers in terms of antibody binding.  The SAMs were assembled directly 
on the QCM gold electrode as dual-component monolayers consisting of tiopronin and  
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Figure 24.  Antibody to functionalized nanocluster binding efficiency increases with 
decreasing density of peptide (peptides/nanocluster). 
 
 
the HA peptide.  A mixed monolayer of this type was assembled in order to mimic the 
surface of a functionalized nanocluster.  Monolayers were assembled over ~16 hours 
using a 3:1 mole ratio of tiopronin to HA peptide and were initially probed by cyclic 
voltammetry to ensure insulation of the electrode, suggesting complete monolayer 
formation (data not shown).  Further characterization provided an indication of the ratio 
of tiopronin to peptide in an assembled SAM.  Piranha (3:1 H2SO4/H2O2) is generally 
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used to clean the QCM electrode after use.  In this case, piranha solution liberated thiols 
from the SAM, which were collected, purified, and examined by 1H NMR.  This data 
indicated that the peptide represented 28 mole percent of the monolayer, which is 19 
times more than the 1.5 mole percent of peptide on the nanocluster.  A representation of 
the dual-component SAM is available in Figure 19c. 
 
Quartz Crystal Microbalance Immunosensor 
A QCM immunosensor was used to detect antibody binding to both 2D monolayers 
and 3D functional nanostructures.  Details of the QCM instrument, setup, and operation 
have been previously reported.2  Electrodeposition of MPC was completed by MPC-
functionalization with both N-(methyl)-N’-(ethylamine)viologen and the HA peptide.  
The average cluster composition in these experiments was Au807Tiop219MEAV17HA10.  
Deposition and detection of MEAV-HA-MPC was conducted in the absence of antibody 
in order to obtain a baseline ∆m for cluster only.  This was achieved through the constant 
flow of MPC and sequential deposition and release for set time periods.  A low 
concentration of 100 nM MPC was used in order to maximize the possible interaction 
between antibody and MPC and increase the signal from antibody detection.  
Unfortunately, this also decreased the amount of MPC electrodeposited onto the QCM.  
Each experiment was completed on a clean Au electrode and deposition was repeated 
four times to obtain an average ∆m of 0.022 µg + 0.002 µg and percent deviation of 
8.9%.  The complete experiment can be seen in Figure 25.  Initial mass adsorption is 
attributed to non-specific binding of the viologen or peptide portion of the MPC to the 
bare gold electrode.  Stepping the voltage from 0.0 to -0.8 V caused a sharp increase in  
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Figure 25.  Electrodeposition of MEAV-HA-MPC.  Mass adsorption is plotted in 
black, while current is plotted in blue. 
 
 
current that is followed by mass adsorption that appears to near saturation in the 30 sec 
timeframe.  Returning the voltage to 0.0 V causes a drop in current and subsequent mass 
stripping.  Electrochemical stripping only removed approximately 70% of the adsorbed 
MPC, suggesting that some viologen reached the second oxidation step and bound 
irreversibly to the electrode.  This changed the effective electrode surface area and 
accounts for a portion of the error. 
In the case of the SAM, monolayer formation was the extent of immunosensor 
assembly and antibody binding to the monolayer was observed (Figure 26, below).  
Nanocluster, on the other hand, required immobilization on the surface of the QCM in 
order to detect antibody binding.  This was completed using a highly charged polymer, or 
polyelectrolyte.  After cleaning the QCM electrode, polyelectrolyte was introduced and 
bound non-specifically with an average ∆m of 0.15 + 0.04 µg.  This provided a thin layer 
of positive charge for the ionic immobilization of functionalized nanocluster.  MPC 
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bound non-specifically with a density of 1.7 x 10-12 mol/cm2 (∆m = 0.44 + 0.06 µg).  
Exposed polyelectrolyte was subsequently blocked with BSA (∆m = 0.20 + 0.04 µg) to 
limit antibody non-specific adsorption, completing the immunosensor assembly.  
Representative QCM data for immunosensor assembly is available in Figure 26. 
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Figure 26.  Representative polyelectrolyte, HA-MPC, BSA, and anti-HA antibody 
binding (top).  Representative antibody binding to a mixed, two-dimensional 
monolayer, which was preassembled overnight (bottom). 
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Antibody Detection 
Preliminary results for the detection of anti-HA via electrodeposition suggested the 
need for an improved detection scheme.  Antibody was incubated with MEAV-HA-MPC 
before introduction to the EQCM.  Unfortunately, exposure of protein antibody to a 
hydrophobic Au electrode caused strong non-specific binding.  Antibody unassociated 
with MPC stuck to the QCM surface, blocking the electrode, before complex deposition 
could occur.  Further work might require passivation of the Au electrode to inhibit IgG 
binding, while allowing electrochemical activity of the MEAV-MPC. 
Monoclonal anti-HA antibodies were introduced to both SAM and MPC-based 
immunosensors in discrete dose amounts (Figure 26).  Antibodies recognized and bound 
to the HA peptide epitope presented either in a 2D monolayer or on a 3D MPC.  Due to 
the equilibrium process associated with biological recognition, buffer rinse that followed 
the binding event initiated antibody desorption for both 2D monolayers and 3D 
nanostructures.  Increasing concentrations of antibody provided increasing adsorption to 
the point of saturation, following a Langmuir adsorption isotherm (Figure 27).   
The mass adsorption for antibody to HA-MPC (Figure 27, solid square) is 
significantly lower than the mass adsorption for antibody to HA-SAM (Figure 27, solid 
triangle).  This is due to the large amount of peptide in a densely packed 2D monolayer.  
In this case, peptide composes 28 mole percent of the SAM monolayer, which is 19 times 
greater than the 1.5 mole percent of peptide in the MPC monolayer.  While this allows 
more antibody adsorption on the 2D surface, it does not necessarily increase the 
efficiency of adsorption.   
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Figure 27.  Antibody binding to immobilized HA-MPC (square, solid line fit) and 
HA-SAM (triangle, dashed line fit) is represented as total adsorbed mass (solid) and 
as the ratio of moles of antibody bound to moles of peptide available (outline).  Lines 
indicate a non-linear fit. 
 
 
When these adsorption values are plotted in terms of moles of antibody bound versus 
the moles of peptide presented, an estimation of antibody binding efficiency can be made.  
For these estimations every peptide in a SAM is considered to be available for binding.  
HA-MPC, on the other hand, is immobilized in such a way that approximately half its 
peptides are buried in polyelectrolyte and half are presented to solution.  At saturation 
antibody binding to HA-MPC is near a ratio of 0.5, which correlates to one antibody to 
every two peptides or one antibody to every nanocluster.  This is reasonable as each 
antibody has two antigen binding regions and suggests a high binding efficiency.  The 
HA-SAM, on the other hand, is far below a ratio of 0.5 at saturation.  There is more 
peptide in the monolayer than antibody can successfully bind to, indicating limited 
antibody binding efficiency.  This poor binding efficiency results from steric effects and 
monolayer packing density in a 2D surface. 
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Antibody binding efficiency is relevant in terms of designing an economical 
nanostructure, but does not relate to antibody binding affinity.  The affinity of the 
antibody for the epitope is determined by the equilibrium association constant (Ka), 
which can be calculated from fitting data to Langmuir isotherms or from kinetic rate 
constant information (kf/kr = Ka).2, 3  Three methods provided three different Ka values for 
both HA-MPC and HA-SAM, ranging from 0.41 x 107 M-1 to 1.8 x 107 M-1 (Table 4).  
Statistics (t-test) reveal that these two sets of association constants are not significantly  
 
Table 4.  Equilibrium association constants and kinetic rate constants for antibody 
binding to HA-MPC and HA-SAM.  aKa determined through Langmuir isotherm plot 
of ∆m vs ∆m/[anti-HA].  bKa determined through Langmuir isotherm plot of [anti-
HA]/∆m vs ∆m.  cKa determined through ratio of kinetic constants (kf/kr = Ka). 
 
 HA-MPC HA-SAM 
aKa (x 107 M-1) 0.9 + 0.3 1.8 + 0.5 
bKa (x 107 M-1) 0.8 + 0.2 1.6 + 0.3 
cKa (x 107 M-1) 0.57 + 0.07 0.41 + 0.07 
   
 HA-MPC HA-SAM 
kf (x 105 M-1s-1) 5.2 + 0.4 1.4 + 0.2 
kr (x 10-2 s-1) 9.2 + 0.5 3.5 + 0.2 
 
 
different from each other.  This suggests that while the nanocluster may present the 
peptide epitope in a more efficient manner, the antibody recognizes and binds to the 
peptide epitope regardless of presentation style.  This is reasonable for a relatively short 
chain, linear peptide epitope, though it may not hold for a more complex peptide epitope 
or nanostructure.  Furthermore, affinities for the MPC and SAM correlate well with 
previously reported association constants.  An early study133 of a similar peptide (acetyl-
YPYDVPDYASLRS-NH2) determined an association constant of 5.0 x 107 M-1 for an 
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anti-HA antibody.  A Ka of 0.32 x 107 M-1 was more recently reported134 for the anti-HA 
recognition of a similar peptide (fluorescein-GYPYDVPDYA) in a fluorescence-based 
assay. 
 
Conclusions 
Two functional nanostructures have been assembled and evaluated for their ability to 
interface with antibodies.  The first, a 3D peptide epitope-presenting nanocluster, was 
optimized for efficient antibody interface and had a low peptide density of 4 peptides per 
nanocluster.  Immobilization of this nanocluster in the assembly of a QCM 
immunosensor was attempted by viologen electrodeposition and by ionic layering, which 
proved to be more successful.  This produced an average association constant of (0.7 + 
0.2) x 107 M-1.  The second was a traditionally-used mixed 2D monolayer that showed 
antibody binding limited by steric effects and an average association constant of (1.3 + 
0.8) x 107 M-1.  The MPC compared well with the SAM and, in fact, had no significant 
difference in terms of equilibrium association constant.  We have synthetically assembled 
nanoparticle antigen mimics that are immuno-functional complements to this monoclonal 
antibody and we did so without the use of the intact protein.  This curtailed the handling 
of delicate, possibly dangerous, protein antigens and has implications for the study of 
more threatening agents.  This design and assembly process has, therefore, produced 
multi-component, antigenic nanoclusters with tremendous potential.  Water-soluble 
nanoparticles that present known neutralizing peptide epitopes from protein antigens of 
the influenza virus could potentially be used in anti-viral influenza vaccines. 
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CHAPTER IV 
 
ENHANCED ANTIGENICITY OF NANOCLUSTERS PRESENTING 
 CONFORMATIONAL PEPTIDE EPITOPES FROM THE PROTECTIVE  
ANTIGEN OF B. ANTHRACIS 
 
Introduction 
Research at the interface between biology and nanomaterials is of recent interest and 
has produced a number of exciting and successful examples of structurally well-defined 
interfaces.3, 4  Progress towards specifically interfacing immunology with nanoparticles is 
highlighted by an important approach that made use of a peptide epitope known to bind 
monoclonal antibody associated with the human malarial parasite, P. falciparum.  This 
was the first example of antigen encapsulated nanoclusters assembling with antibodies 
through the antibody/epitope interface.21  A more recent example used glutathione-
encapsulated nanoclusters and polyclonal anti-glutathione antibodies.  This approach 
confirmed the ability to assemble single-component monolayer nanoclusters with 
antibodies and provided an analytical technique for rigorous evaluation of interface 
assembly using the quartz crystal microbalance.2 
More complex nanostructures, specifically presenting peptide epitopes in a dual-
component monolayer, require scaffold properties that are common to monolayer 
protected clusters (MPCs).  MPCs capped with tiopronin ligand are water soluble; their 
average diameter, ranging from approximately 2 to 5 nm, is on the order of small 
proteins;2, 31, 44 they are easily characterized by conventional techniques, and have 
convenient optical and electronic properties.39  The tiopronin ligand, a thiolated 
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derivative of glycine, is relevant to biological systems and provides the cluster with an 
over all negative charge.44  Well-studied ligand coupling or place exchange reactions34 
have allowed for further functionalization of the cluster and the development of more 
complex antigen mimics.  Specifically, Tiop-MPC presenting a linear decapeptide from 
the hemagglutinin protein of influenza was shown to specifically interface with 
monoclonal anti-hemagglutinin antibody.49  This recognition relied solely on primary 
structure or amino acid sequence as this was a linear epitope, tethered to the MPC at one 
point. 
While linear peptide epitopes are useful under simple conditions, the introduction of 
secondary structure or local conformation, relevant to physiological conditions, could 
increase antibody affinity, producing a more potent, efficient antigen mimic.  To achieve 
this, we have emphasized loop secondary structures for several reasons:  (1) surface 
accessible loops are abundant in many protein antigens; (2) previous epitope mapping 
experiments have revealed loops as common antibody binding sites;10, 48, 110, 135 (3) loops 
are more amenable to nanocluster recapitulation when compared to other types of 
secondary structure.  Surface accessible loops also lack steric interference and are highly 
solvated.  Previously, cyclization of peptides has approximated loop structures with 
limited success,50 but developing and presenting a peptide that reconstitutes a 
physiological conformation is paramount (Figure 28).135  To this end, we have presented 
a conformational loop structure from the protective antigen of B. Anthracis in a bidentate 
fashion on the surface of Tiop-MPCs. 
An example of a loop-rich protein is the protective antigen (PA) of B. Anthracis, 
which is one of three protein precursors to the anthrax toxin.  Edema factor (EF) and  
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Figure 28.  Crystal structure135 of the protective antigen of B. Anthracis and cartoon 
of corresponding antigen mimic displaying a conformational loop structure that 
reconstitutes physiological conformation.  Linear and loop epitopes are highlighted in 
red, blue, and magenta in the crystal structure. 
 
 
lethal factor (LF) depend on PA for membrane transport and activation, making PA 
binding to the cell membrane crucial for toxicity.135  PA has been a target for 
immunological studies, which have shown that levels of anti-PA antibodies correlate well 
with immunity to anthrax.110  Further examination has identified two loops and the c-
terminus as cell receptor binding sites, and therefore, possible sites for toxin 
neutralization by IgG (Figure 28).110, 135-139  Recent studies140 using denatured and non-
denatured PA confirm the necessity of conformation in loop structures, but also suggest 
the presence of a linear epitope, such as the c-terminus.  The identification of these loops 
and the high priority that anthrax has received due to its potential as a bioterrorism agent 
make PA an excellent model for the design of complex, conformational nanostructures 
that mimic an antigen and have the ability to interface with biological systems. 
Antigen mimic design, by faithfully reconstituting the physiologically-relevant 
conformation of a peptide epitope on the surface of a monolayer-protected cluster, is 
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aided by intrinsic properties of the MPCs and their functionalization.  One important 
feature of place exchange reactions and the presentation of conformational peptide 
epitopes is the idea that fast-exchange sites are not static.  Evidence for this has come 
from the exchange of several different ligands onto the same MPC35, 141 and from an 
inability to completely remove ligands that had been previously exchanged onto a 
cluster.34, 35  A significant implication of these results is the ability of thiolates to migrate 
across the monolayer of an MPC.  This migration might allow for the faithful 
reconstitution of a peptide epitope if the two ends of a bidentate ligand are able to move 
and position themselves at a distance similar to that in their physiological conformation.  
Appropriate reconstitution may also be limited by the nanoparticle diameter.  Fortunately, 
the typical size of water soluble MPCs (2 – 6 nm diameter) is an excellent fit for the 
bidentate exchange of many peptide loops.   
 
 
Figure 29.  Calculation and cartoon suggesting that the optimal size of MPC for 
bidentate place exchange of an epitope loop (amino acids 679-693) from PA is 4.104 
nm diameter, which is in the typical size range for water soluble clusters (2 – 6 nm). 
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For example, according to crystal structure measurements,123, 135 the anthrax PA680B 
epitope has a through space distance (from amino acid 679-693) of 2.052 nm in its native 
conformation.  Calculations, assuming an equilateral triangle from points of attachment 
to the center of the cluster, suggest that an MPC with diameter of 4.104 nm would be 
optimal (Figure 29).  Working in this size regime can help to ensure proper bidentate 
exchange and appropriate conformation.  In this way, conformational, physiologically-
relevant antigen mimics can be produced and compared to their linear counterparts (same 
primary sequence, different local conformation) in order to examine differences in 
antigenicity or immunogenicity using polyclonal antibodies or monoclonal antibodies. 
One important application of high-affinity conformational antigen mimics may be in 
the area of epitope mapping.  Epitope mapping is the process of determining the major 
antibody binding sites on an antigen and can provide valuable information to one who is 
attempting to understand an antigen’s mode of action or produce an antiviral vaccine.  
There are established techniques for mapping an antigen, including Western Blot 
analysis, X-ray crystallography, NMR, antibody competition assays, site-specific 
mutagenesis, and flow cytometry.10, 138-140  Each of these techniques present their own 
advantages and disadvantages and tend to excel in one particular aspect of epitope 
mapping.  Many of these experiments place emphasis on distinguishing between 
discontinuous epitopes, where contact points are far apart in amino acid sequence but 
proximal through space, and continuous epitopes that involve a sequential amino acid 
sequence.48  Unfortunately, they often ignore the conformations intrinsic to sequential 
epitopes.  Consequently, many mapping techniques lack the ability to maintain antigen 
secondary structure (local conformation) or ignore it entirely despite the tremendous 
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impact secondary structure can have on the location of contact points and, ultimately, 
antigenicity.  Peptide epitopes are another tool for mapping sequential epitopes and have 
traditionally been used in the creation of synthetic peptide libraries and in phage display 
methods.6, 10  Again, these methods preclude the study of secondary structure, though 
they offer the best potential to incorporate conformation.  Research herein has established 
a method for the study of secondary structure conformational effects on monoclonal 
antibody binding to peptide epitopes.  According to this method we have effectively 
mapped monoclonal anti-protective antigen (anti-PA) antibodies to a protein 
conformational loop region through the assembly of a conformational loop epitope on a 
nanoparticle.   
Epitope mapping using conformational antigen mimics requires the development of a 
sensitive, selective, quantitative assay that allows for 3D nanocluster substrates, 
multilayer adsorptions, and non-rigid biological recognition.  The quartz crystal 
microbalance (QCM) has recently been demonstrated to be well-suited for this type of 
assay,2, 3, 49 has been used in the study of a variety of biological and non-biological 
systems,2, 52 and has numerous benefits over competing techniques for the study of 
nanoscale assembly.3  Through a quantitative QCM binding assay, this research 
demonstrates the accurate reconstitution of epitopes on a nanocluster and the effective 
conformational and linear epitope mapping of PA.  Furthermore, it suggests these 
nanostructures as antigen mimics that have the potential to interact with specific 
immunological systems. 
Other important factors in the study of linear and conformational antigen mimics are 
the immune response they illicit in an animal model (immunogenicity) as well as any 
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deleterious effects they may have (toxicology).  This requires the use of an active 
immune system in living organisms, such as mice, and an antibody production assay.  
These types of assays are commonly used in monoclonal antibody production or vaccine 
development and typically use a range of different antigens, including killed organisms, 
live attenuated organisms, proteins, protein subunits, genes, and peptide epitopes.142  For 
example, several studies attempting to produce neutralizing anti-protective antigen 
antibodies have used recombinant PA protein,136, 138, 140, 143-145 subunits from the PA 
protein conjugated to glutathione-S transferase,137 and DNA encoding for the PA 
protein.146  Peptide epitopes, on the other hand, have not been used in anti-PA antibody 
production, though they have tremendous potential in vaccine development: they can be 
chemically synthesized and characterized, allowing for molecular definition; they are 
extremely stable as compared to their protein counterparts, due to limited conformation 
or folding; no infectious material is used in their assembly, causing limited toxicity 
problems; they can be easily coupled with other peptide epitopes or adjuvants to increase 
potency; they are highly programmable and can be easily configured to a specific 
epitope.147  Due to their small size, intrinsic immunogenicity can be lacking,148 though 
coupling the peptide epitope to a scaffold, typically a protein carrier such as KLH or 
BSA, can increase activity and, simultaneously, introduce an adjuvant.147  While this 
conjugation technique has worked well for continuous, linear epitopes, it provides no 
means for introducing secondary structure or local conformation into the epitope, which 
has been suggested to be very important in many protein antigens.48, 142  An alternative 
scaffold would be MPCs, which have potential for the conformational presentation of 
peptide epitopes.  These conformational nanoparticle antigen mimics could increasingly 
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stimulate the body’s immune system into producing protective immunity against specific 
types of bacterial and viral infections. 
One important consideration when introducing a novel material, such as 
nanoparticles, into a living organism would be that material’s toxicological effects.  
Toxicity and the means for biological processing can be very important for the material’s 
dose response, retention, and overall efficacy.  There are relatively few examples in the 
literature of nanomaterial toxicology studies or even gold nanoparticle injection into 
mice.  Existing studies use a variety of different gold nanomaterials, including citrate-
reduced colloidal gold,149-151 purchased Nanogold,152, 153 silica/gold nanoshells,154 and 
nanorods.155, 156  These materials have sizes ranging from 1.9 to 130 nm in diameter and a 
variety of different surface functionalities.  The majority of these studies are for the 
purpose of cancer treatment151, 152, 154 or in vivo imaging,153, 155, 156 but often include some 
information on toxicological effects.  Paciotti, et al149 injected 5 to 24 µg of citrate-
reduced colloidal gold presenting PEG and TNFα intravenously into C57/BL6 mice with 
no ill effects.  They were able to visualize cluster retention in the liver, spleen, and a 
colon carcinoma tumor over 5+ hours.  Likewise, Hainfeld, et al153 introduced 1.9 nm 
Nanogold at relatively high concentrations intravenously into BALB/c mice without 
morbidity.  The LD50 for this material was determined to be as high as 3.2 g Au kg-1 body 
weight (67 mg Au for a typical 21 g mouse).  Complete blood chemistry and hematology 
showed no abnormalities and pharmacokinetic information showed clearing of the blood 
in ~10 hr, though significant retention in the liver, kidneys, and tumor over 24 hr.  While 
this is important and useful information for specific types of nanomaterials, it is likely to 
only loosely correlate to different materials of different sizes.  There are no examples, to 
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my knowledge, of toxicology studies or antibody production assays using monolayer-
protected nanoclusters.  The difference in synthetic route, size, and composition for these 
nanomaterials may have a profound effect on toxicity and immunogenicity, suggesting 
the need for preliminary examination.  This will elucidate the potential of  conformational 
peptide epitope functionalized nanocluster antigen mimics as immunological materials or 
vaccines. 
 
Experimental 
 
Chemicals 
Gold shot (99.99%) was purchased from precious metal vendors and was initially 
converted to HAuCl4•3H2O by boiling Auo in HCl/HNO3 solution.119  N-(2-
Mercaptopropionyl)-glycine (tiopronin, reagent), protein A (recombinant from 
Escherichia coli, >95%), bovine serum albumin (BSA, fraction V, 96%), and α-cyano-4-
hydroxycinnamic acid (matrix grade, α-CHCA) were purchased from Sigma.  
Poly(diallyldimethylammonium chloride) (400,000-500,000 MW) (polyelectrolyte) was 
obtained from Aldrich.  Ellman’s reagent was purchased from Pierce Biotechnology.  
Anti-PA mouse monoclonal antibodies were purchased from Biodesign International.  
Anti-HA antibodies were purchased from Vanderbilt Molecular Recognition Core 
Facility.  Protective Antigen protein (83 kDa, recombinant) was purchased from Alpha 
Diagnostic International.  Pooled Normal Human Serum (male) was purchased from 
Innovative Research, Inc.  NMR solvents were obtained from Cambridge Isotope 
Laboratories and water was purified using a Modulab Water Systems unit (~18 MΩ).  
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Buffers were prepared according to standard laboratory procedure.  Other chemicals were 
reagent grade and used as received. 
 
Antigen Mimic Synthesis and Characterization 
Peptide epitopes were synthesized according to standard continuous flow fmoc solid-
phase peptide synthesis methods on an Advanced Chemtech peptide synthesizer, purified 
by reversed-phase HPLC, and lyophilized as previously described.49, 157  Identity of 
peptides was confirmed by MALDI mass spectrometry. 
Nanometer-sized gold MPCs were synthesized with tiopronin as the passivating 
substrate, as previously described.31, 39, 49  Characterization of MPCs was completed using 
nuclear magnetic resonance spectroscopy, UV/visible spectroscopy, transmission electron 
microscopy, and thermogravimetric analysis, as previously described.2, 49 
Equilibrium place exchange reactions between tiopronin-MPCs and solution thiols 
were performed according to Hostetler, et al.34  For initial epitope mapping experiments, 
nanocluster was co-dissolved in DI water (final concentration of 3.0 mg/mL MPC) with 
free thiolated peptide in a 25:1 (mol/mol) ligand/peptide ratio.  Solutions were stirred at 
room temperature for approximately 4 days, collected, and purified by dialysis.2, 49  In 
preparing conformational antigen mimics for mouse immunization, exchange was 
upscaled to produce large amounts of functionalized cluster.  In this case, nanocluster 
was co-dissolved in DI water (final concentration of 1 or 2 mg/mL MPC) with free 
thiolated peptide in a 15-25:1 (mol/mol) ligand/peptide ratio.  Solutions were stirred at 
room temperature for approximately 3 days, collected, and purified by dialysis.  Extent of 
place exchange was determined by 1H NMR49 and by iodine reaction.35  In the case of the 
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iodine reaction, ~20 mg of mixed monolayer MPC were co-dissolved with 10 mg I2 in 10 
mL DI water and stirred for several hours.  After centrifugation of the iodine-passivated 
nanoclusters, the supernatant was removed, lyophilized, and examined via 1H NMR.  In 
order to determine the extent of exchange, in either case, peak assignments had to be 
made in the free and MPC-bound peptide.  To facilitate this, total coherence spectra 
(TOCSY) of 1 mM peptide in D2O and 90% H2O/D2O were taken of one peptide using a 
DPX-400 instrument at 400 MHz. 
 
Characterization of Epitope Conformation 
 Bidentate place exchange reactions were attempted using peptides with Cys residues 
at both ends in order to reproduce a conformational loop structure.  Evaluation of the 
attachment, to determine if a bidentate structure was achieved, was performed according 
to several analytical techniques. 
Nuclear Magnetic Resonance.  1H NMR was completed as above to obtain integration 
values and peak widths. 
Circular Dichroism.  AVIV Circular Dichroism Spectrometer Model 215 was used to 
collect CD spectra of monodentate and bidentate free peptide and MPC-associated 
peptide.  Peptides were dissolved in 10 mM pH 6.0 phosphate buffer and in equal parts 
phosphate buffer and trifluoroethanol.  Monodentate peptide was 21.6 µM and bidentate 
was 19.7 µM.  Free tiopronin was 68 µM in phosphate buffer.  Monodentate (1.56 
mg/mL) and bidentate (0.78 mg/mL) peptide-MPC were diluted to have the same 
concentration of peptide displayed to solution.  All samples were scanned from 260 to 
190 nm. 
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MALDI-TOF Mass Spectrometry. Mass spectra were taken on a PerSeptive 
BioSystems Voyager-DE STR instrument run in reflector mode with low mass gate, grid 
voltage of 74.5%, and laser intensity between 2200 and 2450.  Peptide was dissolved in 
aqueous 0.05% TFA, spotted on a gold MALDI plate, and let dry.  α-cyano-4-
hydroxycinnamic acid matrix was then spotted on top of the peptide and allowed to 
crystallize. 
Derivatization with Ellman’s Reagent.  Ellman’s Reagent (ER) is a dithiol that 
becomes a strong chromophore upon reduction of the disulfide bond.  If one end of the 
bidentate peptide were not attached to the MPC, its thiol would be available to react with 
ER, thus derivatizing and marking the lack of bidentate exchange.  ER was reacted with 
both free peptide and peptide-MPC and analyzed by 1H NMR and MALDI-MS as above.  
Free, monodentate peptide was reacted with excess ER in 100 mM pH 8.0 phosphate 
buffer for 15 min.  Peptide was then purified via preparative HPLC as above and 
analyzed.  Peptide-MPC was reacted with excess ER in phosphate buffer for 15 min.  
Unreacted ER was removed by dialysis (above) and peptide-MPC was analyzed.  
Peptide-MPC then underwent reaction with iodine (above) and the organic components 
were collected.  Excess iodine and tiopronin were separated from peptide with a Sep-Pak 
Cartridge Light C18 column.  The cartridge was rinsed with methanol and aqueous 
0.05% TFA before sample loading.  Iodine and tiopronin were eluted with excess 
aqueous 0.05% TFA.  Peptide was then eluted with small amounts of a 50/50 mixture of 
water and acetonitrile (both 0.05% TFA) and 100% acetonitrile (0.05% TFA).  Collected 
fractions were inspected spectroscopically and fractions containing peptide were 
lyophilized and analyzed via 1H NMR and MALDI-MS. 
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Quartz Crystal Microbalance 
Binding events were followed with QCM as previously detailed.2, 3  Three different 
immunosensor assemblies were studied and used for the detection of antibody.  The first 
assembly consisted of a purchased 5 MHz QCM crystal with Au electrode, 
polyelectrolyte, and MPC antigen mimic.  To assemble this immunosensor, the Au 
electrode was first cleaned with piranha and ozone as previously described (CAUTION: 
handle piranha solutions with care).2  The crystal was then mounted in the holder/flow 
cell, rinsed with 50 mM pH 7.2 phosphate buffer (PB), and brought to resonant 
frequency.  A constant flow of 28 µL/min was used through this assembly procedure.  
Polyelectrolyte (0.05%) in PB was then pumped through the flow cell for 15 min.  After a 
10-min rinse with PB, MPC (2.4 µM) in PB was pumped for 30 minutes.  Again the 
crystal was rinsed with PB for 10 min and was followed by BSA (16 µM) for 20 min.  
After a 10 min rinse with PB, the sensor was ready for antibody binding.  Antibody 
binding to antigen mimics was completed by introducing antibody for a set time of 10 
min at a constant flow of 28 µL/min.  Maximum adsorption values were recorded after 
unbound antibody was rinsed out of the flow cell.  Initial antigen mimic screening assays 
used one immunosensor for the binding of no more than two different antibodies, each at 
a concentration of 124 nM in PB.  If the first Ab showed adsorption, a new 
immunosensor was assembled before further Ab addition.  If the first Ab showed no 
adsorption, a second Ab was introduced.  In this case, Ab was thoroughly rinsed out of 
the flow cell before the second antibody was introduced.  Concentration dependent 
studies for both the antigen mimic and the intact protein antigen used a range of 
concentrations and a newly prepared immunosensor for each concentration.  Control 
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experiments were conducted as above and newly prepared immunosensors were used for 
each sample.  Later experiments used optimized fluidic systems (Cole-Parmer Masterflex 
4 channel peristaltic pump with 0.25 mm ID santoprene tubing), allowing for faster flow 
rates and shorter flow times (detection times).  Pooled human sera were also used as a 
blocking agent in mouse sera studies in an attempt to limit non-specific adsorption. 
Antibody binding to nanocluster was also attempted using a covalent strategy for 
MPC immobilization.  SAMs were formed out of dithiol ligands and MPCs were place 
exchanged onto the SAM surface.  Two different SAMs were studied: a single monolayer 
of 1,6-hexanedithiol (HDT) and a mixed monolayer of 50/50 (mol/mol) HDT and β-
mercaptoethanol (BME).  SAMs were formed in ethanol overnight then rinsed in ethanol 
and DI water.  In initial experiments, Tiop-MPC was then reacted with the surface at 0.1 
mg/mL in DI water for 2-3 days.  QCM crystals with SAMs only and with SAM-MPC 
structures were initially characterized by Atomic Force Microscopy (Veeco Digital 
Instruments, Nanoscope IIIa using a monolithic Si tip with 300 kHz resonant frequency 
and 40 N/m force constant).  Further experiments using Tiop-MPC (0.5 mg/mL) involved 
place exchange onto HDT/BME SAMs and subsequent examination of non-specific 
binding using PBS and purchased pooled normal human serum (CAUTION: Biohazard).  
Similar sensors were then assembled using Tiop-MPC presenting conformational PA 
peptides.  PA-MPC was place exchanged onto SAMs for 1-11 days and sensors were 
examined for antibody binding, reusability (regeneration), and for non-specific binding 
(using anti-HA and anti-RSV antibodies). 
Antibody binding to the intact protein, protective antigen (PA), was achieved through 
the assembly of an immunosensor consisting of a 5 MHz QCM crystal with Au electrode, 
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PA, and BSA.  After cleaning, mounting, and rinsing the crystal it was brought to 
resonant frequency.  A constant flow of 28 µL/min was used through the assembly.  PA 
(96 nM) in PB was introduced for 15 min and was followed by PB rinse for 10 min.  BSA 
(16 µM) was then introduced for 15 min.  After a 15-min rinse with PB, the sensor was 
ready for antibody binding.  Antibody binding to the intact protein antigen was completed 
by introducing antibody for a set time of 10 min at a constant flow of 28 µL/min.  
Maximum adsorption values were recorded after unbound antibody was rinsed out of the 
flow cell. 
 
Surface Plasmon Resonance Spectroscopy 
 SPR measurements were made using a Biacore 3000 instrument.  Bare Au sensor 
chips were used in antibody detection strategies and were cleaned with piranha (as above) 
before use.  A custom program was written for the detection of antibody binding to 
antigen mimic and was repeated sequentially to obtain binding data at several antibody 
concentrations.  Flow was set at 50 µL/min through all channels, consecutively, and the 
detection mode was set to all four channels with no reference.  The following sequence 
was then begun:  50 mM NaOH 2 min; wait 1 min; 2.5 M NaCl 2 min; wait 1 min; 50 
mM HCl 2 min; wait 1 min; change flow to 30 µL/min; wait 1 min; 0.05% 
polyelectrolyte in PBS 3 min; wait 1 min; 1 mg/mL MPC in PBS 3 min; wait 2 min; 1 
mg/mL BSA in PBS 2 min; wait 2 min; antibody in PBS 2 min; wait 2 min.  Both MPC 
and antibody were potentially varied with each cycle. 
 CM-5 sensor chips were used for the detection of antigen mimic.  Antibody was 
amide coupled to the dextran-coated chip using standard EDC/NHS techniques.  For 
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coupling experiments the flow rate was set at 10 µL/min.  EDC (0.4 M) and NHS (0.1 M) 
were mixed prior to injection.  Activation lasted for 7 min and was followed by washing 
with PBS.  Antibodies were dissolved at 40 µg/mL in 10 mM acetate buffer at pH 4.5 and 
injected for 5 or 10 min.  Flow cell 1 was exposed to no antibody, flow cell 2 to antibody 
110 (10 min), flow cell 3 to anti-ebola glycoprotein 6D11 (5 min), and flow cell 4 to 
antibody 110 (5 min).  After rinsing with PBS, excess ethanolamine was injected for 7 
min to quench any remaining activated carboxylic acid groups.  Nanocluster was then 
analyzed by setting the flow rate to 30 µL/min and using the following references: FC2-
FC1 and FC4-FC3.  Antigen mimic was then injected for 2 min and was followed by 
regeneration with 2.5 M NaCl for 30 s at 60 µL/min.  A different mimic or concentration 
of mimic was injected with each cycle.  Concentrations ranging from 0.001 to 1.0 mg/mL 
were used. 
 
Mouse Antibody Production 
 Antibody production using conformational peptide epitope functionalized 
nanoclusters required 34 Balb/c, female, 6 week old mice (Harlan, Indianapolis).  Mice 
were injected on three days, each day separated by two weeks.  On the injection day, each 
mouse was injected twice: 200 µL intraperitoneal (peritoneal cavity) and 200 µL 
subcutaneous (skin on back of neck).  A summary of injection groups and concentrations 
is available in Table 9.  All experimental protocols using animals were approved by 
Vanderbilt University Institutional Animal Care and Use Committee (M/05/235).  
Nanoparticles were prepared as described above and had compositions as listed in Table 
6 (A2, E, G).  All solutions were sterile filtered before injection.  Control injections 
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involved the introduction of the linear PA peptide (PA680M) via a keyhole limpet 
hemocyanin (KLH, Pierce Biotechnology) carrier.  KLH (1.2 nmol) was co-dissolved 
with sulfo-SMCC (108 nmols, Pierce Biotechnology) in PBS, vortexed, and reacted for 
30 min at room temperature.  Purification of unbound sulfo-SMCC was achieved by 
Centricon 5000 MWCO spin filter (three washes, centrifuged at 4000 rpm).  PA680M 
peptide (180 nmols) was added to the purified KLH-sulfo-SMCC, vortexed and reacted 
for 30 min at room temperature.  Purification was completed as above.  The washes, 
containing unbound PA peptides, were collected and concentration was determined by 
absorbance at 280 nm (using a standard curve).  Four weeks after the last injection, blood 
was collected via the saphenous vein.  Approximately 100 µL of whole blood was 
collected per mouse.  After waiting for coagulation to occur, samples were centrifuged at 
10000 rpm for 15 min.  The supernatant was collected and stored at either 4 oC (short 
term) or -80 oC (long term).  Sera samples were analyzed by ELISA (below) or QCM, as 
previously described. 
 Mice that expired after the initial injection were dissected for examination and 
collection of heart, lungs, spleen, and liver tissue.  Tissue was briefly examined for 
pathological abnormalities (H. Mok) and examined for gold content.  Tissue from one 
mouse was homogenized in a ground glass apparatus using minimal amounts of aqueous 
NaOH (20 mM).  Samples were centrifuged at 4500 rpm and supernatants were collected.  
Samples were analyzed by energy dispersive x-ray spectroscopy (EDAX) using a Philips 
CM-20 TEM operating at 200 keV and 30,000 x magnification.  Blank grids were used as 
a control and the same volume of sample was spotted onto clean grids for each 
experiment. 
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Enzyme-linked Immunosorbant Assay 
 ELISA was used to initially screen mouse sera samples versus the PA protein, HA 
protein, or antigen mimics.  Checkerboard experiments using the PA protein and anti-PA 
antibody (antibody 110) were conducted to determine optimal conditions.  Immulon well-
plates were used in all cases.  Experiments against the PA protein used 400 or 500 ng of 
antigen per well (in PBS), blocking with 1 mg/mL BSA, sera diluted to 1:10, 1:100, or 
1:1000 in PBS, secondary antibody (goat anti-mouse HRP conjugate) diluted 1:5000 in 
PBS, and washing with PBS/T (50 mM PB, 150 mM NaCl, 0.01% tween-20) between 
each step.  The HRP substrate TMB (3,3’,5,5’-tetramethylbenzidine) was then introduced 
and followed by 0.5 M H2SO4.  Absorbance was read at 450 nm.  Experiments against the 
HA protein used similar conditions except for the use of 100 ng of protein per well and 
1:100 dilution of sera.  Experiments against the PA680B-MPC antigen mimic used 
similar conditions, except for the use of 1 µg of nanocluster per well and 1:100 dilution 
of sera. 
 
Results and Discussion 
 
Antigen Mimic Synthesis and Characterization 
The results of this study demonstrate an ability to assemble conformationally relevant 
antigen mimics and use them in the epitope mapping of a potential bioterrorism agent.  
Traditional mapping techniques place emphasis on discontinuous conformational or 
continuous linear epitopes but have overlooked the local conformation or secondary 
structure present in peptides longer than eight amino acids.  Continuous conformational 
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peptide epitopes offer a potential for enhanced antigenicity, as well as immunogenicity, 
and deserve the attention of those mapping antigens and designing vaccines.   This 
research shows reconstitution of loop structures from the protective antigen of B. 
Anthracis on the surface of monolayer protected clusters to produce linear and 
conformational antigen mimics. 
Peptide epitopes found in Table 5 were synthesized for presentation on MPCs.  Cys 
residues were added at the N- and/or C-terminus to promote bidentate or monodentate 
exchange and Ala residues were similarly added for a lack of reactivity or presentation.  
Concurrently, water-soluble, nanometer-sized, monolayer-protected clusters were 
synthesized with tiopronin, a glycine derivative, as the passivating ligand, as previously 
reported.2, 44  Careful characterization allowed for the calculation of an average diameter, 
compositions, and molecular weight (Table 6, according to established methods, see 
Chapters II and III).  The epitope and MPC scaffold were then brought together through 
place exchange reactions to produce functional nanostructures.34, 35   
 
Table 5.  Amino acid sequences for peptides used in antigen mimic design.  
Highlighted Cys and Ala (red) were not part of the epitope, but added for 
functionalization and immobilization purposes. 
 
Peptide Sequence MW, Da Reference 
PA680B   C KYNDK LPLYI SNP C 1771 110, 135-138, 140 
PA680M     KYNDK LPLYI SNP C 1668 110, 135-138, 140 
PA680A  AA KYNDK LPLYI SNP A 1778 110, 135-138, 140 
PA703B   C KENTI INPSE NGDTS TNGIK C 2339 110, 135-137 
PA730M   C KGYEI G 769 138 
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Figure 30.  1H NMR of (c) free PA680B peptide, (b) pure Tiop-MPC, and (a) peptide 
presenting MPC, showing successful peptide presentation. 
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Figure 31.  2D TOCSY of synthetic peptide (PA680M) and corresponding proton 1D 
spectra (above), highlighting peak assignments. 
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Following each exchange, the extent of presentation was determined by 1H NMR, as 
previously described (Chapter III).49  Representative 1H NMR for the free peptide 
PA680B, Tiop-MPC, and peptide-presenting MPC (PA680B-MPC) are available in 
Figure 30.  Quantitative determination of peptides on an MPC is obtained through the 
ratio of integration values of peaks indicative of tiopronin and of peptide.  Knowledge of 
the number of protons that are associated with an individual peak is, therefore, essential 
to a correct ratio.  In order to facilitate peak assignment in the peptide PA680M, total 
coherence spectroscopy (TOCSY) was performed (Figure 31).  TOCSY is a 2D NMR 
experiment that transfers magnetization between 1H spins that are connected by any 
number of scalar couplings.  The strength of the coupling decreases as the number of 
transfers increases, but strong cross peaks do arise through as many as three or four 
bonds.158  Through these cross peak correlations it is possible to make peak assignments 
and obtain values of 15 protons for the peak at ~0.8 ppm, 4 protons for the peak at ~ 2.9 
ppm, 4 protons for the peak at ~6.7 ppm, and 4 protons for the peak at ~7.0 ppm.  This 
has allowed accurate determination of peptide presentation, which in most cases has been 
confirmed by an iodine kill reaction.  A cartoon schematic and final composition of all 
antigen mimics used in the following studies are available in Figure 32 and Table 6, 
respectively. 
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Table 6.  Final composition of antigen mimics used in the following experiments.  A2 
was used in mice experiments only, while A1 was used in all other studies.  aHA 
peptide comes from the hemagglutinin protein of influenza (see Chapter III). 
 
Peptide MPC Diameter, nm Attachment Composition 
(A1) PA680B 3.5 + 1.0 Conformational         Au807Tiop290Pep4 
(A2) PA680B 3.1 + 1.0 Conformational         Au561Tiop150Pep7 
(B) PA680M 3.5 + 1.0 Linear         Au807Tiop294Pep4 
(C) PA703B 3.5 + 1.0 Conformational         Au807Tiop282Pep8 
(D) PA730M 3.5 + 1.0 Linear         Au807Tiop288Pep10 
(E) aHA 3.1 + 1.0 Linear         Au561Tiop156Pep8 
(F) none 3.5 + 1.0 Control         Au807Tiop298 
(G) none 3.1 + 1.0 Control         Au561Tiop164 
 
 
 
Figure 32.  X-ray crystal structure135 of the protective antigen of B. anthracis 
(middle) and cartoons of PA mimics highlighting the conformational and linear 
epitopes.  Three known epitopes are highlighted in the crystal structure:  amino acids 
680-692 (red), 703-722 (blue), 730-735 (magenta). 110, 135-138, 140 
 
 
Characterization of Epitope Conformation 
The faithful reconstruction of epitope loops in a physiologically-relevant 
conformation is predicated on the ability to assemble loop peptides in a bidentate fashion.  
A linear epitope, such as the c-terminus of PA (PA730M), can easily be attached to the 
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MPC in a monodentate fashion, which will afford the peptide a good chance of 
maintaining its correct conformation.  On the other hand, peptide epitopes that come from 
flexible loop regions of proteins cannot suffer monodentate attachment and be expected 
to adopt the correct conformation.  Immobilizing both ends of the peptide in a bidentate, 
bivalent mode restrains the peptide and promotes a conformation comparable to its native 
form.  This is not an attempt to “fold” a peptide, only an attempt at placing the peptide in 
an environment similar to that of the intact protein.  One challenge was in the 
characterization of the mode of attachment.  The diversity of particle size can affect loop 
attachment, creating a large combinatorial set of epitope conformations.  Techniques like 
circular dichroism and two-dimensional NMR have been successful in evaluating peptide 
conformation.  Using CD spectroscopy, free peptide was determined to be in a random 
coil conformation, with peak at ~197 nm, and was shifted to higher wavelength upon the 
addition of trifluoroethanol, which promotes helicity.  Peptide-MPCs did not exhibit 
random coil characteristics, suggesting some sort of associated conformation.  
Unfortunately, low concentration of peptide on the surface of the MPC, cluster 
absorbance, and characteristically broad NMR peaks limit CD and NMR applicability to 
this study.   
Instead, the mode of peptide attachment to the nanocluster was probed with a free 
thiol labeling molecule, Ellman’s Reagent (ER).159  Incubation of PA680B-MPC (A1) 
with Ellman’s Reagent would cause thiol labeling if one end of the peptide loop was 
attached to the MPC and the other thiol was otherwise free.  Reacting ER with free 
peptide PA680M produced a characteristic yellow color and, after purification, showed  
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Figure 33.  1H NMR of Ellman’s Reagent derivatized free peptide (PA680M), 
showing aromatic peaks (circled blue).  Similar derivaziation of PA680B-MPC 
(circled green) and PA680B-MPC after isolation of ligands only (circled red) show no 
peaks in that region. 
 
 
thiol derivatization in 1H NMR and MALDI-MS.  Conversely, reacting ER with 
PA680B-nanocluster complex (A1) resulted in no indication of derivatization, as seen in 
Figure 33.  Labeling experiment with Ellman’s Reagent have supported bidentate 
attachment by indicating a lack of free, unattached thiol in an MPC solution, but provide 
no information on conformation.  A further test of epitope conformation was to show a 
difference in antibody binding to linear versus conformational antigen mimics. 
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Epitope Mapping 
A sensitive and selective immunosensor involving a QCM quartz crystal with gold 
electrode and the sequential layering of a polyelectrolyte,75, 76 MPC, and blocking with 
BSA, leading to the immobilization of antigen mimics, provided a foundation for 
antibody screening.  Representative adsorption and average binding results of 
polyelectrolyte (0-30 min), MPC (30-60 min), and BSA (80-100 min) can be seen in 
Figure 34 and Table 7, respectively.   
 
 
Figure 34.  Representative polyelectrolyte, PA680B-MPC, BSA, and antibody 110 
binding in phosphate buffer. 
 
 
Binding studies involved seven mouse monoclonal anti-PA antibodies obtained from 
Biodesign International that were known to bind both the full-sized PA (83 kDa) and the 
furin-cleaved PA (63 kDa) (according to Western Blot), but had not been tested for 
ability to neutralize the toxin.160  These antibodies were screened at constant 
concentration against the four PA mimics in order to map the antibodies to different  
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Table 7.  Results of immunosensor assembly (in µg) and for screening monoclonal 
anti-PA antibodies (124 nM) against four antigen mimics (in ng).  Screening was 
completed using QCM and all values represent changes in mass.  Data suggests 
antibody 110 as having strong and specific interaction with PA680B-MPC (A1). 
 
 (A) (B) (C) (D) 
Ave PolyE 0.16 + 0.03 0.16 + 0.03 0.16 + 0.03 0.16 + 0.03 
Ave MPC 1.12 + 0.06 0.80 + 0.07 0.73 + 0.06 0.68 + 0.07 
Ave BSA 0.06 + 0.05 0.13 + 0.05 0.14 + 0.02 0.21 + 0.02 
mAb 110 20 10 0 0 
mAb 201 15 0 10 14 
mAb 301 0 10 0 0 
mAb 410 10 0 10 16 
mAb 501 10 10 0 11 
mAb 601 10 10 0 10 
mAb 613 13 0 10 10 
 
 
conformational and linear regions of the antigen.  At a relatively low concentration (124 
nM) of antibody, screening experiments provided qualitative information on recognition 
or lack of recognition and guided further studies (Table 7).  The results of the screening 
experiments suggest cross reactivity for several antibodies, though antibody 110 was 
identified as being potentially selective for the conformational epitope spanning amino 
acids 680-692. 
 
Monoclonal Antibody Binding 
Monoclonal antibody 110 was studied in more detail using a QCM immunosensor 
similar to that used in the epitope mapping experiments and by varying the concentration 
of antibody and the ionic strength of buffers.  Seven experiments for each of two antigen 
mimics (PA680B-MPC A1 and PA680M-MPC B) differing only in mode of peptide 
attachment (bidentate vs monodentate) showed saturation of the immunosensor.  The four 
highest concentrations for each mimic were fit to a logarithmic curve (Figure 35).   
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Table 8.  Results from equilibrium calculations for two antigen mimics and the 
protective antigen protein.  Experiments were conducted in phosphate buffer (no 
added NaCl) or in phosphate buffered saline (150 mM NaCl).  aEquilibrium constant 
calculated from kinetic constants, where Ka = kf/kr.  bCalculated from SPR 
experiments.  cUnable to calculate due to a lack of binding. 
 
Equilibrium Constants Antigen [NaCl], mM Ka (x 106 M-1) 
MPC-PA680B (A1) 0 5.9 + 0.7 
 0 a4.0 + 0.8 
 150 2 + 1 
 150 b1.1 + 0.2 
MPC-PA680M (B) 0 2.6 + 0.9 
 150 c-- 
Protective Antigen 0 12 + 6 
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Figure 35.  Plot of ∆m against [anti-PA 110] for PA protein antigen (circle) with non-
linear (long/short dashed line), MPC-PA680B (square) with non-linear fit to the four 
highest concentrations (solid line), MPC-PA680M (triangle) with non-linear fit to the 
four highest concentrations (long dashed line), and MPC-PA680B (diamond) in PBS 
with logarithmic fit (short dashed line) showing saturation of the immunosensor in all 
cases. 
 
 
Equilibrium association constants (Ka) were determined for each mimic by fitting the 
four highest concentrations to a Langmuir adsorption isotherm (Table 8).2, 3  PA680B-
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MPC (A1) had a Ka of (5.9 + 0.7) x 106 M-1, which falls within a general range for 
immuno-affinity of 106 – 1010 M-1 and shows an increased affinity over a previously 
reported glutathione-presenting nanocluster with polyclonal antibody (Ka = 3.6 x 105 M-
1).2  Antibody 110 had a decreased affinity for the linear epitope-presenting nanocluster 
(PA680M-MPC (B), Ka = (2.6 + 0.9) x 106 M-1) suggesting a real difference between 
peptide epitopes of identical primary structure but different secondary structure. 
These results were validated by control experiments using Tiop-MPC (F) and buffer 
of increasing ionic strength (Figure 36).   
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Figure 36.  Relative binding percent for 300 nM 110 antibody to seven different 
nanocluster systems, normalized to density of nanocluster displayed on 
immunosensor surface.  All samples were run in 50 mM phosphate buffer with 
varying concentrations of NaCl (1 = 0 mM, 2 = 50 mM, 3 = 150 mM). 
 
 
Salt gradients are typically used in affinity chromatography and are known to decrease 
weak non-covalent interactions.161  In initial studies, the background antibody binding to 
Tiop-MPC (F) and PA680M-MPC (B) in 50 mM phosphate buffer was relatively high.  
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The addition of 150 mM NaCl decreased weak, non-specific adsorption seen in Tiop-
MPC (F) and PA680M-MPC (B), but had a significantly lower effect on PA680B-MPC 
(A1).  Furthermore, the addition of only 50 mM NaCl had essentially no effect on 
antibody binding to PA680B-MPC (A1).  This allowed for the study of concentration 
dependence of antibody 110 binding to PA680B-MPC (A1) in high ionic strength buffer.  
Here the association constant (Ka = (2 + 1) x 106 M-1) was only slightly less than that 
calculated in low ionic strength (Figure 35, Table 8), confirming strong recognition and 
limited non-specific adsorption. 
Kinetic information calculated for PA680B-MPC (A1) (kf = (9 + 2) x 103 M-1s-1 and kr 
= (2.3 + 0.5) x 10-3 s-1) from the time-dependent binding curves supports the equilibrium 
data and the immunorecognition of conformational mimics by antibodies.  The 
equilibrium adsorption constant, Ka, is equal to the ratio of kf/kr and was calculated to be 
(4.0 + 0.8) x 106 M-1, which correlates well with the Ka found in the previous method 
(Figure 35, Table 8).  Kinetic constants relate to the kinetics of polyclonal antibody 
binding to glutathione-MPC, where kf = 5.4 x 101 M-1s-1 and kr = 1.5 x 10-4 s-1.2  It is 
reasonable that this forward rate constant is less than the forward rate constant for 
monoclonal anti-PA antibody due to the heterogeneity of the polyclonal anti-GSH 
sample.  The binding kinetics for snake neurotoxin α-bungarotoxin to synthetic peptide 
mimitopes have been reported114 with kf in the range of 101 – 104 M-1s-1 and kr in the 
range of 10-3-10-4 s-1.  The kinetic rate constants for monoclonal antibody 110 binding to 
PA680B-MPC (A1) also fall within these ranges. 
Antibody binding to intact protein antigen was studied for comparison with the 
antigen mimics.  Antibody was shown to specifically bind the protein in PB with a Ka 
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value slightly larger than that calculated for the nanocluster antigen mimic (Figure 35, 
Table 8).  The antibody did display high background adsorption to BSA in 50 mM 
phosphate buffer, but decreased in high ionic strength buffer, while antibody binding to 
PA was only slightly affected by an increase in ionic strength.  Antibody binding at one 
concentration (300 nM) in PBS showed binding at a level consistent with a possible Ka of 
approximately 6 x 106 M-1 (rough extrapolation), which is only three times greater than 
that reported for PA680B-MPC in PBS.  Furthermore, anti-HA antibody, which is not 
specific for PA, showed no binding to the PA protein in low ionic strength buffer.  The 
similarity of antigen and antigen mimic Ka values points to the exceptional reconstitution 
of the conformational peptide epitope on the surface of the nanocluster. 
Antibody 110 binding to a second, separate batch of PA680B-MPC (composition 
essentially identical to that of A1) was examined using a covalent, rather than ionic, MPC 
immobilization strategy.  A robust, covalent, synthetic sensor would allow for sensor 
regeneration and reusability as well as long term stability and storage.  Immunosensor 
assembly involved the place exchange of soluble antigen mimics onto the QCM surface 
via dithiol intermediates.  An HDT (1,6-hexanedithiol) SAM was self-assembled and 
Tiop-MPC (F) was place exchanged onto the surface in initial experiments.  AFM was 
used to confirm attachment and suggested successful exchange according to variations in 
surface roughness (Figure 37).  These Tiop-MPC presenting crystals were then used to 
study non-specific binding characteristics using pooled human sera at various dilutions in 
PBS.  Results suggested that dilutions between 1/500 and 1/1000 gave acceptably low 
non-specific binding under these conditions.  The next step was to immobilize PA680B-
MPCs (A1) that had been confirmed to be able to bind antibody 110 under standard 
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conditions (ionic, non-covalent immobilization procedure).  Five crystals were 
functionalized with HDT and allowed to react with PA680B-MPC (A1) for 3, 5, 7, 10, or 
11 days in order to study the effect of place exchange time on sensor sensitivity.   
a b
 
Figure 37.  AFM measurement of (a) HDT SAM on gold QCM electrode, showing 
smooth surface with small features; (b) HDT SAM after place exchange with Tiop-
MPC (F) on gold QCM electrode, showing roughened surface with larger, 3-5 nm 
height features. 
 
 
Unfortunately, antibody 110 binding to all the sensors was minimal or similar to binding 
by non-specific antibodies (anti-HA or anti-RSV).  Due to the length of time required for 
place exchange, it is difficult to know the actual amount of mimic presented on the QCM 
surface.  It is thought that the slow kinetics of place exchange at a heterogeneous 
interface resulted in an unacceptable level of MPC density and an elevated limit of 
detection.  Further progress in the area of covalent MPC immobilization is needed and 
may require a kinetically-favorable reaction, possibly involving amide coupling or a 
biotin/avidin interaction. 
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Surface plasmon resonance spectroscopy is a surface optical wave technique that is 
widely used in immunosensing.  It has recently been compared to QCM in a number of 
different settings.2, 3  In order to further confirm the affinity of anti-PA antibody 110 for 
PA680B-MPC (A1), SPR binding measurement were carried out on a Biacore 3000 
instrument.  Two binding methods were pursued.  First, the standard polyelectrolyte 
immobilization of MPC was used to detect antibody binding.  Since optical techniques 
can often be sensitive to molecules with high molar absorptivities, the MPC 
immobilization and antibody detection strategy was intended to limit these effects.  At the 
beginning of each binding cycle the bare gold chip was rinsed with 50 mM NaOH, 2.5 M 
NaCl, and 50 mM HCl to remove any previously bound antibody or MPC.  The  
 
 
Figure 38.  Representative SPR experiment involving chip washing, PA680B-MPC 
(A1) immobilization, and antibody detection.  (A) Washing with 50 mM NaOH; (B) 
washing with 2.5 M NaCl; (C) washing with 50 mM HCl; (D) polyelectrolyte 
adsorption; (E) PA680B-MPC adsorption; (F) BSA blocking of non-specific 
adsorption sites; (G) antibody binding and detection.  Washing with PBS occurred 
between each step. 
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polyelectrolyte, MPC, and BSA layers were then assembled before introduction of the 
antibody.  A representative sensogram for the assembly and detection is available in 
Figure 38.  Various MPCs and antibody concentrations were used in each binding cycle.  
The results are available in Figure 39 and show significant binding of antibody 110 to 
PA680B-MPC in PBS, as expected.  Binding appears to approach saturation at high 
concentrations and a detection limit of approximately 100 nM is observed, which is 
similar to QCM detection limits.   
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Figure 39.  Plot of [Ab110] versus RU for binding to PA680B-MPC (A1) with a non-
linear fit to the three highest concentrations.  A control experiment (o) at 300 nM 
shows lack of binding to underivatized tiopronin MPC (F). 
 
 
This data was used in the calculation of the equilibrium binding constant, where Ka = (1.1 
+ 0.1) x 106 M-1 (Table 8).  This agrees very well with the Ka calculated in QCM 
experiments, previously detailed (2 x 106 M-1).51  Control experiments confirm specificity 
of this interaction as antibody 110 did not bind to underivatized Tiop-MPCs (F).  The 
error bars on the graph (Figure 39) are relatively large and come from the average of the 
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four SPR flow cells.  This might be indicative of intrinsic differences in each flow cell, 
differences in the layer assembly for each flow cell, or may result from MPC interference 
with optical detection. 
The second SPR binding method involved the coupling of antibody to a CM-5 
dextran chip and the attempted detection of nanocluster.  Antibody was successfully 
amide coupled to the chip with final Response Units of 247 for FC1 (control), 5989 for 
FC2 (antibody 110), 2533 for FC3 (anti-ebola glycoprotein antibody), and 3937 for FC4 
(antibody 110).  Initial injection of MPCs showed refractive index changes of 20 to 100 
RUs, suggesting possible interference with the optical measurements.  While the Biacore 
3000 instrument uses a light source at 760 nm, where nanoclusters have relatively low 
absorbance, a large refractive index change is not unlikely.  Previous examples of 
nanocluster detection in SPR instruments plotted percent reflectance versus time,16, 72 
rather than the angle of minimal reflectance versus time, which in common in Biacore 
instruments and may result in poor detection.  Nanocluster detection made use of FC1 
and FC3 as reference cells, allowing for the subtraction of non-specific refractive index 
changes.  While subtraction seemed to work well, binding was only minimally detected 
(S/N ~ 2) at the highest concentrations of antigen mimic (1 mg/mL), resulting in a high 
detection limit and a lack of data for the calculation of an equilibrium association 
constant.  While SPR was useful in confirming antibody binding to PA680B-MPC (A1) 
under certain circumstances, it was ineffective in other cases. 
These results highlight the antigenicity of conformational peptide epitope 
functionalized nanoclusters and confirm the importance of secondary structure in addition 
to primary sequence for antibody recognition.  A monoclonal antibody (110) was 
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effectively mapped to the amino acids spanning 680-692 in the protein sequence of the 
protective antigen of B. Anthracis and we have shown there to be a significant difference 
between linear and conformational antigen mimics. 
 
Antigen Mimic Immunogenicity 
 Linear and conformational peptide epitope functionalized nanoclusters or antigen 
mimics have been shown to be antigenic (interface effectively with antibodies) in several 
cases.2, 21, 49, 51  Conformational antigen mimics have also been shown to interface more 
effectively with antibodies as compared to their linear counterparts.51  The next step in 
characterizing these antigen mimics would be to evaluate their immunogenicity (ability to 
interface with an immune system and illicit an immune response) using a mouse model 
system.  Thirty four mice were used in these experiments and were divided into 8 groups 
(Table 9).  Each mouse was injected with 200 µL of material both subcutaneous and 
intraperitoneal for a total of 400 µL.   
 
Table 9.  Summary of injection groups and concentrations of antigens used in 
antibody production assay.  aPA680M peptide conjugated to KLH carrier protein.  
bGroup inadvertently injected with one dose of PA-KLH on Day 1 and (A2) at 9.5 µM 
on Day 14.  This group was not used in further experiments. 
 
Antigen [Antigen], µM 
[Effective Epitope], 
µM 
Material/Dose, 
mg 
# of 
Mice 
PA680B-MPC (A2) 9.5 66 0.52 5 
 73.7 516 4.04 5 
HA-MPC (E) 8.0 64 0.44 3 
 64 510 3.5 3 
Tiop-MPC (G) 40 0 2.2 5 
aPA-KLH 0.30 9.0 1.0 4 
bKLH/MPC N/A N/A N/A 5 
No Injection 0 0 0 4 
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This injection was repeated on two additional days as booster shots.  While this study was 
intended as an antibody production assay, toxicology issues also became a priority.  Upon 
injection of high concentrations of nanocluster (73.7 µM PA680B-MPC A2 and 64 µM 
HA-MPC E), mice experienced visible distress, ruffled fur, and lethargy in less than 72 
hr.  By this time two mice had expired and the rest were euthanized by CO2 inhalation 
(Figure 40).   
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Figure 40.  Percent of mice surviving 72 hr after injection with various concentrations 
of antigen.  Concentrations are normalized to moles of nanoparticle injected, not to 
the moles of peptide epitope presented.  LD50 may be approximated at 50 µM. 
 
 
After euthanization, the mice were dissected and initially inspected visually for 
misinjection, pooled precipitated nanocluster, or darkened organs.  None of these 
occurrences were observed, indicating that the nanoclusters were soluble and were 
distributed throughout the body via the blood stream.  Heart, lungs, liver, and spleen 
organs were collected from at least three mice and fixed in formalin.  The organs from  
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Table 10.  Qualitative Au detection in organ tissue extraction using EDAX. 
 
Tissue Presence of Au 
none - 
Heart ++ 
Lungs + 
Liver + 
Spleen +++ 
 
 
one mouse were collected for analysis of gold content, while the organs from other mice 
were analyzed for pathological abnormalities by Hoyin Mok.  No abnormalities were 
reported.  Organs collected for gold analysis were homogenized and extracted with 20 
mM NaOH.  The samples were centrifuged and the supernatant was collected and further 
filtered.  Qualitative gold analysis was completed via energy dispersive x-ray 
spectroscopy using an EDAX-equipped TEM and showed significant levels of gold in the 
spleen and heart and reduced levels in the lungs and liver (as compared to a blank grid, 
Table 10).  While quantitative analysis may be possible using EDAX, a second method of 
analysis may be elemental analysis.  Future toxicology studies should focus on these 
quantitative techniques as well as blood and urine analysis.  While this impromptu study 
provided no conclusive explanation for the toxicity of these nanoparticles, the relatively 
high retention of gold in the spleen and heart after 72 hrs may be important.  Studies 
involving similar gold clusters show clearance from the blood in approximately 24 hrs 
and stable/increasing retention in the liver and kidneys at 72 hrs post-injection.153, 156  
This suggests good retention, which is important for extended interaction with the 
immune system and the production of antibodies.  On the other hand, related studies 
report no significant toxic effects,149, 152-154, 156 while these peptide-presenting 
nanoclusters show significant toxicity at high concentrations.  A possible explanation for 
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this may involve excessive stimulation of the immune system or a form of 
hypersensitivity or immunopotentiation.162, 163  It is possible that this size and 
composition of gold nanoparticle act as a potent adjuvant in stimulating an immune 
response.  Over stimulation could then result in a number of different deleterious 
effects.162, 163  These toxicological effects certainly require further attention before more 
progress is made in immunogenicity studies. 
 All other mice, injected with low concentrations (8-40 µM) of nanoparticle or KLH, 
experienced slight discomfort (slightly ruffled fur), but were generally active and 
unaffected by nanoparticle toxicity.  An exception to this would be one mouse in the 
Tiop-MPC (G) group that received a moderate dose of nanoparticle (40 µM) and expired 
6 days post-injection.  These remaining mice received injections on two more days, 
spaced two weeks apart.  Four weeks after the final injection, blood was drawn via the 
saphenous vein and a second collection of blood was completed two weeks after the first 
blood draw to obtain more samples.  Mice were euthanized shortly thereafter.  Whole 
blood samples were allowed to coagulate and then centrifuged in order to collect the sera.  
Sera samples were screened against the PA protein, the HA protein, and the PA680B-
MPC antigen mimic (A2), initially using ELISA and later confirming results using QCM.  
ELISA experimental parameters were first optimized using a checkerboard assay with PA 
protein and anti-PA antibody (antibody 110) as well as HA protein and anti-HA antibody.  
This same positive control was repeated in all subsequent experiments.  An initial 
experiment using mouse sera and PA protein showed that the best signal to noise ratio 
was achieved using a 1:10 dilution of sera in PBS, though a 1:100 dilution would also 
work.  Therefore, due to limits in sample availability, all subsequent ELISA experiments  
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Figure 41.  Results of ELISA experiments for immunized mice sera binding to (a) PA 
protein, (b) HA protein, (c) PA680B-MPC.  Results of t-test (99% confidence) 
comparing sera binding from mice immunized with (A2) or (E) to all other antigens 
are listed as + (significant difference) or – (no significant difference). 
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were run using a 1:100 dilution.  Sera from each mouse were then run in triplicate at 
1:100 dilutions against the PA protein.  The results are available in Figure 41a and show 
a slight increase in binding from sera coming from mice immunized with the PA680B-
MPC antigen mimic (A2).  Sera from mice injected with HA-MPC mimic (E) bound 
slightly less, followed by sera from mice injected with Tiop-MPC (G), which was similar 
to the unexposed mice.  Similar binding was observed for PA680B-MPC (A2) immunized 
mice as compared to those mice immunized with the PA-KLH conjugate, which indicates 
a possible lack of conformational control.  Though the differences are small in these 
cases, statistics (t-test) show that there is a significant different between binding from 
PA680B-MPC (A2) sera versus HA-MPC (E), Tiop-MPC (G), and no injection sera.  In 
general, absorbance values for this ELISA are low as compared to the positive control, 
indicating less than stellar binding overall.  These results were generally confirmed by a 
standard QCM immunosensor experiment (as above), where binding of sera diluted 1:500 
from PA680B-MPC (A2) was significantly different from binding of sera from no 
injection as well as PA-KLH mice (Figure 42a).  This QCM data, as opposed to the 
ELISA, suggests that there is a difference between immunization with the conformational 
antigen mimic and the linear PA-KLH.   
 Similar results were obtained for binding to the HA protein (Figure 41b).  Sera from 
mice immunized with HA-MPC (E) bound slightly better than sera from PA680B-MPC 
(A2), Tiop-MPC (G), and no injection.  Again there are statistically significant 
differences, but overall binding is low as compared to the positive control of monoclonal 
anti-HA antibody binding to the HA protein. 
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 More promising and perhaps relevant results were obtained from sera binding to the 
PA680B-MPC antigen mimic (A2) (Figure 41c).  Absorbance was higher in these cases, 
indicating stronger overall binding, and there were more pronounced statistically  
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Figure 42.  Results of QCM experiments for immunized mice sera binding to (a) PA 
protein, (b) PA680B-MPC.  Results of t-test (99% confidence) comparing sera 
binding from mice immunized with (A2) to all other antigens are listed as + 
(significant difference) or – (no significant difference). 
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significant differences between sera from PA680B-MPC (A2) immunization as compared 
to sera from all others.  Absorbance for sera from PA680B-MPC (A2) was over double 
than that for sera from Tiop-MPC (G) and PA-KLH.  Again, this data was supported by 
QCM experiments using polyelectrolyte to immobilize the PA680B-MPC (A2) antigen 
mimic and pooled human sera to block non-specific sites (Figure 42b).  Sera diluted 
1:500 from mice immunized with PA680B-MPC (A2) showed substantially more binding 
than any other samples.  This data indicates several things about the induced immune 
response:  1) the response is predicated on peptide epitope presentation and not the Tiop-
MPC scaffold; 2) there is a significant difference in the presentation style of peptide on 
the MPC as opposed to peptide conjugated to KLH; 3) nanoparticle antigen mimics are 
immunogenic to themselves.  Peptide-presenting gold MPCs are immunogenic in the 
sense that they can illicit an immune response and spur the production of antibodies that 
bind specifically to the antigen mimic.  Further success of sera binding to the intact 
protein is therefore dominated by an ability to faithfully reconstitute the physiological 
conformation of the epitope.  While antigenicity experiments (above) have suggested the 
conformational antigen mimic’s proximity to physiological conformation, there are 
advances to be made.  Due to the large variation in cluster size within a batch of MPCs, it 
is likely that only a subset of nanoparticles is able to mimic the true protein conformation.  
Control over nanoparticle size is a need in future experiments and is already an area of 
intense research focus.164 
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Conclusions 
The sum of these results suggests several things about the efficacy of these complex 
antigen mimics.  First, it is apparent that we are able to successfully assemble peptides on 
nanoclusters to produce functional, immunoreactive nanoscale components.  Second, we 
are able to employ functionalized nanoclusters in the screening of available monoclonal 
antibodies and effectively map an antibody to a peptide epitope.  Third, we were able to 
differentiate between conformational and linear epitopes and include that degree of 
complexity into mapping experiments.  Antibody 110 has an apparent increased affinity 
(>2x) for the conformational antigen mimic over the linear antigen mimic and an even 
greater affinity difference in isotonic ionic strength buffers.  Control experiments 
confirmed the enhanced affinity and place the antigen mimic in the same affinity range as 
the intact protein.  These monoclonal antibodies could be used in the selection and 
isolation of tight binding, conformationally-relevant antigen mimics, providing 
information which could guide future mimic assembly.  Finally, we showed these 
conformational epitope-presenting nanoclusters to be immunogenic in eliciting an 
immune response and prompting the production of antibodies that specifically bind to the 
antigen mimic.  While produced antibodies bound only minimally to intact protein 
antigens, there is potential to enhance binding by optimizing nanocluster size and peptide 
presentation.  The placement of artificial conformational epitopes on a nanoparticle 
framework represents a significant early advance in our ability to control 
immunomodulation at the nanoscale. 
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CHAPTER V 
 
COUPLED MONOLAYER-PROTECTED CLUSTERS EXHIBIT ENHANCED NEAR 
 IR FLUORESCENCE 
 
Introduction 
Nanometer-sized monolayer-protected metal clusters (MPCs) have received 
considerable attention for their intense optical properties, including broad fluorescence 
emission in the visible and near infrared spectrum,33, 165-168 which makes them potential 
candidates for chemical and biological sensing applications.  Important experiments165, 166 
have helped to elucidate the mechanism of fluorescence as well as dependence on metal 
core composition, metal core size, and passivating ligand composition.  Generally, 
nanoparticles with gold or silver cores of diameter less than 5 nm with organic or water 
soluble passivating ligands have shown the most promising results.165  Specifically, small 
(1.8 nm diameter) tiopronin-protected gold nanoparticles were shown to have high 
efficiency (~ 0.3%) visible luminescence.166  The mechanism of visible luminescence has 
been suggested to involve a size-dependent opening of the HOMO-LUMO energy gap 
and interband emission from 6sp to 5d energy levels.33, 166  It has also been postulated that 
near-IR luminescence is generated from a transition at an energy lower than the sp to d 
interband model and rather originates from an sp to sp-like transition.165 
In addition to their intrinsic visible and near-infrared fluorescence, nanoparticles offer 
convenient size, stability, solubility, and reactivity as molecular scaffolds.35, 169  
Specifically, nanoparticles have supported various fluorescent probes and have been 
shown to efficiently quench fluorescent emission.170-174  This fluorescent quenching has 
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not only been used to study the phenomenon of energy transfer, but has also been used in 
a variety of chemical and biological sensors.  Recently, the Murray group has examined 
the different settings for quenching by soluble MPCs, including static, reversible, and 
collisional interactions.  Experiments were carried out using several different 
fluorophores and a variety of MPCs with different sizes (1-4 nm diameter) and 
solubilities and point to a clear relationship between cluster size and quenching 
efficiency.171  Quenching efficiency has also been related to the distance from 
fluorophore to gold nanoparticle in work recently completed in the Decher labs.172  
Layer-by-layer addition of oppositely charge polyelectrolyte created polymer 
encapsulated nanoparticles and provided exquisite control over the distance between the 
metal and fluorophore.  In this way, dye fluorescence was shown to increase with 
additional polymer layers (i.e. increasing distance from the metal) and also increased 
upon slow chemical removal of the metal core.172  Nanoparticle quenching ability has 
also been used in sensor design.  In 2001, single mismatches were detected in DNA using 
a self-complimentary single strand that hybridizes to a hairpin-shaped structure, thereby 
placing a 1.4 nm gold cluster in proximity to a fluorescent dye.  Fluorescence quenching 
is then alleviated by introducing free complimentary ssDNA.174  These examples point to 
the interest in nanoparticle quenching efficiency and their potential in sensor applications. 
Conversely, the phenomenon of nanoparticle fluorescence enhancement has been 
minimally reported.  Initially, luminescence enhancement was studied with organic dyes 
near surface-deposited silver islands and later through the aggregation of silver 
nanoparticles decorated with fluorescent dyes.175, 176  Enhancement using gold has been 
reported when fluorescent dyes are attached with the molecular dipole parallel to the 
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nanoparticle surface177 and when nanoparticles suppress the non-radiative decay of 
attached dyes.178  These few examples report on the ability of gold and silver 
nanoparticles to augment the fluorescence intensity or lifetime of common organic dyes.  
The intrinsic fluorescence of water-soluble Au-MPCs and fluorescence enhancement is 
the focus of this research.  To our knowledge, we make the first report on Pt-MPCs lack 
of near-infrared fluorescence and, importantly, on their ability to increase the fluorescent 
intensity of Au-MPCs when covalently attached or decrease fluorescence intensity when 
non-covalently mixed. 
 
Experimental 
 
Chemicals 
Gold shot (99.99%) was purchased from precious metal vendors and was initially 
converted to HAuCl4•3H2O by boiling Auo in HCl/HNO3 solution.119  TMA ligand 
(N,N,N-trimethyl-10-undecenylammonium) was synthesized as previously described.179  
H2PtCl6•6H2O was purchased from Strem Chemical.  The peptide NH2-C6H12-
AVRWLLTA-C6H12-Cys-COOH was obtained from Dr. Oliver McIntyre and the peptide 
NH2-YPYDVPDYAC-COOH was obtained from Dr. David Wright.  All other chemicals 
were reagent grade and used as received. 
 
Monolayer-Protected Cluster Synthesis and Characterization 
Au-MPCs were synthesized with N,N,N-trimethyl(11-mercaptoundecyl)ammonium 
ligand (TMA) as previously described.179  Briefly, 2.5 mmol of HAuCl4 and 3.5 mmol of 
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TMA ligand were co-dissolved in 18 MΩ water and stirred for 30 min.  An excess of 
aqueous sodium borohydride (25 mmol) was then added rapidly to initiate vigorous 
reduction (caution!) of the metal salt to the metal MPC.  After one hour of stirring, 
nanoparticles were loaded into cellulose ester membrane tubing (Spectra/Por CE, MWCO 
= 10,000 daltons) and impurities were dialyzed into water over several days.  Pt-MPCs 
were synthesized in a similar fashion180 with tiopronin (N-(2-mercaptopropionyl)-
glycine) ligand.  Equimolar H2PtCl6 and tiopronin were co-dissolved in 6:1 (v/v) 
methanol/glacial acetic acid, chilled to 0 oC, and reduced with excess NaBH4.  
Purification was achieved by dialysis, as above.  Characterization of MPCs was 
completed using nuclear magnetic resonance spectroscopy, UV/visible spectroscopy, 
transmission electron microscopy, and thermogravimetric analysis, as previously 
described.49  UV-visible absorbance and near-IR fluorescence of Au-MPCs and Pt-MPCs 
was obtained at 100 nM concentration in 0.1 M MES buffer, pH 6.0, 0.5 M NaCl.  
Fluorescence spectra were recorded on a Horiba Jobin Yvon Fluorolog 
spectrofluorometer.  Typical experiments involved excitation at 400 or 680 nm with 
emission recorded from 750 to 1250 nm.  A standard Au-MPC sample at known 
concentration was used as a reference sample throughout the experiments. 
 
Place Exchange and Coupling 
Peptide linkers (Figure 45) were place exchanged onto Au-MPCs for the purpose of 
nanoparticle coupling, as previously described.49, 51  Briefly, 3.1 mg of linker in 10 mL 
methanol was added to 10 mg of Au-MPCs in 10 mL of water and stirred for 7 days.  The 
methanol was removed by rotary evaporation and the linker-presenting Au-MPCs (D) 
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were purified by dialysis, as above.  The approximate number of peptides per nanocluster 
was determined to be 30 by 1H NMR, as previously described (Figure 44b).49  Coupling 
experiments used equimolar amounts of D and Pt-MPCs.  A six-fold molar excess of 
EDC and sulfo-NHS were added to Pt-MPCs in 0.1 M MES/0.5 M NaCl and stirred for 
15 minutes to allow activation of the carboxylic acid groups.  D was subsequently added, 
stirred for two hours, at which time 10 mM hydroxylamine was added to quench the 
reaction.  The reaction mixture was purified by size exclusion chromatography (Sephadex 
G50, Sigma), similar to previous experiments.181 
 
Enzymatic Linker Cleavage 
Reaction of coupled MPCs with trypsin protease was carried out in 0.1 M borate 
buffer pH 9.0 at approximately 0.4 µM (D) and a 50:1 molar ratio of Au-MPC peptides 
(12 µM) to trypsin (240 nM).  Fluorescence spectra were recorded every 10-15 min, 
following manual mixing of the solution.  Samples were held at 37 oC with a water bath 
or allowed to remain at room temperature. 
 
Results and Discussion 
 
Monolayer-Protected Cluster Synthesis and Characterization 
Au-MPCs were synthesized with TMA as the passivating ligand, while Pt-MPCs 
were synthesized with tiopronin, according to established procedure.179, 180  Careful  
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Figure 43.  Characterization of Au-MPCs and Pt-MPCs.  (a) Proton NMR of Au-
MPCs showing composition of monolayer and purity of the sample; (b) Proton NMR 
of Au-MPCs presenting peptide linker (peaks indicative of peptide are denoted by *); 
(c) Proton NMR of Pt-MPCs showing composition of the monolayer and purity of the 
sample; (d) TEM image of Au-MPCs showing spherical cluster, approximate size, 
and size dispersity; (d) TGA data of Au-MPCs showing a decomposition transition at 
~200 oC and the overall percent of organic molecules by weight. 
 
 
characterization of both nanoparticles allowed for size and composition approximation 
(Au-MPCs ave diameter = 4.3 + 1.7 nm, ave composition = Au1460TMA776; Pt-MPC ave 
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diameter = 2.5 nm, ave composition = Pt294Tiop104) as well as determination of 
absorbance and fluorescence properties.  Proton NMR of Au-MPCs, Au-MPCs 
presenting peptide, and Pt-MPCs are available in Figure 43 a, b, and c, respectively.  
TEM and TGA data for Au-MPCs can be found in Figure 43 d and e, respectively.  UV-
visible absorbance and near-IR fluorescence of Au-MPCs and Pt-MPCs are available in 
Figure 44.   
 
 
Figure 44.  Absorbance (300-750 nm) and fluorescence (ex 680 nm, em 775-1250 
nm) of Au-MPCs at 100 nM, Pt-MPCs at 100 nM, and of a mixture of Au-MPCs and 
Pt-MPCs, each at 100 nM. 
 
 
While both nanoparticles exhibit broad absorbance across the UV and visible region, Au-
MPCs have a distinct plasmon resonance band centered at 520 nm and a brown/red hue 
due to their relatively large diameter.169, 179  Pt-MPCs show little to no plasmon resonance 
band and an orange-brown color due to their smaller diameter.180  Furthermore, Au-
MPCs show significantly stronger near-IR fluorescence as compared to Pt-MPCs when 
excited at either 400 or 680 nm.  This may be due to the composition or size of the metal 
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core or could be related to the length or polarity of the capping ligand.  Mixing equimolar 
solutions of Au-MPCs and Pt-MPCs (Figure 44) shows an additive absorption spectrum, 
but quenched fluorescence.  This quenching is believed not to come only from self-
absorbance or self-quenching (upon effectively doubling the solution absorbance), but 
from a collisional or reversible, electrostatic interaction.171 
 
Fluorescence Enhancement of Coupled Nanoparticles 
We also report on static enhancement of near-IR fluorescence upon coupling of Au-
MPCs directly to Pt-MPCs.  A significant advantage of monolayer-protected clusters is 
the ease with which they are functionalized or derivatized.  Either through reactions with 
the protecting ligand (i.e. amide coupling)35 or through direct reaction with the metal core 
(place exchange),34 functional units ranging from redox molecules44 to peptide epitopes49, 
51 have been presented on MPCs.  Similar strategies have been used to couple or bridge 
nanoparticles.121, 182-185  Rigid, conjugated, thiol-terminated linkers have allowed for 
spatial arrangement of gold and silver nanoparticles into dimers, trimers, and tetramers, 
which has led to the study of optical and electromagnetic coupling.183  Feldheim, et al. 
observed a small shift in the plasmon resonance band upon coupling gold particles into 
dimers and trimers.182  Long, flexible peptide linkers (D, Figure 45) were place 
exchanged onto Au-MPCs for the purpose of nanoparticle coupling.  Interestingly, the 
intrinsic fluorescence of Au-MPCs was enhanced by addition of the peptide linker, but 
was still quenched by mixing with Pt-MPCs (E, Figure 45). 
Direct coupling of D to Pt-MPCs was achieved through the free amine of the peptide 
linker, the multiple carboxylic acids on Pt-MPCs, and standard amide coupling reagents.   
 140
 
Figure 45.  Idealized cartoon of monolayer-protected clusters, conjugates, and 
mixtures and their fluorescence when excited at 400 nm or 680 nm.  The 
concentrations of gold or platinum nanoparticles in all solution were approximately 
0.36 µM at 400 nm excitation and 0.24 µM at 680 nm excitation.  Fluorescence for 
each solution was normalized to a standard solution of A.  *Artifact fluorescence 
from 2nd and 3rd overtone of 400 nm.  (A) Gold nanoparticle capped with TMA 
ligand; (B) Platinum nanoparticle capped with tiopronin ligand; (C) non-conjugated 
equimolar mixture of A and B; (D) Gold nanoparticle A presenting approximately 30 
peptide linkers per nanoparticle; (E) non-conjugated, equimolar mixture of B and D; 
(F) Nanoparticles B and D covalently coupled through the peptide linker. 
 
 
Equimolar amounts of D and Pt-MPCs were used in order to promote one-to-one Au-
MPC to Pt-MPC coupling.  The reaction mixture was purified by size exclusion 
chromatography (Sephadex G50, Sigma), similar to previous experiments,181 in order to 
remove impurities and possibly separate products by size or coupling efficiency.  
Initially, four fractions were collected from the column: the beginning of the nanoparticle 
band, the middle, the end of the band until no visible nanoparticle remained, and 
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remaining buffer eluent.  Initial characterization of these fractions shows a slight red shift 
in the Au-MPC plasmon resonance band, indicating coupled or aggregated clusters.  
Proton NMR also shows Au-MPCs and Pt-MPCs in the same solution, though cannot 
confirm conjugation (Figure 46a).  TEM images show a lack of broad aggregation, but 
MPCs in proximity to each other, suggesting the presence of dimers or trimers (Figure 
46b).   
 
 
Figure 46.  Characterization of MPC conjugates.  (a) 1H NMR of Au-MPC/Pt-MPC 
conjugates.  At the high concentrations generally needed for NMR, aggregation 
between the positively-charged Au-MPCs and the negatively-charged Pt-MPCs 
causes interesting peak shifts, which makes peak analysis difficult.  Peaks indicative 
of Au-MPCs, peptide, and Pt-MPCs are present, but overlapping.  (b) TEM image of 
Au-MPC/Pt-MPC conjugates showing a lack of broad aggregation, a relatively large 
number of isolated, unconjugated nanoclusters, and the possibility of dimers and 
trimers. 
 
 
The most conclusive data is the fluorescence enhancement upon conjugation.  
Representative fluorescence of coupled nanoparticles (F) from early and middle 
fractions, as compared to uncoupled and mixed nanoparticles, is available in Figure 45.  
When excited at both 400 and 680 nm, a significant increase in fluorescence intensity is 
observed as compared to all other nanoparticle mixtures at similar concentrations (A-E, 
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concentrations confirmed by visible absorbance).  Fluorescence measurements taken on 
different days were normalized to a standard solution of A.  Comparable results were 
obtained upon repeating this procedure in two additional replicate experiments.  The 
increase in fluorescence intensity for F as compared to D is available in Table 11 and 
ranges from a small increase of 1.35x when excited at 400 nm to a larger increase of 
4.65x when excited at 680 nm.   
 
Table 11.  Fluorescence ratio of F relative to D. 
 
Replicate Column Excitation Wavelength 
Experiment Fraction 400 nm 680 nm 
1 2 2.34 + 0.11 4.65 + 0.08 
2 2 1.89 + 0.11 4.52 + 0.08 
3 2 1.35 + 0.09 1.48 + 0.09 
3 3 2.52 + 0.09 2.55 + 0.09 
 
 
While excitation at 680 nm appears to provide overall lower fluorescence intensity, 
emission from that wavelength seems to be more sensitive to nanoparticle coupling.  A 
much larger increase in fluorescence can be obtained when coupled nanoparticle F is 
compared to a gold/platinum mixture E, where collisional or reversible quenching occurs.  
This is evidenced in Figure 45 where F fluorescence is enhanced 14.6x at 400 nm 
excitation and 12.2x at 680 nm excitation.  The differences in fluorescence measurements 
from replicate experiments certainly come from differences in excitation wavelength, 
variability in column separation and fraction collection, and small differences in sample 
preparation.  The large nanoparticle size dispersity, which could affect nanoparticle 
optical properties, the distance between coupled nanoparticles, as well as the number of 
peptide linkers per particle, may also play a role in the measurement precision. 
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In order to limit some of these differences and better understand the contents of our 
sample, further size exclusion chromatography experiments were conducted on 
nanoparticles from the 3rd replicate experiment.  The fractions from this sample were 
recombined and subsequently reseparated in order to collect volume-defined fractions.  
The chromatogram from this separation is available in Figure 47.  The fluorescence 
spectrum for each 1 mL fraction from this separation was obtained and compared to D at 
similar concentrations (concentrations of fractions were matched to controls via visible 
absorbance).  The percent increase in fluorescence intensity, as compared to the control, 
is also plotted in Figure 47 and indicates that nanoparticles in early fractions exhibit 
larger fluorescence enhancement.  This agrees with the principles of size-exclusion 
chromatography; that larger analytes will pass through the column more quickly than 
smaller analytes. 
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Figure 47.  Fluorescence enhancement after fractionation of coupled nanoparticles 
using size-exclusion column chromatography.  Absorbance of each fraction is plotted 
to show the retention of the nanoparticle on the column.  The percent increase in 
fluorescence is plotted by fraction and shows that a greater increase in fluorescence is 
observed in early fractions. 
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It is also interesting to note the fluorescence peak shape in Figure 45.  Regardless of 
excitation wavelength, Au-MPCs exhibit two distinct peaks in their emission band.  
These two peaks, at 942 nm and 1045 nm, are of roughly equal intensity in a Au-MPC 
solution (A).  Changing the overall charge and polarity of Au-MPCs via place exchange 
of the peptide linker (D) also changes the peak shape.  The higher energy peak is 
intensified and slightly blue shifted to 935 nm as compared to the lower energy peak, 
which remains around 1045 nm.  Further coupling of D to Pt-MPCs elicits another 
change in peak shape.  The low energy peak remains at 1045 nm, but is intensified 
compared to the higher energy peak, which is red shifted back to 950 nm.  These changes 
in peak shape and intensity appear to be due to polarity changes in the nanoparticle ligand 
and suggest that the interesting phenomenon of fluorescence enhancement may also be 
related to electronic interactions between the metal nanoparticle cores facilitated by the 
opposite polarities of the MPC protecting ligands.  The Au-MPCs are permanently 
positively charged due to the trimethylammonium ligand and the Pt-MPCs are negatively 
charged at neutral pH due to the carboxylic acid termini of the tiopronin ligand.  This 
opposite polarity facilitates an electrostatic interaction of the nanoparticle ligands, which 
may promote an electronic interaction between the metal cores.  This interaction may 
create an electronically conjugated system that enhances fluorescence emission of the 
Au-MPCs.  Preliminary experiments using Au-MPCs with tiopronin ligands, a similar 
peptide linker (amino acid sequence: NH2-YPYDVPDYAC-COOH), and Au-MPCs with 
TMA ligand showed comparable fluorescence enhancement (data not shown).  This 
suggests that the composition of the linker may not be important, but the linker length 
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may play a role.  It also indicates that enhancement of gold nanoparticle fluorescence 
may be possible using different types of metal cores with different electronic structures. 
 
Enzymatic Linker Cleavage 
This observed fluorescence enhancement has applications in the realm of biosensors.  
Changes in optical properties have long been used in molecular identification and in 
chemical and biological sensing.  Nanoparticle-based optical sensors have been important 
additions as analytical methods and have been used in the detection of many different 
analytes.  For example, techniques have made use of shifts in plasmon resonance band 
absorbance upon extended aggregation and polymeric network formation for the 
sequence-specific, sensitive detection of DNA.186  A similar approach was used for 
studying molecular recognition and lectin-carbohydrate interactions.187  Single-mismatch 
detection in oligonucleotides has also been achieved using a FRET-based molecular 
beacon and the phenomenon of gold nanoparticle fluorescence quenching.174  Enzyme-
active probes have also been predicated on these phenomenon and have been assembled 
from organic dyes,188, 189 conjugated fluorescent polymers,190 semi-conductor quantum 
dots,191 and gold nanoparticles191, 192 for the detection of different proteases.  A peptide-
linked near-IR active transducer using a combination of fluorescence enhancement from 
coupled nanoparticles and fluorescence quenching from separated nanoparticles could 
also be used in protease detection.  Numerous cleavable peptide linkers could be 
employed to couple gold and platinum nanoparticles, creating enhanced fluorescence.  
Specifically severing the linker would liberate the nanoparticles and reduce fluorescence 
intensity.  The peptide linker used in these studies (NH2-C6H12-AVR*W#LLTA-C6H12-
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Cys-COOH) was designed as a substrate for the common serine protease trypsin and the 
cancer-related protease matrix metalloprotease-9 (MMP-9).193  Trypsin is known to 
cleave after basic amino acids such as lysine (K) and arginine (R, denoted by *), while 
MMP-9 cleaves after tryptophan (W, denoted by #).193  The advantages of a MMP sensor 
that could potentially be used in near-IR imaging experiments are obvious, though initial 
enzyme experiments were carried out using the widely available and well-studied trypsin. 
Fluorescence spectra for reactions of coupled MPCs with trypsin protease were 
recorded every 10-15 min for three different solutions:  (1) coupled MPCs with enzyme, 
held at 37 oC; (2) coupled MPCs with no enzyme, held at 37 oC; (3) coupled MPCs with 
enzyme, held at room temperature.  The percent decrease in fluorescent intensity for 
these solutions over 3-4 hours is plotted in Figure 48.   
 
 
Figure 48.  Decrease in fluorescence upon enzymatic cleavage of the peptide linker in 
(F).  Coupled nanoparticle show 38% decrease in fluorescence intensity when 
incubated with the protease trypsin at 37 oC (diamond).  Fluorescence decrease 
occurred more slowly when incubated at ~25 oC (triangle).  Coupled nanoparticle in 
the absence of enzyme did not show photobleaching or loss of fluorescence (square).  
Slight increase in fluorescence is attributed to minor evaporation of solvent and 
concentration of particle. 
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Solution (1) shows a constant decrease in fluorescence intensity to 74% of initial 
intensity over approximately 200 min.  Solution (2), coupled cluster with no enzyme, 
shows some variability in fluorescence but retains nearly 100% of initial fluorescence.  A 
slight increase in fluorescence is attributed to the slow evaporation of solvent leading to 
concentration of the analyte.  This not only confirms the activity of the enzyme, but also 
removes the possibility of fluorescence decrease from photobleaching.  Solution (3), 
which was run at room temperature, showed a decrease in fluorescence intensity to 83% 
of the initial intensity, as expected due to the lower temperature.  The two solutions 
initially held at 37 oC were revisited after 3 subsequent days at room temperature to show 
that only 62% of initial fluorescence remained for solution (1) while solution (2) 
remained around 100%.  Final fluorescence intensity that is 62% of initial intensity is 
likely due to incomplete cleavage of all peptide linkers.  Complete cleavage would yield 
a solution of coupled, mixed nanoparticles exhibiting quenched fluorescence, as in (E).  
However, the stable fluorescence after 3 days suggests the achievement of an endpoint 
where all of the accessible peptide is cleaved.  Further optimization of enzyme 
experiments and longer time studies may elucidate this point.  In general, the length of 
these initial studies and relatively slow rate of cleavage suggests a lack of kinetic lability 
for peptide cleavage.  Steric hindrance is likely a dominating factor in this case as the two 
linked nanoparticles block enzymatic access to the coupling peptide in between.  While 
additional spacer units on either end of the peptide linker may provide for easier access to 
the protease, it may also alter the fluorescent properties of the couple.  Practical use of 
this phenomenon as a device would certainly require the optimization of these and other 
parameters. 
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Conclusions 
These experiments highlight the interesting and useful phenomena of gold/platinum 
nanoparticle fluorescence quenching when untethered and fluorescence enhancement 
when coupled.  Gold TMA-MPCs have intrinsic near-IR fluorescence, while platinum 
tiopronin-MPCs have little to no fluorescence.  The Pt-MPCs are able to quench the 
fluorescence of the Au-MPCs when mixed in solution, but are also able to cause 
fluorescence enhancement when coupled by a peptide linker.  Enhancement of up to 
4.50x as compared to peptide-presenting Au-MPCs and nearly 15x when compared to a 
quenched mixture of Au-MPCs and Pt-MPCs was observed.  Fluorescence enhancement 
is speculated to be derived from the opposite polarity of the two nanoparticle ligands 
promoting an electronic interaction between the metal cores, creating an electronically 
conjugated system.  This enhancement has potential in the design of numerous 
biosensors.  A 38% decrease in fluorescence intensity was observed upon cleavage of the 
peptide linker by the protease trypsin.  Further study and optimization of this system 
would be possible and necessary for practical use as an enzyme sensor. 
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APPENDIX A 
 
DETECTION OF EBOLA VIRUS GLYCOPROTEINS USING A QUARTZ CRYSTAL  
MICROBALANCE IMMUNOSENSOR  
 
Ineffective Ebola virus detection methods, as well as a lack of preventative medical 
measures, have prompted the study of alternative strategies.  Attempts to develop an 
assay to detect and distinguish between Ebola Envelope Glycoproteins (EBO/G) from the 
Sudan/Gulu and Zaire strains began with the identification of polyclonal and monoclonal 
anti-glycoprotein antibodies.  Four antibodies (rabbit antiserum and monoclonal 
antibodies 17A3, 6D11, and 15H10), as well as their corresponding glycoproteins, were 
obtained through the Southeast Regional Center for Excellence in Emerging Infections 
and Biodefense (SERCEB).  These antibodies are produced by different methods, are of 
different subtypes, and are thought to have strain and subunit specificity.  Using these 
antibodies and a Quartz Crystal Microbalance (QCM) transducer2, 3, 52 we have designed 
a biosensor that employs monoclonal antibody 15H10 to directly detect EBO/G with 
good sensitivity and in real-time. 
Several immunosensor assembly strategies, including covalent, non-specific, and 
recognition-based immobilization, were employed in the optimization of antibody 
presentation on the QCM surface.  In all cases, biological antibody capture agents 
provided the most consistent antibody presentation.  As such, the biosensor was 
comprised of the QCM quartz crystal, a gold electrode, antibody capture agent (Protein 
A, Protein G, or Protein L), and anti-EBO/G.  Protein A and G are known to non-
specifically adsorb to a hydrophobic gold electrode and specifically bind the Fc region of 
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IgG.  This particular antibody immobilization method benefits from the presentation of 
IgG in such a way that antibody CDRs are unobstructed.2, 194  Protein A and G also show 
species and subtype specificity.  For example, Protein A binds strongly to mouse IgG2a, 
but weakly to mouse IgG1, while Protein G shows moderate binding to IgG1.194  Protein L 
is thought to bind the kappa light chain region of immunoglobulin without interfering 
with antigen binding.  For this reason, Protein L binds strongly to all mouse IgG subtypes 
as well as mouse IgM.194  Using these capture agents, all four antibody samples were 
immobilized and used in the detection of Zaire and Sudan/Gulu EBO/G, similar to a 
manner previously described (Chapter II).   
After immunosensor assembly, EBO/G was diluted to various concentrations in 50 
mM phosphate buffer and introduced to the assembled sensor for a set time of 12 minutes 
at a flow rate of 30 µL/min.  A new sensor was assembled for each EBO/G binding event.  
Binding of either strain to rabbit antiserum, 6D11, and 17A3 was largely unsuccessful.  
Adsorption at low concentrations did not seem to follow a linear trend, while adsorption 
at high concentrations either indicated apparently low Ka values or non-specific binding.  
Successful adsorption at relevant concentrations was observed with monoclonal antibody 
15H10 for both strains of EBO/G, though the antibodies appeared to have an increased 
affinity for the Zaire strain glycoprotein over the Sudan/Gulu strain glycoprotein.  
Adsorption increased with increasing concentration until saturation was reached (Figure 
49a).  This data allowed the calculation of an equilibrium adsorption constant (Ka) by 
fitting to a Langmuir isotherm3 for the Zaire strain EBO/G of (9 + 1) x 106 M-1.  
Although concentration dependent binding occurred for the Sudan/Gulu strain, the large 
error in isotherm fitting precluded Ka calculation.  Kinetic constants were also calculated  
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Figure 49.  (a) EBO/G adsorption to immobilized antibody, fit to a non-linear curve 
(Zaire, solid diamond; Sudan/Gulu, open square).  (b) Linear region of low 
concentrations were used to obtain limits of detection. 
 
 
for the Zaire strain using individual EBO/G binding curves.  The forward rate constant 
(kf) was found to be (7.9 + 0.6) x 103 M-1s-1 and the reverse rate constant (kr) was (1.9 + 
0.1) x 10-3 s-1.  The quotient of these is equal to the Ka and was determined to be (4.1 + 
0.3) x 106 M-1, which is in reasonable proximity to the Ka calculated by isotherm fitting.  
Affinity (Ka) in the range of 106 – 107 is consistent with previously studied 
immunological systems,2, 24, 49, 51 though it is somewhat lower than anticipated for 
monoclonal antibody.  Several methods exist for potentially obtaining a higher affinity 
antibody.10, 11, 22, 23  Another, relatively new approach would be to complete 
conformational epitope mapping of 15H10 to EBO/G using peptide epitope presenting 
nanoclusters.51  Tight binding antigen mimics could then be used in the creation of new 
antibodies.   
Detection limits were calculated for this system by comparing the lowest detectable 
mass change (11 ng at a signal-to-noise ratio of 3) to the low concentration linear 
adsorption regions in Figure 49b.  Accordingly the lowest detectable concentration of the 
Zaire and Sudan/Gulu strain glycoproteins would be 14 nM and 56 nM, respectively.  
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Improved detection limits could be achieved by using a higher affinity antibody, by 
presenting a higher density of antibody on the QCM surface, or by using a higher MHz 
crystal.  Furthermore, limits for the detection of the intact ebola virus will be significantly 
better due to the weight of a large virus particle. 
Short term future work might include the exploration of antibody immobilization 
strategies, instrument setup optimization, and detection of EBO/G in more complex 
samples.  The design of a portable, hand-held QCM for environmental and physiological 
testing is another important goal in instrument development.  Peptide epitope presentation 
on nanoclusters for epitope mapping and to simulate virus particle weight is a further 
option.  Complete details of this work have been published by Yu, et al.195 
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APPENDIX B 
 
QUARTZ CRYSTAL MICROBALANCE STUDY OF PIEZOELECTRIC INK JET  
PROCESSING OF MATERIALS 
 
Piezoelectric ink jet printing is a non-contact, non-destructive, rapid prototyping 
technique for patterning materials used in medicine and biology.  A quartz crystal 
microbalance sensor was initially used in the study of printing reproducibility and in 
determining the weight of single printed spots.  In initial experiments, the frequency of a 
9 MHz crystal was recorded in air before and after printing a 289 single-drop array of 
multi-walled carbon nanotubes.  After accounting for changes in the density and viscosity 
of the printed solution, a measurement of 861 ng was recorded (Figure 50).   
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Figure 50.  Weight measurement of multi-walled carbon nanotubes solutions using a 
quartz crystal microbalance. 
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This equates to 2.978 ng/drop or a ~3 pL drop (assuming a density of 1 g/mL).  Future 
experiments should include a mass/drop calculation for the printing of 1 to 289 drops, the 
reproducibility of printing any number of drops, and the evaporation time for any number 
of drops.  One potential application for such piezoelectric printing would be in the realm 
of QCM sensing, where two or more antibodies could be independently, spatially 
patterned onto a single QCM electrode.  This would allow rapid sensor fabrication and 
multi-analyte detection on a single crystal.  The detail of piezoelectric printing were 
recently published by Sumerel, et al.196 
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APPENDIX C 
 
ELECTROSPRAY MASS SPECTROMETRY STUDY OF TIOPRONIN 
MONOLAYER-PROTECTED GOLD NANOCLUSTERS 
 
Electrospray ionization time-of-flight mass spectrometry (ESI-TOF-MS) was used in 
the study of gold monolayer-protected cluster synthesis.  Studies involved the mass 
spectral analysis of MPC precursors (Au-Tiop polymers) before and after reduction with 
sodium borohydride.  Standard Tiop-MPC synthetic strategies2, 49 were employed, though 
progress was arrested at certain points to allow for characterization.  Co-dissolving 
HAuCl4 (0.33 mmol) and tiopronin (1.1 mmol) in 6:1 methanol/glacial acetic acid 
resulted in the formation of a white, flocculent, light sensitive polymer that grew and 
precipitated over time.  This polymer was determined to grow from the aggregation of a 
Au4Tiop4 cyclic or cubic structure.  Interestingly, this structure was also seen as a minor 
component in the MPC sample post-reduction/purification, indicating the presence of the 
structure in solution or, more likely, on the surface of the MPC.  These results may 
influence the synthesis of future MPCs, the structural understanding of MPCs, and the 
mechanistic understanding of MPC reactivity.  UV/visible absorbance and transmission 
electron microscopy measurements were also involved in these studies.  Further details 
can be found in worked recently accepted for publication.197 
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APPENDIX D 
 
SINGLE-CHAIN FRAGMENT-VARIABLE RECOMINANT ANTIBODIES WITH 
AFFINITY FOR ZERO-VALENT METALS 
 
QCM studies have been involved in the development of biological interfaces for 
inorganic materials.  One approach has harnessed the power of the immune system to 
identify antibodies that bind selectively with zero valent metals.  Phage-selected, single 
chain (ScFv) recombinant antibodies22 to several classes of nanoparticles have been 
identified.  Binding such antibodies directly to bare metal electrodes on QCM crystals is 
an effective method for confirming activity.  Preliminary results have suggested that 
these recombinant antibodies do bind to the metal for which they have been selected, 
though the composition of the metal surface (i.e. oxide) may also play an important role 
in recognition.  As seen in Figure 51a, an anti-Ag antibody bound to an unpolished Ag 
electrode immediately after washing with nitric acid and reforming the oxide layer.  
Oxide layer formation can be detected after washing with nitric acid (Figure 51a), but the 
mass adsorption for antibody binding plus oxide formation is far greater than oxide 
formation only.  The ∆m due to antibody binding (the difference between the two curves) 
is 0.6 µg.  Unfortunately, attempted removal of bound antibody upon washing of the 
QCM surface with phosphate buffer does not show mass stripping.  This suggests non-
specific adsorption over equilibrium recognition.  Anti-Ag antibody adsorption was 
further reinforced by the addition of an anti-E antibody bound FITC fluorescent tag to a 
short peptide chain (E-tag) on the anti-Ag antibody.  Fluorescent emission from the FITC 
tag/anti-E/E-tag/anti-Ag/Ag QCM complex was captured in an image from fluorescent 
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microscopy (Figure 51b).  Controls (anti-E antibody binding to a silver surface) were 
performed and yielded a background with significantly less fluorescence (Figure 51b, 
inset).  This two-fold detection shows adsorption of this antibody to its inorganic target 
and suggests the possibility of a new biology/inorganic interface. 
 
 
Figure 51.  (a) Anti-Ag ScFv antibody binding to a newly formed silver oxide surface 
(red) shows a larger ∆m than oxide formation only (black).  (b) Fluorescence 
microscopy image of anti-Ag antibody bound to Ag substrate and control experiment 
(inset). 
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